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	ABSTRACT		 In	2017,	36.7	million	people	worldwide	were	living	with	Human	Immunodeficiency	Virus	(HIV)	and	of	that	total,	1.8	million	people	were	new	infections.	Sub-Saharan	Africa	was	recognized	 as		the	most	afflicted	regions	worldwide	accounting	for	26	million	people,	68%,	living	with	HIV.	 The	 difficulty	 in	 fighting	 this	 epidemic	 has	 raised	 the	 urgent	 need	 for	 research	exploring	ways	in	which	HIV	transmission	can	be	curbed	worldwide.			 Our	laboratory	previously	showed	that	crude	saliva	and	purified	salivary	mucins	(MUC5B	and	MUC7)	inhibit	HIV-1	infection	in	vitro.	However,	it	is	not	known	whether	the	specific	arrangement	of	mucin	carbohydrate	residues	 is	 important	 for	mucin	 interactions	with	HIV-1,	or	if	the	negative	charge	afforded	by	sialic	acid	and	sulfated	sugars	allows	binding	to	 viral	 receptors.	 While	 giving	 some	 important	 insight	 into	 the	 mechanism	 of	 HIV	inhibition,	we	hope	that	this	study	will	determine	the	minimum	peptide	chain	length	and	structure	of	a	gel	forming	mucin	that	retains	the	anti-HIV	activity.	In	addition,	we	aim	to	determine	if	the	reduced	salivary	subunits	and	trypsin	digested	fragments	retained	this	inhibitory	activity	against	HIV-1.			 Saliva	was	collected	and	stirred	overnight	 in	6M	guanidine	hydrochloride	with	10mM	Na2HPO4,	10mM	EDTA,	1mM	PMSF	and	5mM	NEM.	Salivary	mucins	(MUC5B	and	MUC7)	were	purified	using	caesium	chloride	ultracentrifugation	and	separated	on	a	Sepharose	CL-4B	 column.	 Thereafter,	 mucin	 rich	 fractions	 were	 either	 reduced	 with	 10mM		dithiothreitol	 (DTT)	 or	 proteolytically	 digested	 with	 0.25%	 trypsin.	 The	 resultant	fractions	were	dialysed	and	freeze	dried.	Slot	blots	were	used	to	determine	the	identity	of	 the	 void	 volume	 (Vo)	 fractions	 and	 the	 included	 volume	 (Vi)	 fractions	which	were	identified	as	MUC5B	and	MUC7	respectively.	The	Vo	and	Vi	fractions	were	subjected	to	4-	20%	sodium	dodecyl	sulphate	polyacrylamide	gel	(SDS-PAGE)	to	determine	the	size	and	mucin	concentration.	In	addition,	mucin	oligosaccharides	were	enzymatically	removed	using	the	de-glycosylation	kit	(EDEGLY)	purchased	from	Sigma	Aldrich	(UK).	Following	this,	all	mucin	lyophilized	aliquots	were	tested	for	cell	cytotoxicity	using	an	MTT	assay.	This	was	 then	 followed	by	 a	neutralisation	 assay	which	uses	HIV-1	 env	pseudo	 virus	
	(DU422.1	and	YU2	subtype	C	and	subtype	B	respectively)	and	a	luciferase	reporter	gene	involving	modified	TZM-bl/JC	 cells	was	 used	 to	 test	 the	 inhibitory	 activity	 of	 the	 test	samples.			 Comparison	of	the	anti-HIV	activity	of	crude	saliva,	MUC5B	and	MUC7	against	the	DU422	virus	 showed	 that	 both	 crude	 and	 purified	 saliva	 indeed	 inhibits	 the	 infection	 of	 the	DU422.1	pseudo-virus	strain	to	TZM-bl/JC	cells	(Kruskal-Wallis,	p=0.00025).	MUC5B	was	more	potent	in	inhibiting	the	DU422	virus	as	compared	to	crude	saliva	and	MUC7	(Mann-	Whitney	 U,	 p=0.0227	 and	 p=0.0195	 respectively).	 Furthermore,	 no	 difference	 was	observed	 in	 inhibiting	 the	DU422	 virus	 by	MUC7	 and	 crude	 saliva	 (Mann-Whitney	U,	p=0.128).	While	the	three	cohort	of	samples	did	inhibit	the	YU2	pseudo	virus	(Kruskal-	Wallis,	 p=0.0078),	 MUC7	 showed	 a	 higher	 inhibition	 compared	 to	 MUC5B	 and	 crude	saliva	(Mann-Whitney	U,	p=0.0341	and	p=0.176	respectively).	A	significant	difference	in	the	 inhibition	 of	 the	 YU2	 virus	was	 detected	 between	MUC7	 and	 crude	 saliva	 (Mann-	Whitney	U,	 p=0.0031).	 In	 addition,	 reduced	 and	digested	 salivary	 fragments	 inhibited	both	 viruses	 suggesting	 the	 possibility	 that	 even	 when	 the	 gel	 forming	 properties	 of	mucins	are	compromised,	mucins	still	retain	their	inhibitory	activity.			 Interestingly,	the	removal	of	oligosaccharides	showed	MUC5B	as	the	most	potent	mucin	in	the	inhibition	of	both	DU422	and	the	YU2	pseudo	virus	(Kruskal-Wallis,	p=0.0312).	De-	glycosylated	 MUC7	 displayed	 minimal	 inhibition	 against	 the	 YU2	 and	 DU422	 virus	suggesting	that	oligosaccharides	are	important	for	maximal	inhibition.	Furthermore,	this	highlights	that	the	mechanism	through	which	mucins	inhibit	viruses	involve	glycans.			 In	conclusion,	the	results	of	this	study	suggest	that	MUC5B	can	be	harnessed	and	used	as	a	core	component	of	a	microbicide	which	can	be	used	to	prevent	HIV	transmission.	Its	extensive	glycosylation	compared	to	MUC7	makes	it	a	better	candidate	for	this	anti-HIV-	1	inhibitory	activity.	
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		 CHAPTER	ONE:	GENERAL	LITERATURE		 1.1 The	Human	Immunodeficiency	Virus	Epidemic		 In	2017,	the	United	Nations	Joint	Programme	on	Human	Immunodeficiency	Virus	/Acquired	 Immunodeficiency	 Syndrome	 (UNAIDS)	 reported	 that	 approximately	 36.7	million	people	worldwide	were	living	with	Human	Immunodeficiency	Virus	(HIV)	and	of	that	 total,	1.8	million	people	were	new	 infections	 (UNAIDS,	2017).	About	21,7	million	people	 worldwide	 were	 accessing	 antiretroviral	 treatment	 in	 2017,	 and	 despite	 the	availability	of	treatment,	1.2	million	people	died	globally	of	Acquired	Immunodeficiency	Syndrome	(AIDS)	related	illness	(UNAIDS,	2017).			 Sub-Saharan	Africa	was	recognised	as	the	most	afflicted	regions	worldwide	accounting	for	26	million	people	≅	68%,	living	with	HIV.	More	than	half	of	the	affected	individuals	were	women.	By	the	end	of	2017,	7.1	million	people	in	South	Africa	were	living	with	HIV	with	around	270	000	new	infections.	Of	these	newly	infected	cases,	only	54%	had	access	to	antiretroviral	therapy	drugs	(UNAIDS	2017).	By	year-end	of	2016,	the	South	African	National	Aids	Council	released	the	HIV	provincial	data	which	highlighted	Kwazulu	Natal	(KZN),	 Gauteng	 and	 Eastern	 Cape	 as	 the	 provinces	 with	 the	 highest	 burden	 of	 HIV	(National	Department	of	Health	2015).	 Furthermore,	when	 the	 statistics	were	broken	down	according	to	age	and	gender,	the	burden	of	HIV	was	high	amongst	woman	between	the	age	of	20-34	(National	Department	of	Health	2015).			 Regardless	of	the	steady	increase	in	the	number	of	people	living	with	HIV	in	South	Africa	from	2016	to	2017,	the	number	of	infected	individuals	still	remains	high	as	compared	to	other	 countries	 in	 the	world.	 This	 increase	 in	 infection	may	 be	 due	 to	 an	 increase	 in	unsafe	 sexual	 practices	 such	 as	 multiple	 partners,	 no	 condom	 use	 or	 no	 condom	adherence	in	infected	individuals	(UNAIDS	2013).	South	Africa	currently	struggles	with	this	epidemic	and	effective	treatment	and	preventative	strategies	are	required	to	reduce	
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the	prevalence	and	incidence	of	HIV.	With	that	being	said,	this	indicates	a	necessity	for	research	exploring	ways	in	which	HIV	transmission	can	be	curbed	in	the	region.				 1.2 HIV	Taxonomy	and	Characteristics				 HIV	is	part	of	the	Retroviridae	family.	This	class	of	envelope	viruses	infects	the	cells	by	using	an	enzyme	called	reverse	transcriptase,	which	transcribes	viral	RNA	into	DNA.	This	viral	 DNA	 is	 then	 integrated	 into	 the	 human	 genome	 for	 viral	 replication	 to	 occur.	Furthermore,	HIV	is	classified	into	the	lentiviruses	genus	which	is	characterized	by	long	periods	 of	 incubation	which	 usually	 results	 in	 chronic	 illness	 (Narayan	 and	 Clements	1989).			 Based	on	the	genetic	characteristics	and	difference	in	viral	antigens,	HIV	is	divided	into	two	main	groups	mainly	HIV	type	1	and	HIV	type	2	usually	written	as	HIV-1	and	HIV-2	respectively	(Sharp.et	al.	2005).	The	evolution	of	these	viruses	differ.		HIV-1	is	thought	to	 have	 evolved	 from	 a	 chimpanzee	 in	 Central	 Africa	while	 HIV-2	 is	 thought	 to	 have	evolved	from	the	West	African	Mangabeys	(Hahn	et	al.	2000;	Sharp.et	al.	2005;	Lemey	et	al.	2003).	HIV-1	is	more	prevalent	and	progresses	faster	to	AIDS	whereas	HIV-2	is	less	virulent	and	has	a	slower	progression	(Nyamweya	et.al	2013).	Phylogenetic	analysis	has	shown	 that	 HIV-1	 is	 further	 divided	 into	 the	 three	 main	 subtypes	 based	 on	 their	transmission	mainly	Major	(M),	Outlier	(O),	and	non-Outlier	(N)	(Cohen	et	al.	2008).	The	most	common	HIV-1	group	is	the	M	group	which	comprises	of	13	subtypes	namely	A1,	A2,	A3,	A4,	B,	C,	D,	F1,	F2,	G,	H,	J	and	K	(Cohen	et	al.	 2008).	These	subtypes	contain	distinct	different	DNA	sequences	which	differ	by	15-20	%	(McChutan	2000).	Most	individuals	in	Australia	,	Asia	and	Europe	are	usually	infected	with	the	subtype	B	of	the	M	group	HIV-1	virus	while	the	subtype	A,	C	and	D	are	concentrated	in	Africa	(Teixeira	et	al.	2011).	HIV-	2	consist	of	different	subtypes	from	A-E	with	subtype	A	and	B	being	the	most	prevalent	(Chen	et	al.	 1997).	
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Different	HIV-1	M	 strains	 have	 been	 spreading	 leading	 to	 global	 epidemic.	 Subtype	 C	accounts	for	48%	of	the	total	HIV-1	infections	globally	and	it	has	the	highest	prevalence	rate	in	South	Africa.	In	2003,	Kwazulu	Natal	was	one	of	the	most	affected	provinces	which	had	the	highest	infection	rate	of	the	subtype	C	virus	(Gordon	et	al.	2003).	It	is	still	one	of	the	most	affected	provinces	in	South	Africa.				 1.3 The	Structure,	Genome	and	Morphology	of	HIV-1		 HIV	is	an	enveloped	virus	and	during	its	replication	process,	it	buds	off	with	some	of	the	hosts	 cell	membrane	which	 allows	 the	 virus	 to	 replicate	without	 eliciting	 an	 immune	response	(Engelman	and	Cherepanov	2012).	The	genetic	material	of	this	virus	consists	of	two	identical	single	stranded	RNA	molecules	which	contain	nine	viral	genes	namely	gag,	pol,	 env,	 tat,	 rev,	nef,	 vif,	 vrf	and	vpu	 (Rajarapu	2014).	Gag,	pol	and	 the	env	viral	proteins	are	the	structural	proteins	while	the	rest	of	the	viral	proteins	are	 involved	in	regulating	 viral	 replication	 and	 infection.	 The	 genomic	 RNA	 together	 with	 the	 viral	proteins	are	enclosed	by	the	viral	nucleocapsid	protein	(Rajarapu	2014).			 Reverse	 Transcriptase	 (RT),	 Integrase	 (IN)	 and	 Protease	 (PR)	 are	 the	 three	 major	enzymes	that	are	involved	in	the	replication	cycle.	These	enzymes	are	encoded	by	the	pol	gene	and	are	cleaved	products	of	the	Gag-Pol	precursor	polyprotein	(Rajarapu	2014).	The	enclosing	capsid	called	the	p24	is	also	a	product	of	the	gag	precursor	together	with	the	matrix	often	called	the	p17	protein.	All	these	proteins	are	enclosed	within	a	lipoprotein	rich	viral	envelope	which	consists	of	host	membranes	that	are	incorporated	during	the	budding	off	process	to	infect	new	cells	(Sandquist	and	Krausslich	2012;	Engelman	and	Cherepanov	 2012).	 This	 viral	 envelope	 consists	 of	 a	 trimer	which	 is	 composed	 of	 an	external	glycoprotein	called	gp120	and	a	transmembrane	protein	gp41	which	anchors	the	heterodimer	 complex	 (Engelman	and	Cherepanov	2012;	 Sandquist	 and	Krausslich	2012;	Rajarapu	2014).	These	two	proteins	are	encoded	by	the	env	viral	protein	and	are	cleaved	products	of	gp160.	
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The	 HIV-1	 virion	 is	 circular	 in	 shape,	 approximately	 80nm-100nm	 in	 diameter	 and	consists	 of	 a	 lipid	 bilayer	 that	 comes	 from	 the	 host	 cell	membrane.	 The	 lipid	 bilayer	consists	of	cellular	membrane	proteins	which	are	derived	from	the	cell	membrane	of	the	hostand	 these	 include	Major	histocompatibility	complex	1	and	2	 (MHC1	and	MHC	11)	proteins	and	the	intercellular	adhesion	molecule	(ICAM-1)	(Briggs	et	al.	2003;	Rubbert	et	al.	2007;	Turner	and	Summers	et	al.	1999).				 1.4 Sexual	Transmission	of	HIV	In	Host	Cells		 Dendritic	cells,	CD4	T	cells	and	macrophages	are	susceptible	cells	which	are	usually	found	in	 the	 genital	 and	 corelectal	mucosae	where	 exchange	 of	 bodily	 fluids	 usually	 occurs	(Haase	2011).	HIV-1	targets	cells	that	display	Cluster	of	differentiation	(CD4)	receptors	on	their	surfaces	in	particular	CD4	T	lymphocytes	(Maddon	et	al.1986).	These	CD4	cells	have	 co-receptors	 that	 are	either	CCR5	or	CXCR4.	The	CCR5	co-receptor	 is	 commonly	utilized	during	HIV	transmission	and	viruses	that	are	macrophage-trophic	and	use	this	receptor	are	known	as	R5	viruses	(Levy	1996;	Bergery	1999).	X4	viruses	use	the	CXCR4	coreceptors	to	infect	CD4	T	cells	(Berger	et	al.	1999;	Tersmette	et	al.	1998).			 The	first	phase	of	 the	viral	replication	begins	with	the	binding	of	 the	virus	to	the	host	cells.	This	interaction	occurs	between	the	gp120	extracellular	domain	of	the	virus	and	the	CD4	 host	 cell	 receptor	 found	 on	 the	 surface	 of	 the	 target	 cells	 which	 also	 includes	macrophages,	dendritic	cells	(Maddon	et	al.	1986).	The	binding	of	the	virus	to	the	CD4	receptor	results	in	a	structural	change	which	exposes	the	CCR5	and	CXCR4	coreceptors	which	results	in	a	high	affinity	bond	being	created	between	either	the	co-receptors	or	the	gp120	extracellular	domain	(Pancera	et	al.	2010;	Haase	2011;	Klasse	2012).	In	addition,	these	 receptor	 binding	 changes	 induces	 some	 conformational	 changes	 in	 the	 gp41	protein	resulting	in	the	formation	of	the	viral/target	cell	membrane	complex	(Pancera	et	al.	2010).	The	virus	particles	enter	the	host	cell	cytoplasm	and	it	releases	its	viral	RNA	which	is	converted	into	double	stranded	viral	DNA	by	reverse	transcriptase	enzyme.	This	process	tends	to	be	highly	error	prone	which	gives	rise	to	many	mutants	that	are	drug	resistant	(Yu	et	al.	2003).	The	viral	DNA	then	become	integrated	in	the	nucleus	of	the	host	
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cell	genome	by	the	enzyme	integrase	resulting	in	a	nucleoprotein	complex	that	consists	of	viral	DNA	and	Integrase	(Klasse	2012,	Chen	et	al.	2012).	During	the	latent	stage	of	HIV	transmission,	the	proviral	DNA	usually	remains	dormant	and	any	efforts	to	eliminate	the	plasma	viremia	by	highly	active	antiretroviral	drugs	(HAART)	may	still	allow	the	virus	to	persist	creating	a	major	barrier	on	how	to	eradicate	this	virus	(Finzi	et	al.	1999).		 1.5 Transmission	Of	HIV-1		 Sexual	 intercourse	 is	 one	 of	 the	 most	 prevalent	 route	 for	 HIV-1	 transmission.	Interestingly,	 other	modes	of	 transmission	 such	as	mother	 to	 child	 transmission	have	become	 common	 routes	 for	 HIV	 acquisition	 (Royce	 et	 al.	 1997).	 The	 rate	 at	 which	transmission	occurs	depends	on	a	number	of	factors	such	as	the	type	of	sexual	activity,	presence	 of	 ulceration	 or	 inflammation	 in	 the	 genitalia	 or	 even	 circumcision	 status	(Powers	et	al.	2008).	Moreover,	the	concentration	of	HIV	and	the	number	of	HIV	infected	cells	 in	 the	relevant	bodily	 fluid	has	 to	be	high	 for	 transmission	to	occur	(Cohen	et	al.	2008).	Viral	shedding	of	HIV	has	been	found	in	blood,	semen,	breast	milk,	saliva,	seminal	fluid,	rectal	fluid,	and	cervicovaginal	fluids	all	of	which	form	a	media	through	which	the	virus	can	be	transmitted	(Pudney	et	al.1992;	Zuckerman	et	al.	2004;	Pilcher	et	al.	2009).			 The	skin	provides	an	excellent	barrier	against	viral	infection	as	it	does	not	contain	any	cells	susceptible	to	HIV.	 However,	compromising	the	architecture	of	the	skin	via	physical	impairment	or	wounds	creates	entry	points	for	the	virus	(Luizz	et	al.	1996).	Due	to	the	target	cells	present	 in	the	bloodstream,	blood	to	blood	contact	is	clearly	a	highly	efficient	route	through	which	HIV	transmission	occurs	(Ho,	Moudgil	and	Alam	1989;	Liuzz	et	al.	1996).	Blood	to	blood	contact	via	sharing	of	needles	is	another	mode	through	which	HIV	is	transmitted.	Abdala	et	al.	(2000)	demonstrated	that	HIV	could	remain	viable	in	a	needle	for	up	till	42	days	depending	on	the	environmental	conditions	providing	another	route	for	viral	infection.			 The	primary	route	through	which	HIV	is	transmitted	is	via	the	mucous	membranes.	These	membranes	 line	 the	 epithelium	 of	 the	 internal	 tracts	 of	 the	 body	 thereby	 creating	 a	
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barrier	against	pathogens	and	bacteria.	The	delicate	nature	of	these	membranes	makes	them	more	susceptible	 to	damage	and	consequently	 lead	 to	HIV-infection.	Since	 these	mucous	membranes	are	more	delicate	than	the	skin	and	also	contain	a	significant	number	of	dendritic	cells	which	are	target	cells	for	HIV,	no	damage	to	the	membrane	is	required	for	HIV	transmission	to	occur.	For	example,	Wu	and	KewalRamani	(2006)	demonstrated	that	dendritic	cells	in	the	vaginal	epithelium	and	the	rectal	mucosa	can	bind	HIV	particles	from	the	lumen	and	transport	it	to	CD4	+	cells	providing	a	route	for	HIV	to	disseminate	throughout	the	immune	system	(Wu	and	KewalRamani	2006).			 Globally,	 HIV	 transmission	 is	 mainly	 via	 heterosexual	 intercourse	 .	 The	 chances	 of	contracting	HIV	are	greater	when	 the	 transmission	 is	passed	 from	a	man	 to	a	woman	rather	than	from	the	woman	to	a	man	(Durieux-Smith	and	Goodman	1992;	Pettifor	et	al.	2005).	The	increase	in	susceptibility	is	because	of	the	larger	surface	area	of	the	vagina	that	consists	of	HIV	targeted	cells	and	a	higher	viral	concentration	in	semen	as	compared	to	vaginal	secretions.	Young	girls	are	also	at	a	higher	risk	of	getting	infected	because	the	genital	mucosa	has	not	yet	fully	developed	(Muula	2008;	Ramjee	and	Daniels	2013).	Anal	intercourse	presents	a	higher	risk	of	 transmission	as	compared	 to	vaginal	 intercourse	because	 of	 the	 high	 viral	 loads	 that	 are	 present	 in	 the	 rectal	 fluids.	 In	 addition,	 the	epithelium	 of	 the	 anus	 is	 not	 as	 elastic	 as	 the	 vaginal	 mucosa	 which	 makes	 it	 very	susceptible	to	tears	and	abrasions	which	creates	entry	points	for	the	virus	(Zuckerman	et	al.	 2004).			 The	transmission	of	HIV	from	mother	to	child	accounts	for	approximately	30%	to	40%	of	the	 majority	 of	 infant	 infections	 and	 transmission	 which	 occurs	 during	 birth,	 via	breastfeeding	or	when	 the	 child	 is	 in	utero	(Dickover	et	 al.	1996;	Lehman	et	al.	2013;	Mofenson	et	al.	1999).	The	risk	of	transmission	depends	on	a	number	of	 factors,	but	a	high	maternal	virus	 load	has	been	demonstrated	 to	 cause	a	major	 risk	 (Lehman	et	al.	2013,	Mofenson	 et	 al.	 1999,	Dickover	 et	 al.	 1996;	 John	 et	 al.	 1996).	 In	 the	 absence	of	treatment,	 the	 risk	 of	 mother	 to	 infant	 transmission	 via	 breastfeeding	 accounts	 for	approximately	16%	(John-Stewart	2008).	The	provision	of	a	single	dose	of	nevirapine	during	labour	to	the	mother	can	significantly	decreases	the	risk	of	transmission	rate	by	
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50%	while	 the	 taking	of	antiretroviral	drugs	during	pregnancy	and	breastfeeding	also	reduces	the	risk	by	5%	(Shapiro	et	al.	2010;	Lancet	Infect	Dis	2010).	Ziegler	et	al.	(1985)	recorded	the	first	ever	case	of	mother	to	child	transmission	which	was	observed	in	an	HIV-negative	woman	who	had	given	birth	via	caesarean	section	(Ziegler	et	al.	 1985).	This	woman	 lost	 a	 significant	 amount	 of	 blood	 due	 to	 the	 operation,	 and	 she	was	 given	 a	transfusion	to	compensate	for	blood	loss.	After	six	weeks	she	realised	that	herself	and	the	infant	 whom	 was	 breastfeeding	 at	 the	 time	 were	 both	 HIV	 positive.	 After	 a	 major	investigation	 as	 to	 how	 this	 occurred,	 it	was	 revealed	 that	 the	 unit	 of	 blood	 she	was	transfused	with	was	contaminated	with	the	virus	(Ziegler	et	al.	1985).			 1.6 Lack	of	Transmission	In	The	Oral	Cavity		 Although	viral	RNA	and	proviral	DNA	has	been	detected	in	saliva,	its	transmission	via	the	oral	route	is	rare.	This	rarity	suggests	that	either	the	fragments	of	the	virus	present	in	saliva	are	unable	to	produce	an	infection	or	saliva	contains	some	macromolecules	that	can	 inhibit	 the	 replication	 of	 this	 virus	 in-vitro	 (Fultz	 1986;	 Arrietal	 et	 al.	 2007).	Furthermore,	 the	oral	 cavity	 consists	of	 epithelial	 cells	which	do	not	express	CCR5	or	CXCR4	 co-receptors	making	 the	 oral	 cavity	 less	 prone	 to	 HIV	 infection	 (Millman	 and	Sharma	1994).	However,	Lamm	(1997)	demonstrated	that	epithelial	cells	from	humans	could	 be	 infected	 by	 HIV	 in	 vitro	 and	 that	 once	 this	 infection	 is	 transmitted	 to	neighbouring	 leukocytes,	 secretory	 immunoglobulin	 A	 (slgA	 )neutralises	 it.	Immunoglobulins	such	as	IgM	and	IgG	have	also	been	shown	to	inhibit	the	transcytosis	of	HIV	via	epithelial	cells	in	the	oral	cavity	(Bomsel	et	al.	1998;	Hocini	and	Bomsel	1999).	Histological	studies	have	also	demonstrated	that	epithelial	cells	are	indeed	infected	by	HIV	therefore	elucidating	the	impression	that	the	absence	of	infection	in	the	oral	cavity	is	due	to	presence	of	non-infectious	viral	particles.			 Researchers	then	proposed	that	the	virus	particles	may	be	viable	but	unable	to	infect	the	receptive	cells	(Baron	et	al.	1999;	Philips	et	al.	1994).	Fox	et	al.	(1988)	showed	that	in	the	presence	of	viable	RNA	particles,	the	hypotonic	nature	of	saliva	caused	lysis	of	virus	and	prevented	the	attachment	of	those	fragments	to	any	cells	that	were	present	in	the	
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oral	cavity	(Fox	et	al.	1988).	Archibald	et	al.	(1990)	then	demonstrated	that	whole	saliva	except	parotid	saliva	played	a	role	 in	preventing	HIV	replication	and	subsequently	the	infection	of	targeted	cells.	These	findings	were	further	supported	by	Bergey	et	al.	(1990)	;	Miller	et	al.	(2005)	;	Habte	et	al	(2006	;	2008)	suggesting	that	saliva	is	indeed	inhibitory.		 1.7 The	Production	and	Secretion	Of	Human	Saliva		 Human	Saliva	consist	of	dilute	secretions	which	are	produced	by	various	salivary	glands.	These	salivary	glands	include	the	parotid,	the	sublingual	and	the	submandibular	and	they	all	have	a	similar	anatomical	structure	which	includes	secretory	end	pieces,	acini	and	an	arborized	ductal	structure	that	opens	into	the	oral	cavity	(Holmberg	and	Hoffman	2014).			 Various	 salivary	glands	aid	 in	 the	production	and	 secretion	of	 saliva.	The	parotid,	 the	submandibular	and	the	sublingual	glands	are	the	major	salivary	glands	in	the	oral	cavity.	The	 type	of	 saliva	produced	 in	each	gland	 is	dependent	on	 the	amount	of	 acinar	 cells	present	(Bikker	et	al.	2004).	The	parotid	gland	comprises	of	serous	acinar	cells	which	result	 in	 the	production	of	watery	 serous	 saliva	 (Amino	 et	 al.	 2012).	 This	 is	 however	different	to	the	submandibular	and	the	sublingual	glands	which	consist	of	both	mucous	and	serous	acinar	cells.	The	mucous	cells	of	these	glands	secrete	an	appreciable	amount	of	mucins	and	glycoconjugates	which	gives	saliva	its	visco-elastic	properties	(Holmberg	and	Hoffman	2014).	Saliva	also	consist	of	a	number	of	proteins	whose	function	is	crucial	in	the	protection	of	the	oral	cavity.	The	different	proteins	which	are	found	in	saliva	each	have	a	different	and	unique	role.	The	role	of	saliva	is	most	evident	in	patients	that	suffer	from	hyposalivation,	 a	 condition	 in	which	 the	 secretion	of	 saliva	 is	 low.	Most	of	 these	patients	 suffer	 from	microbial	 colonization	 of	 oral	 tissue	 and	 opportunistic	 infections	such	as	Candida	albicans	and	Streptococcus	mutans	giving	saliva	the	ability	to	protect	the	oral	cavity	from	the	colonization	by	microorganisms	(Fox	et	al.	1985).	Saliva	is	initially	isotonic	when	it	is	made	in	the	acinar	cells	but	as	it	passes	through	the	duct	systems,	the	composition	of	electrolytes	is	modified	by	the	reabsorption	of	sodium	and	the	secretion	of	potassium	and	bicarbonate	ions	making	saliva	hypotonic	(Humphrey	and	Williamson	2001).	This	hypotonicity	allows	for	the	expansion	and	hydration	of	mucin	glycoproteins	and	also	allows	taste	buds	to	perceive	the	different	tastes.	
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	 The	parasympathetic	 and	 the	 sympathetic	branches	of	 the	autonomic	nervous	 system	stimulates	the	secretion	of	saliva	(Kahle	et	al.	2003).	The	amount	of	saliva	produced	by	each	 gland	depends	 on	 the	 extent	 of	 gland	 stimulation	 and	during	 resting	 conditions,	0.3mL/min	is	released	(Wang	et	al.1998).	This	value	differs	among	different	individuals.	The	flow	rate	of	saliva	during	sleep	is	approximately	zero.	During	the	resting	conditions,	the	amount	of	 saliva	produced	by	 the	 submandibular	gland’s	accounts	 for	65%	of	 the	0.3mL/min	 while	 the	 parotid	 gland	 and	 the	 sublingual	 accounts	 for	 20%	 and	 15%	respectively	(Humphrey	and	Williamson	2001).	During	resting	conditions,	any	flow	rate	below	0.1mL/min	is	considered	hypofunction	(Wang	et	al.	1998).	During	stimulation,	the	flow	 rate	 increases	 to	 1.9mL/min	 and	 the	 relative	 contribution	 of	 each	 gland	 varies	significantly	(Wang	et	al.	1998).				 1.8 Human	Saliva	Composition	and	Function		 The	composition	and	flow	rate	of	saliva	differ	from	one	individual	to	another	as	a	result	of	 the	 fluctuations	 in	 secretions	made	 in	different	 salivary	 glands.	 Saliva	 consists	 of	 a	variety	of	electrolytes	such	as	sodium,	magnesium	,	calcium	and	potassium	(Humphrey	and	Williamson	2001).	About	99%	of	the	salivary	fluid	secretion	is	water.	In	addition	to	that,	proteins,	enzymes,	mucosal	glycoproteins	together	with	other	antimicrobial	factors	form	the	core	components	of	saliva	(De	Almeida	et	al.	2008).	Although	the	concentration	of	glucose,	urea	and	ammonia	is	minimal,	they	also	form	part	of	the	complex	components	of	saliva.	The	combination	of	these	factors	gives	saliva	its	multifunctional	characteristics	such	as	digestion,	buffering	effect,	lubrication,	remineralisation	and	the	anti-bacterial	and	anti-fungal	properties	(Levine	et	al.	 1993).	
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1.8.1 Antimicrobial	Properties	of	Saliva		 Several	 antibodies	 and	 non-immunological	 factors	 play	 a	 role	 in	 the	 antimicrobial	defence	of	saliva.	Secretory	immunoglobulin	A	(slgA)	is	the	most	common	antibody	that	plays	a	significant	antimicrobial	role	in	all	mucosal	linings.	It	prevents	the	direct	binding	of	 the	 oral	 cavity	 pathogens	 to	 the	 mucosal	 and	 pellicle	 surfaces.	 It	 also	 aids	 in	 the	agglutination	of	pathogens	by	creating	cross	links	thereby	promoting	clearance	from	the	oral	 cavity	 (Marcotte	 and	 Lovoie	 1998).	 Furthermore,	 slgA	 inhibits	 the	 synthesis	 of	bacteria	in	the	oral	cavity	by	decreasing	the	production	of	siderophores,	a	molecule	which	scavengers	iron	from	lactoferrin	as	a	result	inhibiting	the	proliferation	and	production	of	bacteria	 (Miethke	 and	 Marahiel	 2007).	 IgA	 play	 a	 vital	 role	 in	 inhibiting	 adherence	between	bacteria	and	the	oral	mucosal	surfaces	(Schenkels	et	al.	1995).	In	addition,	slgA	has	been	shown	to	block	bacterial	interactions	with	complementary	surface	receptors	by	binding	to	adhesins	which	reduce	the	surface	charge	of	and	hydrophobicity	of	bacteria	leading	to	steric	hindrance	with	the	host	surface	receptors	(Marcotte	and	Lovoie	1998).	IgM	 and	 IgG	 are	 found	 in	 low	 concentrations	 as	 compared	 to	 IgA.	 These	 antibodies	perform	similar	antimicrobial	functions	(Gronblad	1982).	However,	a	hereditary	lack	of	IgA	has	been	shown	to	cause	an	increase	in	the	susceptibility	of	oral	diseases	questioning	the	clinical	relevance	of	IgA	(Nikfarjam	et	al.	2004).			 On	 the	other	hand,	 saliva	 contains	other	non-immunological	 salivary	proteins	 such	as	lysozymes,	 lactoferrin,	 histatins,	 cystatins,	 proline	 rich	 proteins	 (PRP),	 peroxidases,	salivary	agglutinin	(SAG)	and	mucin	glycoproteins	which	play	a	vital	role	in	protecting	the	oral	cavity	either	by	preventing	the	adhesion	of	the	pathogen	to	the	oral	mucosa	or	neutralising	 the	 pathogen.	 The	 role	 these	 proteins	 play	 protecting	 the	 oral	 cavity	 is	explained	below.			 Lysozyme	is	a	cationic	hydrolase	which	is	found	in	salivary	glands,	leukocytes	and	also	in	gingival	crevicular	fluid	(Dawes	et	al.	2015).	The	cationic	nature	of	this	enzyme	activates	endogenous	 bacterial	 autolysins	 which	 disrupts	 the	 integrity	 of	 the	 cell	 wall	 which	subsequently	destroys	them.	Another	mode	of	action	of	this	enzyme	is	that	it	hydrolyses	
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of	the	𝛃 (1-4)	bond	that	is	found	in	the	peptidoglycan	layer	of	bacterial	cell	walls	between	N-acetylmuramic	acid	and	the	N-acetylglucosamine	which	 inhibits	bacterial	adherence	(Laible	and	Germaine	1985;	Dawes	et	al.	 2015).			 Several	serous	cells	in	saliva	secrete	lactoferrin	which	has	a	broad	range	of	antimicrobial	activities.	This	enzyme	is	a	scavenger	for	iron	and	aids	in	the	process	of	phagocytosis	by	marking	antigen	for	immune	response	and	in	bacterial	clearance	(Jenssen	and	Hancock	2009).	 The	 removal	 of	 iron	 in	 the	 oral	 cavity	 causes	 harm	 on	 the	 survival	 of	 many	microorganisms	 that	 require	 iron	 for	 their	metabolic	 activities	 such	 as	 Streptococcus	mutants	 (Bullen,	 Rogers	 and	 Griffith	 1978;	 Weinberg	 1978;	 Dawes	 et	 al.	 2015).	Furthermore,	the	surface	area	of	lactoferrin	consists	of	large	cationic	charges	which	bind	to	the	cell	membrane	of	gram-negative	bacteria	resulting	in	an	increase	in	the	cell	wall	permeability	that	ultimately	causes	bacterial	lysis	(Jenssen	and	Backvoll	1998).			 The	parotid	and	the	submandibular	glands	produce	peroxidase	or	sialo-peroxidase	which	offers	 antimicrobial	 activities	 by	 oxidizing	 thiocyanate	 in	 the	 presence	 of	 hydrogen	peroxide	 to	hypothiocyanite	which	 is	 a	potent	 antibacterial	 substance	 (Tenovuo	et	 al.	1994).	As	a	result	of	this	process,	the	cells	and	proteins	are	protected	from	the	corrosive	effects	of	hydrogen	peroxide	in	the	oral	cavity	(Edgar	1992;	Humphrey	and	Williamson	2001;	Amerongen	2002).			 Histatins	are	also	secreted	by	the	parotid	and	the	submandibular	glands	and	they	offer	antimicrobial	activity	against	some	strains	of	bacteria	that	are	found	in	the	oral	cavity	by	acting	as	potent	 inhibitors	of	 growth	and	development	 such	as	 in	 the	 case	of	Candida	
albicans	 (Amerongen	 et	 al.	 2002).	 In	 addition	 to	 this,	 the	 histidine	 rich	 peptides	 also	inhibit	 hemagglutination	 of	 perio	 pathogens	 in	 the	 cavity	 mainly	 Porphyromonas	gingivalis	(Murakami	et	al.	1992).	Three	main	types	of	histatins	namely;	histatin	1,	3	and	5	are	found	in	saliva	and	are	all	derivatives	of	histatin	3	(Opeinheim	et	al.	1998).	This		protein	is	also	known	for	its	anti-inflammatory	properties	by	releasing	histamines	which	targets	fungal	mitochondria	(Helmerhost	et	al.	 1994).	
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	 Secretory	 leukocyte	 protease	 inhibitor	 (SPLI)	 is	 a	 serine	 protein	 inhibitor	 that	 also	contributes	to	the	defense	of	the	oral	cavity.	Apart	from	its	antiviral	properties,	SPLI	has	antifungal	and	antibacterial	properties	(Amerongen	et	al.	2002;	Dawes	et	al.	2015).	The	cationic	 nature	 of	 this	 inhibitor	 allows	 it	 to	 bind	 to	 bacterial	 mRNA	 and	 DNA	which	interferes	 with	 the	 translation	 process	 thereby	 inhibiting	 the	 synthesis	 of	 certain	bacterial	strains	in	particular	Escherichia	coli	(Miller	et	al.	1987).			 Salivary	Agglutinin	(SAG)	together	with	mucins	particularly	MUC5B	and	MUC7,	which	are	heavily	glycosylated	proteins,	contribute	to	the	oral	innate	system	via	agglutination	and	aggregation	(Amerongen	et	al.	2002).	This	process	aids	in	the	removal	of	pathogens	by	preventing	them	to	bind	to	the	oral	mucosa	thereby	ensuring	there	is	maximal	clearance	of	the	microorganism	(Fabian	et	al.	2015).	Often	these	heavily	glycosylated	proteins	are	associated	 with	 other	 salivary	 proteins	 such	 as	 slgA	 to	 initiate	 these	 antimicrobial	activities.	The	inhibition	and	clearance	of	bacteria	by	MUC5B	and	MUC7	in	the	oral	cavity	is	well	documented	in	literature.	The	inhibitory	potential	of	these	heavily	glycosylated	mucins	will	be	discussed	further	in	section	two.				 1.9.	Inhibition	Of	HIV-1	by	Human	Saliva		 The	 first	 study	 that	 showed	 evidence	 of	 the	 anti-HIV-1	 activity	 of	 saliva	 in	 vitro	was	demonstrated	by	Fultz	in	1986.	His	resulted	were	further	supported	by	the	findings	of	Fox	 et	 al.	 in	 1990.	 Ever	 since	 then,	 researchers	 have	 conducted	 many	 studies	 in	 an	attempt	 to	 determine	 the	 key	 components	 that	 gives	 saliva	 this	 inhibitory	 potential.	Interestingly,	while	saliva	 inhibited	the	activity	of	HIV-1	in	vitro,	 little	to	no	inhibitory	activity	was	demonstrated	 for	herpes	 simplex	virus	1	 (HSV-1),	 adenovirus,	HIV-2	and	simian	immunodeficiency	virus	(SIV)	(Malamud	et	al.	1993;	Malamud	et	al.	1997).			 Even	 though	 the	 anti-HIV	 activity	 of	 whole	 saliva	 and	 other	 glandular	 secretions	primarily	the	submandibular	has	been	well	documented	and	reported	in	literature,	there	
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is	still	some	inconsistencies	as	to	which	secretion	is	the	most	effective	at	inhibiting	HIV-	1.	(Fox	et	al.	1988;	Archibald	and	Cole	1990;	Malamud	et	al.	1993;	Bergey	et	al.	1994;	Kazmi	et	al.	2006).	At	the	same	time,	less	inhibition	is	shown	from	saliva	secreted	by	the	parotid	gland	(Bergey	et	al.	1993;	Malamud	et	al.	1993;	Kazmi	et	al.	2006).	Most	evidence	of	the	inhibitory	potential	of	saliva	has	been	attributed	to	the	isotonic	nature	of	whole	saliva,	 the	 presence	 of	 immunological	 factors	 that	 defend	 against	 virus	 and	 non-	immunological	 proteins	 of	 the	 innate	 cavity	 which	 provide	 antimicrobial	 defense	(Matsuda	et	al.	1993;	Artenstein	et	al.	1997;	Yasuda	et	al.	1998).			 Cell	to	cell	transmission	of	HIV-1	across	the	mucosal	surfaces	has	been	suggested	to	be	more	 efficient	 as	 compared	 to	 the	 transmission	 of	 cell-free	 virus	 (Kolodkin-Gal	 et	 al.	2013).	 The	 presence	 of	 non-proviral	 DNA	 in	 saliva	was	 demonstrated	 by	 Baron	 et	 al.	(1991).	These	findings	were	supported	by	Baron	et	al.	(1999)	who	demonstrated	that	the	hypotonicity	of	saliva	resulted	in	the	lysis	of	infected	leukocytes	by	osmosis	subsequently	affecting	 the	 replication	 cycle.	 Furthermore,	when	 these	 effects	were	 reversed	 by	 the	addition	of	concentrated	salts	 to	saliva,	no	 lysis	of	cells	occurred	clearly	 indicating	the	function	of	hypotonic	saliva	(Baron,	Poast,	and	Cloyd	1999).			 A	similar	study	was	conducted	on	breast	milk	to	investigate	the	effect	of	its	isotonic	nature	on	 infected	 cells.	 This	 study	 demonstrated	 that	 breast	milk	 is	 diluted	 by	 saliva	which	changes	 its	 tonicity	which	prevents	 the	disruption	of	 infected	 leukocytes	 (Baron	 et	 al.	2000).	 This	 observation	 could	 be	 the	 reason	 why	 there	 is	 variable	 HIV	 transmission	during	 breastfeeding.	 Experiments	 that	 were	 conducted	 on	 physiological	 semen	 also	showed	 the	 same	 observations.	 According	 to	 Baron	 et	 al.	 (2002),	 during	 oral	 sex,	 the	amount	of	HIV	found	in	semen	is	sufficient	to	cause	an	infection	but	the	hypotonicity	of	saliva	inhibits	the	infection	process	allowing	the	viral	particles	to	cross	the	oral	cavity.	However,	these	results	contradict	what	we	know	about	the	rare	nature	of	transmission	of	HIV-1	via	the	oral	cavity	(Romero	et	al.	2002;	Page-Shafer	et	al.	2002).	In	addition	to	this,	the	oral	mucosa	is	susceptible	to	cell	free	virus	which	is	not	disrupted	by	the	hypotonicity	of	saliva	(Moore	et	al.	2003).	Therefore	this	suggests	that	there	are	other	mechanisms	of	inhibition	that	are	provided	by	saliva.	
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	 Salivary	antibodies	namely	SlgA	and	SlgM	are	known	to	play	a	role	 in	the	 inhibition	of	HIV-1.	These	antibodies	are	highly	detected	 in	HIV	positive	 individuals	 (Matsuda	et	al.	1993;	Artenstein	et	al.	1997;	Yasuda	et	al.	1998).	Furthermore,	studies	have	shown	that	individuals	 that	are	exposed	but	not	 infected	with	HIV	have	detectable	 levels	of	active	HIV-1	specific	antibodies	(Devito	et	al.	2000;	Broliden	et	al.	2001;	Farquhar	et	al.	2008).	These	salivary	antibodies	have	been	shown	to	inhibit	HIV-1	in	vitro.	(Cartry	et	al.	1997;	Moja	et	al.	2000).	IgA	is	one	of	 the	major	mucosal	antibody	with	the	highest	concentration	in	the	parotid	secretions.	It	shows	a	high	reactivity	against	the	pol	and	env	products	of	HIV-1	(Cartry	et	al.	1997;	Moja	et	al.	2000).	The	inhibition	of	HIV-1	by	saliva	from	both	positive	and	negative	individuals	provides	proof	that	HIV	specific	antibodies	cannot	solely	be	responsible	for	the	inhibition	of	saliva	against	HIV	(Fox	et	al.	1989).			 Although	HIV-1	infection	elicit	an	immune	response,	there	is	still	a	 lot	of	evidence	that	demonstrates	the	role	of	non-immunological	 factors	 in	the	 inhibition	of	HIV-1.	Mucins,	SAG,	 SPL1,	 defensins	 and	 lactoferrin	 are	 the	 major	 salivary	 proteins	 that	 have	 been	implicated	in	the	anti-HIV-1	activity	of	human	saliva.	The	degree	to	which	these	proteins	contribute	towards	this	inhibitory	activity	is	debatable.			 A	number	of	electron	microscopy	studies	and	filtration	experiments	have	shown	that	the	inhibition	of	the	HIV-1	particles	by	saliva	is	via	aggregation	or	agglutination	and	this	has	become	the	proposed	mechanism	through	which	viral	inhibition	occurs	(Archibald	and	Cole	1990;	Yeh	et	al.	1992;	Malamud	et	al.	1993;	Bergey	et	al.	1993).	The	incubation	of	whole	saliva	and	secretions	from	the	submandibular	glands	with	HIV-1	particles,	followed	by	a	passage	through	a	0.45μm	filter	showed	a	reduction	in	the	transmission	of	the	virus	(Archibald	and	Cole	1990;	Yeh	et	al.	1992;	Malamud	et	al.	1993).	This	reduction	in	viral	activity	was	 proposed	 to	 be	 caused	 by	 high	molecular	weight	mucin	 glycoproteins	 in	saliva	(Bergey	et	al.	1994).	This	postulation	was	supported	by	Malamud	(1993),	when	he	demonstrated	that	saliva	from	the	parotid	gland,	which	is	devoid	of	mucins	showed	no	interaction	or	activity	with	HIV-1	particles.	Moreover,	the	highest	antiviral	activity	was	detected	from	the	secretions	of	the	sublingual	and	the	submandibular	glands	(Malamud	
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et	al.	1993).	Further	studies	also	demonstrated	that	there	is	a	strong	association	which	occurs	 between	 the	 salivary	mucin,	MUC7	 and	 the	 submandibular	 protein,	 SAG	which	results	in	the	formation	of	a	complex	with	the	HIV-1	env	protein	gp120	virus,	causing	the	dissociation	of	gp120	from	the	virus	(Nagashunmugam	et	al.	1998).	Therefore,	it	has	been	hypothesized	 that	 salivary	 glycoproteins	 inhibit	 viral	 infection	 and	 replication	 by	aggregation	of	viral	particles	or	by	shedding	of	the	viral	envelope.	(Nagashunmugam	et	al.	1998).			
In-vitro	studies	have	confirmed	MUC5B	and	MUC7	as	the	major	salivary	glycoproteins	that	inhibits	HIV-1	transmission.	In	addition	to	this,	crude	and	purified	breastmilk,	pregnant	mucus	plugs	together	with	other	purified	mucins	from	other	parts	of	the	body	have	also	been	demonstrated	to	 inhibit	viral	replication	(Habte	et	al.	2006;	Habte,	de	Beer,	Lotz,	Tyler,	Schoeman,	et	al.	2008;	Mthembu	et	al.	2014).			 Yeh	et	al.	(1992)	noted	that	after	the	filtration	of	whole	saliva	with	HIV	particles,	there	still	 remained	 intact	 HIV-1	 particles	 in	 the	 filtrate	 that	 were	 sufficient	 to	 cause	 viral	infection	 (Yeh	 et	 al.	 1992).	 This	 experiment	 provided	 a	 possibility	 that	 other	 small	filtrable	soluble	components	played	an	important	role	in	the	inhibition	of	HIV-1.	One	such	factor	is	SLPI,	a	cationic	serine	protein	which	has	a	molecular	weight	of	11.7kDa.	Its	anti-	activity	 was	 first	 demonstrated	 in	 monocytes	 and	 CD4	 cells	 at	 physiological	concentration.	 This	 protein	 interacts	 with	 the	 host	 cells	 preventing	 viral	 binding	 and	subsequent	viral	 infection	to	occur	(McNeely	et	al.	1995;	McNeely	et	al.	1997;	Shugars,	Sauls,	and	Weinberg	1997;	Ma	et	al.	2004).	SLPI	is	also	a	target	to	annexin	11,	a	cofactor	protein	for	macrophage	HIV-1	infection	(Ma	et	al.	2004).	Contrary	to	this	finding,	a	study	by	 Turpin	 et	 al.	 (1996)	 showed	 no	 inhibitory	 activity	 of	 HIV-1	 by	 SLPI	 	 when	 tested	under	different	conditions	such	as	 the	use	of	different	strains	of	HIV-1,	using	different	target	cell	lines	(Turpin	et	al.	1996).	These	results	were	further	supported	by	findings	of	Konopka	et	 al.	 (1999)	who	 suggested	 that	 the	 variable	 effects	 shown	by	SLPI	when	 it	came	to	viral	replication	and	infection	was	because	of	the	differential	expression	of	cell	surface	molecules	on	the	target	cells.	These	surface	molecules	could	either	allow	SLPI	to	
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																bind	to	host	cells	and	hinder	host	cell	infection	or	they	could	cause	steric	hindrance.			 In	 an	 attempt	 to	 elucidate	 the	 role	 of	 	 SLPI,	 Kazmi	 et	 al.	 (2006)	 demonstrated	 that	 in	addition	to	SLPI,	two	other	salivary	proteins	of	different	molecular	weight	sizes	displayed	inhibition	against	HIV-1.	These	results	revealed	lactoferrin,	an	80	kDa	protein	as	the	most	potent,	 followed	 by	 SLPI	 and	MUC7	 (Kazmi	 et	 al.	 2006).	He	 then	 proposed	 that	 these	salivary	 components	 affect	 the	 HIV-1	 cycle	 at	 different	 stages	 hence	 the	 difference	 in	potency.	This	postulation	was	 in	agreement	with	 the	 findings	of	Bolscher	et	al.	 (2002)	when	he	showed	 that	inhibition	can	occur	before	and	after	HIV-1	replication	(Bolscher	et	al.	 2002).			 The	two	different	forms	of	lactoferrin,	human	and	bovine	have	been	shown	to	inhibit	HIV-	1	in	vitro	(Harmsen	et	al.	1995;	Berkhout	et	al.	2002;	Berkhout	et	al.	2004).	Lactoferrin	has	been	shown	to	inhibit	the	HIV-1	infection	cycle	enzyme,	reverse	transcriptase	(Ng	et	al.	2001).	Furthermore,	it	has	been	shown	to	cause	viral	shedding	of	HIV-1	particles	by	binding	to	the	V3	domain	of	HIV-1	gp120	(Swart	et	al.	1998)	and	blocks	viral	transmission	to	host	cells	by	binding	to	the	dendritic	cell-specific	 intercellular	adhesion	molecule-3-	grabbing	non-integrin	(DC-SIGN)	(Groot	et	al.	2005).	
	
	 An	agreement	as	to	which	salivary	factor	contribute	the	most	in	providing	defense	against	microbial	colonization	in	the	oral	cavity	is	still	yet	to	be	reached.	It	is	still	very	difficult	to	 compare	which	 salivary	 protein	 has	 the	 greatest	 potency	 due	 to	 the	 variation	 that	exists	between	the	viral	strains,	the	type	of	target	cells	used,	experimental	conditions	and	the	benchmark	 that	 is	used	 to	determine	 inhibition.	 In	 spite	of	 that,	 the	 experimental	results	and	hypothesis	postulated	all	provide	evidence	that	saliva	contains	components	which	provide	a	synergistic	effect	(Yeh	et	al.	1992;	Bolscher	et	al.	2002;	Kazmi	et	al.	2006).	
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CHAPTER	TWO:	THE	INHIBITION	OF	HIV-1	BY	SALIVARY	MUC5B	AND	MUC7	FROM	SELF	DECLARED	HIV-	NEGATIVE	INDIVIDUALS.		 GENERAL	INTRODUCTION		 2.1 Mucus		 The	 epithelial	 surfaces	 of	 the	 respiratory	 tract,	 the	 reproductive	 tract,	 the	 auditory	system,	the	gastrointestinal	tract,	the	oral	cavity	and	the	lacrimal	glands	are	protected	from	dehydration	by	a	viscoelastic	gel	secreted	by	the	mucosa	(Allen	1978;	Perez-Vilar	&	Mabolo	2007).	This	mucus	gel	is	composed	of	water,	mucus	secretions,	ions,	proteins	and	lipids	together	with	mucous	glycoproteins	but	the	composition	of	these	molecules	vary	in	some	pathophysiological	cases	(Creeth	1978;	Rachagani	et	al.	2009).	The	main	function	of	this	crude	mucus	gel	is	to	act	as	a	lubricant	and	provide	a	barrier	against	the	external	hostile	 environment	 of	 the	 lumen	 (Allen	 1978;	 Sellers	 et	 al.	 1988).	 Its	 localisation	 is	usually	associated	with	the	specific	function	of	the	organ.	For	example,	in	the	stomach	the	mucus	secreted	protects	the	epithelial	lining	of	the	stomach	from	the	mechanical	force	and	abrasive	effects	of	hydrochloric	acid	used	in	digestion	(Allen	1981).	In	the	respiratory	tract,	foreign	particles	are	trapped	by	this	mucus	gel	and	are	subsequently	removed	with	the	help	of	the	ciliary	action	(Fahy	et	al.	2010;	Mall	et	al.	2017).	In	addition,	the	mucus	produced	 in	 the	 vagina	 protects	 the	 epithelium	 during	 sexual	 intercourse	 and	 during	menstruation,	 the	 cervical	mucus	plug	 thickness	 change	 in	anticipation	of	 fertilisation	(Allen	1981;	Carlstedt	et	al.	1983).	The	epithelial	surface	of	the	colon	is	protected	by	a	mucus	layer	from	bacteria	and	the	hard	faecal	material.	This	muco-adhesive	layer	also	acts	as	a	lubricant	against	the	detergent	effects	of	bile	and	other	surface	active	chemicals	in	the	epithelium	of	the	gallbladder	(Van	der	Sluis	et	al.	2006;	Johansson	et	al.	 2008;	Mall	et	al.	2017).		 2.2 Mucins	and	Their	Types		 Mucins	 are	 high	molecular	weight,	 heavily	 glycosylated	 proteins	which	 form	 the	 core	components	of	mucus	gels	(Forstner	et	al.	1994;	Corfield	et	al.	2001).	They	provide	the	
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rheological	and	physicochemical	properties	of	crude	mucus	which	gives	them	the	ability	to	form	gels	and	aid	in	their	viscosity	(Allen	1978;	Sellers	et	al.	1988).	The	protein	cores	of	mucins	(apo	mucins)	are	encoded	by	mucin	genes	and	they	undergo	extensive	post	translational	modification	which	 results	 in	 the	 heavily	 glycosylated	 nature	 of	 mucins	(Zalewska	et	al.	2000).	The	amino	acid	composition	and	chromosomal	location	of	mucins	divides	 them	 into	 structurally	 and	 functionally	 distinct	 groups	 (Sasaki	 et	 al.	 2007).	Currently,	 mucins	 are	 divided	 into	 three	 categories	 namely;	 the	 membrane	 bound	mucins,	the	secreted	gel	forming	mucins	and	the	non-gel	forming	mucins	also	known	as	the	 soluble	mucins	 (Rose	and	Voynow	2006;	Corfield	2015).	MUC2,	MUC5AC,	MUC5B,	MUC6	and	MUC19	are	secreted	gel	forming	mucins	and	they	have	cysteine	rich	domains	whilst	MUC7,	MUC8	and	MUC9	are	the	non-gel	forming	mucins	(Rose	&	Voynow	2006;	Rousseau	et	al.	2008;	Rachagani	et	al.	2009;	Zalewska	et	al.	2000).	The	membrane-bound	mucins	include	MUC1,	MUC3,	MUC3B,	MUC4,	MUC11,	MUC12,	MUC13,	MUC16,	MUC17,	MUC20	together	with	MUC21	(Rose	and	Voynow	2006;	Mall	2008	Corfield	2015;	Frenkel	et	al.	2015).These	mucins	are	important	for	cell	to	cell	signal	transduction	and	for	cell	to	extracellular	matrix	interactions	due	to	their	association	with	cytosolic	and	cytoskeletal	proteins	(Rachagani	et	al.	2009;	Jonckheere	et	al.	2010	;	Mall	et	al.	2017).	Transmembrane	mucins	 also	 play	 a	 role	 in	 the	 biological	 properties	 of	 cancerous	 cells.	 For	 example,	MUC16	is	used	as	a	diagnostic	marker	for	ovarian	cancer	because	of	its	highly	elevated	levels	in	patients	that	suffer	from	this	disease	(Jonckheere	et	al.	2010;	Marcos-Silva	et	al.	2014;	Das	et	al.	2015;	Mall	et	al.	2017).		 2.3 The	Physical	and	Biochemical	Structure	Of	Mucins		 Mucins	consists	of	a	protein	backbone	which	is	linked	to	a	carbohydrate	side	chain	via	an	O-linked	glycosidic	bond	to	either	serine	and	threonine	residues	(Yurewicz	&	Moghissi,	1981).	 Each	 mucin	 subunit	 consists	 of	 areas	 that	 are	 both	 glycosylated	 and	 non-	glycosylated.	It	should	be	noted	that	glycosylation	of	mucins	mainly	occurs	in	the	protein	core	region	that	has	variable	tandem	repeats	of	serine,	proline	and	threonine	residues	(Pigman	et	al.	1973;	Allen	1982;	Zalewska	et	al.	2000).	The	tandem	repeats	in	the	protein	core	of	mucins	vary	considerably	and	are	altered	by	either	O-linked	glycans	or	a	few	N-	linked	glycans	(Rachagani	et	al.2009).	About	80%	of	the	mucin	moiety	 is	composed	of	oligosaccharides	which	results	in	their	high	molecular	weight	and	also	serve	to	protect	
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the	protein	 core	 structure	of	mucins	 from	proteolytic	 degradation	 (Carlstedt	&	 Sheen	1984).	The	sequence	and	extent	of	glycosylation	vary	depending	on	the	localisation	of	the	mucin	(Wu,	Sako	and	Herp	1994).	Mucin	 oligosaccharides	 consists	 primarily	 of	 N-acetylgalactosamine	 (GalNAc),	 N-	acetylglucosamine	 (GlcNAc),	 N-acetylneuraminic	 acid	 (NeuAc,	 a	 sialidase)	 fucose	 and	galactose	(Zalewska	et	al.	2000	Bansil	et	al.	2006).	The	N-acetylgalactosamine	(GalNAc)	is	responsible	for	linking	the	carbohydrates	side	chains	to	the	protein	core	of	mucins	via	serine	 and	 threonine	 residues	 (Allen	 1981).	 The	 proline	 residue	 is	 responsible	 for	keeping	the	interactions	between	the	carbohydrate	side	chains	tight	(Allen	1981).	The	cysteine	residues	found	in	the	naked	regions	of	the	protein	core	structure	of	mucins	are	joined	together	by	disulphide	bonds	to	form	mucin	subunits	(Carlstedt	&	Sheehan	1984).	These	 subunits	 have	 carbohydrates	 side	 chains	 which	 repel	 one	 another	 resulting	 in	mucin	 gel	 polymers,	 which	 upon	 increase	 in	 mucin	 concentration,	 increases	 their	viscosity	(Sellers	et	al.	1988).	The	negative	charge	found	on	mucins	is	due	to	the	presence	of	sialic	acid	and	fucose	(Rose	and	Voynow	2006).		 2.4 Confirmation	of	Mucin	Structure		 When	 it	 comes	 to	 the	 structure	 and	 conformation	 of	 mucins,	 there	 has	 been	 some	controversy.	 Two	 different	models	 have	 been	 hypothesised.	 Using	 pig	 gastric	 mucus,	Allen	and	co-workers	proposed	the	 ‘windmill’	 theory	of	mucins.	He	demonstrated	that	when	purified	mucins	of	molecular	weight	2	x	106	daltons	were	reduced	by	disrupting	the	disulphide	bonds,	four	glycoprotein	subunits	each	weighing	5x106	were	produced.	The	C	terminal	 region	of	 these	 subunits	were	 joined	 together	by	disulphide	bonds	via	a	 low	molecular	weight	 interlinking	protein	(Figure	1).	The	structure	 looked	 like	a	windmill	and	this	became	known	as	the	windmill	theory	(Allen	and	Snary	1972;	Scawen	and	Allen	1977;	Pearson,	Allen,	and	Parry	1981).	
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Figure	1	The	windmill	model	of	mucin	structure	as	described	by	Allen	et	al.	(1972).This	illustration	showed	4	 glycoprotein	
subunits	that	were	joined	together	by	disulphide	bonds	via	an	interlinking	protein.	
	
	
	 A	different	model	in	which	mucins	were	joined	end	to	end	through	disulphide	bonds	in	a	linear	structure	was	proposed	by	Carlstedt	et	al.	(1984).	The	conformation	of	these	linear	bound	 mucins	 had	 naked	 regions	 in	 between	 the	 glycosylated	 regions	 resulting	 in	 a	random	coil	structure	(Carlstedt	and	Sheehan	1984a;	Carlstedt	and	Sheehan	1984b).	This	random	 coil	 theory	 was	 supported	 by	 the	 molecular	 weight	 and	 shape	 sensitive	parameters	 of	 the	mucin	 glycoprotein	 (Carlstedt	 and	 Sheehan	 1984b).	 The	molecular	weight	observed	by	Carlstedt	group	was	larger	as	compared	to	the	one	reported	by	Allen	and	Snary.	Mucins	weighed	between	10	x	106	Dalton	and	45	x	106	Daltons	and	upon	
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Figure	2	The	random	coil	model	of	mucin	structure	proposed	by	Carlstedt	et	al.	(1984).	Mucins	joined	end	to	end	through	
disulphide	bonds	in	a	randomly	coiled	manner.	
	 further	experiments,	the	shape	sensitive	parameters	did	not	change	on	reduction	of	these	macromolecules(Figure	2)	(Carlstedt	and	Sheehan	1984a;	Carlstedt	and	Sheehan	1984b).			 In	trying	to	solve	the	disparities	between	the	two	structures,	Mall	et	al.	(1988)	attributed	these	 differences	 to	 the	 extraction	methods	 that	was	 used	 during	mucin	 purification.	Allen	et	al.	(1972,	1977,	and	1981)	used	0.2M	sodium	chloride	(NaCl)	as	an	extraction	buffer	and	did	not	consider	the	effects	of	endogenous	proteolysis.	It	is	thought	that	the	absence	of	protease	inhibitors	in	this	medium	could	have	caused	mucins	to	separate	into	subunits	 or	 lead	 to	 the	 proteolytic	 degradation	 of	 the	 naked	 regions	 of	 mucins	subsequently	 resulting	 in	 a	 smaller	 size	 mucin	 conformation	 or	 the	 windmill	 model	(Scawen	and	Allen	1977;	Allen	and	Snary	1972;	Pearson,	Allen,	and	Parry	1981).	On	the	other	 hand,	 Carlstedt	 and	 co-workers	 (1984)	 used	 a	 highly	 chaotropic	 medium,	Guanidinium	chloride	(GuHCL),	which	contained	a	cocktail	of	protease	inhibitors.	These	Inhibitors	denatured	all	the	proteolytic	enzymes	and	also	disrupted	the	tertiary	structure	of	mucins	 resulting	 in	 the	 linear	model	 (Carlstedt	 and	 Sheehan	 1984a;	 Carlstedt	 and	Sheehan	1984b;	Mall	et	al.	1988).	Even	though	there	is	still	some	dispute	regarding	the	
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conformation	 of	 mucins,	 the	 linear	 model	 has	 been	 proposed	 to	 be	 an	 accurate	description	of	 the	conformation	of	 the	gel	 forming	mucins	 (Mall,	1988).	GuHCL	 is	 still		being	used	as	an	extraction	buffer	for	mucins	because	of	its	ability	to	keep	the	integrity	of	 mucins	 intact	 and	 also	 during	 purification	 where	 it	 prevents	 proteins	 and	 other	impurities	 from	 binding	 to	 mucin	 glycoproteins	 (Thornton	 et	 al.	 2001).	 It	 has	 been	suggested	by	Mall	 (1988)	 that	 the	dialysis	removal	of	GuHCL	results	 in	aggregation	of	mucins.		 2.5 Salivary	Mucins		 Two	structurally	distinct,	carbohydrate	rich	mucins	namely	MG1	and	MG2	are	present	in	saliva	(Thornton	et	al.	1999).	These	mucins	contribute	to	the	rheological	properties	of	saliva	such	as	viscosity	and	elasticity	and	they	are	secreted	by	the	submandibular	and	the	sublingual	glands	(Zalewska	et	al.	2004).	On	the	other	hand,	the	parotid	gland	is	devoid	of	salivary	mucins	(Veerman	et.al	1996).	MUC5B	also	known	as	MG1	is	a	high	molecular	weight	 mucin	 whose	 function	 is	 associated	 with	 the	 encapsulation	 of	 a	 number	 of	microorganisms	(Thornton	et.	al.	1999).	This	mucin	mainly	contributes	to	the	viscous	and	elastic	 nature	 of	 saliva.	 MUC5B	 is	 a	 heavily	 glycosylated	 protein	 of	 higher	molecular	weight,	 which	 is	 encoded	 by	 MUC5B	 gene	 on	 chromosome	 11,	 locus	 p15.5	 (Rose	 &	Voynow,	2006).	It	is	one	of	the	widely	distributed	mucins	in	saliva,	the	female	genital	tract	and	 in	 the	respiratory	 tract	 (Argueso	et.	 al,	2002).	MUC7	also	known	as	MG2	 is	a	 low	molecular	weight	mucin	which	gives	saliva	its	stickiness	(Amerongen	et	al.	2007).	This	mucin	is	located	on	Chromosome	4q13.q21	and	has	of	approximately	120	000	Da	(Rose	&	Voynow,	2006).	Unlike	MUC5B,	MUC7	is	only	found	in	saliva.	These	two	salivary	mucins	have	distinctive	domain	structure	which	influence	their	physical	characteristics	and	their	localization	in	the	oral	cavity	(Linden	et.	al	1998).	Chen	et	al.	(2004)	demonstrated	the	presence	of	MUC19	in	human	saliva	but	no	putative	peptides	have	been	detected	since	then	(Rousseau	et	al.	2008).		 2.6 MUC5B		 MUC5B	is	one	of	the	largest	oligomeric	gel	forming	mucins	which	has	subunits	linked	to	disulphide	bonds	which	are	estimated	to	be	between	2.5-2.9x106Da	each	(Thornton	et	al.	
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1999).	This	mucin	is	primarily	secreted	by	the	salivary	mucous	cells	(Bolscher	et	al.	1995;	Nielsen	et	al.	1997).	MUC5B	has	been	detected	in	the	epithelium	of	the	esophageal,	the	endocervix	and	in	the	pancreatobiliary	system	(Audie	et	al.1993;	Thornton	et	al.	1999;	Vandenhaute	et	al.	1997).			 The	gene	coding	for	MUC5B	is	clustered	with	MUC2,	MUC5AC	and	MUC6	which	are	all	gel	forming	mucins	on	chromosome	11p15.5	(Desseyn,	Guyonnet-Dupérat	et	al.	1997).	The	apo	mucin	core	of	MUC5B	is	made	up	of	5000	amino	acids	which	are	divided	into	different	domains	namely	the	N-terminal,	the	central	and	the	C	domain.	The	N-terminal	domain	has	4	sites	where	N-linked	glycosylation	occurs,	and	this	cysteine	rich	domain	consists	of	450	amino	acids	(Cao	et	al.	2012).	The	glycosylated	structure	of	MUC5B	results	in	a	heavy	molecular	weight	of	14	–	40MDa	(Piras	et	al.	2011).			 The	central	domain	is	made	up	of	3750	amino	acids	which	are	encoded	by	an	exon	and	are	divided	into	19	subdomains	(Desseyn,	Guyonnet-Dupérat,	et	al.	1997;	Zalewska	et	al.	2000).	 The	 central	 subdomains	 contain	 seven	 cysteine	 rich	 domains	 named	 (Cys1-7),	three	subdomains	that	have	no	repeats	known	as	(RO1-RO3),	five	tandem	rich	repeats	regions	 that	 are	 irregular	 called	 (RI-RV)	 and	 four	 uniquely	 conserved	domains	which	have	no	repeats	known	as	(RI-end	–	RIV-end)	(Desseyn,	Guyonnet-Dupérat,	et	al.	1997;	Zalewska	et	al.	2000;	Cao	et	al.	2012).	These	subdomains	tend	to	form	composite	super	repeats	which	have	alternating	subdomains	of	 the	cysteine	 rich	 repeats,	one	 irregular	tandem	 repeat	 subdomain	 with	 11	 repeats	 of	 the	 irregular	 repeat	 of	 29	 amino	 acid	residues,	 and	 a	 unique	 conserved	 subdomain	with	 no	 typical	 repeats	 (Zalewska	 et	 al.	2000).			 The	amino	acid	content	of	the	central	domain	consists	of	serine,	proline	and	threonine.	Serine	constituents	27%	of	 the	whole	amino	acid	content	while	 threonine	and	proline	contribute	12.9%	and	10.6%	respectively	(Zalewska	et	al.	2000).	The	irregular	tandem	repeats,	RI-end	subdomains	and	subdomains	with	no	repeats	are	sites	that	are	usually	O-	glycosylated	(Zalewska	et	al.	2000).	The	site	at	which	a	GalNAc	attachment	forms	has	an	amino	 acid	 sequence	 known	 as	 TXXP	 (where	 X	 is	 any	 amino	 acid)	which	 starts	with	
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threonine	 followed	by	 any	 two	 amino	 acids	 and	proline.	 This	 site	 also	 contains	many	irregular	tandem	repeats	subdomains	and	most	of	this	sequence	is	 found	in	the	R-end	subdomain	(Zalewska	et	al.	2000).	There	are	only	seven	potential	sites	of	N-glycosylation	throughout	the	whole	central	domain	of	MUC5B	(Zalewska	et	al.	2000).	The	cysteine	rich	residues	found	in	the	central	domain	are	the	formation	sites	of	disulphide	bridges	and	it	is	reported	that	little	glycosylation	occurs	in	this	area	(Zalewska	et	al.	2000).			 MUC5B	structure	is	referred	to	as	the	bottle	brush	because	of	the	oligosaccharide	chains	which	range	between	1-20	residues	that	are	clustered	on	the	super-repeat	subdomains.	Each	monomeric	unit	consists	of	approximately	290	O-linked	chains	that	have	sialic	acids	at	 the	non-reducing	ends	(Thomsson	et	al.	2002).	The	presence	of	different	sulphated	oligosaccharides	 and	 sialic	 acid	 side	 chains	 on	 MUC5B	 has	 resulted	 in	 different	glycoforms	of	MUC5B	 (Bolscher	 et	 al.	 1995;	Wickström	et	 al.	 1998).	 The	C	domain	of	MUC5B	contains	808	amino	acid	residues	which	have	a	high	proline	and	cysteine	content	(Desseyn,	Aubert,	 et	 al.	 1997).	 The	 location	 and	number	of	 cysteine	 residues	 in	 the	C	domain	of	MUC5B	 is	 similar	 to	MUC2,	MUC5AC	and	 the	 on	 the	 von	Willebrand	 factor	(Troxler	et	al.	1997;	Gum	et	al.	1992;	Meezaman	et	al.	1994;	Titani	et	al.	1986).	In	addition,	this	section	is	also	largely	N-glycosylated	and	contains	many	naked	protein	regions	which	are	sites	of	hydrophobic	binding	(Cao	et	al.	2012;	Loomis	et	al.	1987).	The	gel	forming	properties	of	MUC5B	are	because	of	its	ability	to	form	disulphide	bonds	with	other	mucin	subunits	(Zalewska	et	al.	2000).	
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2.6.1 MUC7		 MUC7	 has	 a	 molecular	 mass	 that	 ranges	 between	 150-200	 kDa	 and	 is	 smaller	 as	compared	to	the	other	salivary	mucin	MUC5B	(Mehrotra,	Thornton	and	Sheehan	1998).	The	glycosylation	sites	present	 in	MUC7	are	 less	as	compared	to	MUC5B	and	so	 is	 the	length	of	the	oligosaccharide	chains	(Levine	et	al.	1987;	Thomsson	et	al.	2002).	This	non-	gel	forming	mucin	is	located	on	chromosome	4q13-2	and	is	found	only	in	saliva,	secreted	by	 the	 serous	 cells	 of	 the	 submandibular,	 sublingual	 and	 palatine	 salivary	 glands	(Bolscher	et	al.	1999).			 Similar	to	MUC5B,	MUC7	has	a	mid-section	domain	that	which	is	flanked	by	an	N-terminal	and	C-terminal	domain.	The	apo	mucin	core	of	MUC7	is	made	of	357	amino	acids	of	which	144	residues	together	with	the	only	two	cysteine	residues	found	in	MUC7	make	up	the	N-	terminal	domain	(Zalewska	et	al.	2000).	This	domain	 is	a	site	 for	both	N	and	O	 linked	glycosylation	 specifically	 4	 N-glycosylation	 sites	 and	 9	 O-linked	 glycosylation	 sites	(Zalewska	et	al.	2000).	The	central	domain	of	MUC7	has	a	high	content	of	proline	and	serine	 and	 is	 a	 potential	 0-glycosylation	 site.	 The	O	 linked	 glycosylation	 chain	 of	 this	domain	 forms	 a	 chain	 of	 about	 2	 to	 7	 monosaccharides	 that	 are	 held	 together	 by	disulphide	bonds	(Reddy,	Levine,	and	Prakobphol	1985;	Levine	et	al.	1987).	This	domain	contains	138	amino	acids	which	compose	of	23	 tandem	repeats	 residues	 (Vinall	 et	 al.	2000).	The	oligosaccharide	composition	of	MUC7	consist	of	NeuAcα2,	3Galβ1,	3GalNAc,	Galβ1,	3GalNAc,	and	Fucα1,	2Galβ1,	3GalNAc	(Levine	et	al.	1987).			 No	cysteine	residues	are	found	in	the	C-terminal	domain	of	MUC7,	but	this	domain	has	a	high	 proline	 content	 and	 consequently	 it’s	 a	 potential	 site	 for	 both	 N	 and	 O	 linked	glycosylation	(Zalewska	et	al.	2000).	The	 lack	of	cysteine	residues	on	 the	C	domain	of	MUC	causes	MUC7	to	form	monomers	only	rather	than	polymers.	This	monomeric	mucin	is	non-	gel	forming,	comprises	of	74	amino	acids	and	its	subunits	tend	to	aggregate	due	to	the	presence	of	cysteine	residues	found	on	the	N	terminal	domain	that	self-associate	(Mehrotra,	Thornton,	and	Sheehan	1998).	To	date,	two	forms	of	MUC7	have	been	
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identified	and	these	glycoforms	have	the	same	core	amino	acid	sequence	but	the	content	of	fucose	and	sialic	acids	differ	(Ramasubbu	et	al.	1991).				 2.7 The	Role	of	Salivary	Mucins		 Salivary	 mucins	 play	 a	 number	 of	 functions	 in	 the	 oral	 cavity.	 They	 are	 involved	 in	lubrication,	modulation	of	the	oral	flora,	formation	of	mucosal	coat,	and	the	production	of	an	enamel	pellicle	(Tabak	et	al.	1985).	MUC5B	aids	in	the	formation	of	this	pellicle	coat	whose	function	is	associated	with	the	protection	of	the	tooth	and	oral	surfaces	from	acidic	challenges	 (Tabak	 et	 al.	 1985;	Nieuw	Amerongen,	Oderkerk,	 and	Driessen	1987).	 The	removal	of	mucins	from	submandibular	and	sublingual	saliva	before	the	formation	of	the	pellicle	 coat	 has	 shown	 a	 70%	 reduction	 in	 artificial	 pellicle	 ability	 to	 inhibit	demineralisation	of	dental	enamel	i.e	(dental	caries)	showing	the	importance	of	salivary	mucins	(Nieuw	Amerongen,	Oderkerk,	and	Driessen	1987).			 An	 important	 function	 of	 salivary	 mucins	 is	 the	 modulation	 of	 the	 oral	 flora	 which	subsequently	control	the	colonisation	of	oral	microorganisms.	A	number	of	mechanisms	are	involved	in	the	regulation	of	the	oral	microflora	by	MUC5B	and	MUC7.	As	discussed	in	chapter	1,	they	associate	with	antimicrobial	protein	such	as	SlgA	at	the	mucosal	surface	where	 they	 are	 concentrated	 and	 retained	 to	 perform	 their	 antimicrobial	 activity	(Frenkel	and	Ribbeck	2015a;	Gibbins	et	al.	2015).	They	also	exert	direct	association	with	oral	 bacteria.	 For	 example,	 MUC5B	 is	 known	 to	 decrease	 the	 ability	 of	 Streptococcus	
mutans	to	attach	to	the	oral	surface	and	form	biofilms	by	isolation	(Frenkel	and	Ribbeck	2015b).	This	isolation	prevents	the	formation	of	oral	infections,	which	are	caused	by	the	metabolic	by-products	of	S.	mutans	(Frenkel	and	Ribbeck	2015).	It	has	been	postulated	that	salivary	mucins	protect	the	oral	cavity	by	aggregation	of	bacteria,	which	facilitates	their	removal	during	swallowing.	In	addition,	bacteria	also	bind	specifically	to	different	glycans,	which	facilitates	their	selective	disposal.	
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Salivary	mucins	are	also	known	to	facilitate	oral	clearance	of	microorganisms	by	inducing	bacterial	aggregation	and	by	preventing	bacterial	adherence	to	the	oral	cavity	(Gibbons	and	 Qureshi	 1978;	 Koop	 et	 al.	 1990).	 It	 has	 been	well	 documented	 that	MUC7	 is	 the	bacterial	binding	mucin	unlike	MUC5B.	MUC7	has	been	associated	with	specific	bacterial	strains	in	particular	the	streptococci	strain	(Murray	et	al.	1982;	Ligtenberg	et	al.	1992;	Murray	et	al.	1992).	Tabak	(1990)	demonstrated	that	saliva	that	was	depleted	of	MUC7	and	not	MUC5B	could	cause	agglutination	and	subsequently	abolish	the	activity	of	certain	
streptococci	strains.	Moreover,	 he	demonstrated	 that	 sialic	 acids	present	on	 the	MUC7	glycans	 were	 involved	 in	 the	 binding	 to	 bacteria	 including	 several	 Streptococcus	
gordonii	and	Streptococcus	sanguis	strains	(Murray	et	al.	1992;	Levine	et	al.	1978).			 The	trisaccharide	sequence	NeuAcα2,	3Galβ31,	3	GalNAc	found	on	MUC7	is	a	target	site	for	 bacterial	 binding	 (Murray	 et	 al.	 1982).	E.	 coli	and	 Staphylococcus	aureus	are	 non-	streptococcal	 bacteria	 known	 to	 bind	 to	 this	 salivary	 mucins	 (Moshier,	 Reddy,	 and	Scannapieco	1996;	Heo	et	al.	2013).	In	addition,	the	N	terminal	region	of	MUC7	consists	of	cationic	peptides	and	histatin	5	peptides	that	are	shown	to	exert	antifungal	activity	in	vitro	 (Bobek	 and	 Situ	 2003;	 Smith	 and	 Bobek	 2001).	 Furthermore,	 Situ	 et	 al.(2003)	demonstrated	that	MUC7	had	a	strong	antifungal	activity	against	Candida	albicans	and	
Cryptococcus	 neoformans.	 The	 loss	 of	 salivary	 function	 has	 been	 reported	 in	 cases	associated	 with	 speech	 impairment,	 in	 orodental	 disease	 and	 in	 dysphagia,	 which	significantly	affects	the	quality	of	life.	This	gives	more	insight	on	the	role	of	saliva.			 2.7.1 Mucins	and	Anti-HIV	Activity		 After	 Fultz	 (1986)	 discovered	 the	 inhibitory	 potential	 of	 saliva,	 most	 researchers	conducted	numerous	experiments	to	elucidate	the	main	factor	that	brought	about	this	action.	Most	evidence	implicated	salivary	mucins	as	the	main	constituents	in	particular	MUC5B	and	MUC7	(Fox	et	al.	1988;	Yeh	et	al.	1992;	Bergey	et	al.	1993;	Malamud	et	al.	1993).	Electron	microscopy	studies	showed	the	aggregates	of	HIV	particles	by	the	high	molecular	weight	glycoproteins	subsequently	reduce	viral	infection	(Archibald	and	Cole	1990;	Yeh	et	al.	1992).	This	gave	a	definitive	role	of	the	inhibitory	effect	of	
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mucins	on	the	transmission	of	HIV-1.	This	observation	was	further	supported	by	the	gel	filtration	studies	of	Bergery	et	al.	(1993)	and	Mamalaud	(1993)	which	demonstrated	that	the	mucin	rich	 fractions	of	 the	submandibular	and	sublingual	glands	showed	a	higher	inhibition	as	compared	to	the	mucin	free	parotid	secretion.	Moreover,	a	direct	association	between	 the	 mucin	 rich	 saliva	 and	 the	 filtered	 HIV	 particles,	 specifically	 MUC7	 was	observed	 and	 this	 partially	 answers	 the	 rarity	 of	 HIV	 transmission	 via	 the	 oral	 route	(Bergey	et	al.	1994).	The	study	by	Nagashunmugam	et	al.	(1997)	further	strengthened	this	 anti-HIV	 activity	 concept	 by	 showing	 a	 higher	 inhibitory	 activity	 in	 the	submandibular	 secretions	 than	 the	 parotid	 secretions.	 He	 also	 demonstrated	 the	concepts	of	inter-individual	variation	among	the	secretions	that	had	a	higher	inhibitory	potential.	 Furthermore,	 using	 anion	 exchange	 chromatography,	 he	 demonstrated	 that	high	 molecular	 weight	 glycoproteins	 stripped	 the	 virus	 gp120	 envelope	 thereby	hindering	the	virus	ability	to	infect	cells	(Nagashunmugam	et	al.	1998).			 The	 Inhibitory	 properties	 of	 purified	 salivary	 MUC5B	 and	 MUC7	 in	 vivo	 have	 been	confirmed	 in	 our	 laboratory	 (Habte	 et	 al.	 2006;	 Peacocke	 et	 al.	 2012).	 It	was	 further	demonstrated	 that	 salivary	 mucins	 inhibited	 HIV	 transmission	 via	 aggregation	 or	trapping	of	the	virus	(Habte	et	al.	2006).	These	findings	led	to	the	investigation	of	other	mucin-based	secretions	(both	crude	and	purified)	such	as	breast	milk,	human	pregnancy	plugs,	pig	saliva	and	horse	saliva.	While	purified	breast	milk	mucins	MUC1	and	MUC4	showed	inhibition	against	HIV-1	in	vivo	(Habte,	de	Beer,	Lotz,	Tyler,	Kahn,	et	al.	2008;	Mthembu	et	al.	2014),	crude	breast	milk	did	not	show	any	anti-HIV	activity	(Kahn	et	al.	2008;	Mthembu	et	al.	2014).	 It	was	suggested	that	 this	observation	was	a	result	of	 fat	globules	 in	crude	breast	milk,	which	prevented	a	physical	entrapment	of	 the	virus,	by	breast	mucins	(Mthembu	et	al.	2014).	However,	these	findings	were	refuted	by	Kazmi	et	al.	 (2006)	 who	 demonstrated	 high	 anti-HIV	 activity	 in	 crude	 breast	 milk	 which	 was	comparable	to	saliva.	These	findings	were	also	supported	by	the	in-vivo	experiments	and	findings	 of	Wahl	 et	 al.	 (2015).	 The	 complexity	 of	 this	 controversy	was	 highlighted	by	Lyimo	et	al.	 (2009)	in	which	he	explained	that	breast	milk	indeed	provided	a	certain	level	of	protection	against	cell	 free	HIV	but	might	be	 insufficient	at	blocking	cell	associated	infection.	 Furthermore,	 when	 crude	 breast	 milk	 is	 inoculated	 by	 cell	 free	 or	 cell	associated	virus	and	heated	or	pasteurised,	the	virus	is	inactivated	providing	 an	
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explanation	as	to	how	crude	milk	might	inhibit	HIV	activity	(Lyimo	et	al.	2009).	Purified	human	pregnancy	plug	together	with	MUC1,	MUC2,	MUC5AC	has	been	demonstrated	to	possess	 the	 anti-HIV	 property	 (Habte,	 de	 Beer,	 Lotz,	 Tyler,	 Schoeman,	 et	 al.	 2008).	However,	crude	pregnancy	plug	does	not	have	this	anti-HIV	activity	and	it	was	suggested	that	the	mucin	concentration	is	low	to	elicit	an	inhibitory	activity	(Habte	et	al.	2008).			 Despite	most	electron	studies	showing	viral	entrapment	by	mucins,	the	exact	mechanism	through	which	mucins	 inhibits	HIV	 has	 not	 yet	 been	 identified.	 There	 has	 been	 some	evidence	which	shows	interaction	between	HIV-1	and	both	whole	saliva	and	glandular	salivary	secretions.	Viral	inhibition	by	submandibular	saliva	was	shown	to	affect	the	virus	rather	 than	the	target	cells	 (Malamud	et	al.	1997).	This	 inhibition	was	only	specific	 to	HIV-1.	 No	 inhibitory	 activity	 was	 detected	 against	 HSV-1,	 HIV-2,	 adenovirus	 and	 SIV	(Malamud	et	al.	1993;	Malamud	et	al.	1997;	Nagashunmugam	et	al.	1997).	These	findings	suggest	that	mucins	offer	some	degree	of	interaction	specificity.			 Dendritic	cells	have	been	demonstrated	to	transfer	HIV-1	in	vivo	to	CD4+T	lymphocytes	cells	without	eliciting	infection	(Geijtenbeek	et	al.2000a).	These	antigens	presenting	cells	express	binding	receptors	for	HIV-1	called	dendritic	cell-specific	intercellular	adhesion	molecule-3	grabbing	non	integrin	(DC-SIGN)	(Van	Liempt	et	al.,	2004;	Van	Liempt	et	al.,	2006;	Guo	et	al.,	2004;	van	Kooyk	and	Geijtenbeek,	200).	On	 the	other	hand,	O-linked	mucins	glycans	are	rich	in	Lewis	X	structures	known	as	DC-SIGN	epitopes.	Saeland	et	al.	(2009)	demonstrated	the	ability	of	MUC1	from	breast	milk	to	inhibit	transmission	of	HIV-	1	from	dendritic	cells	to	CD4+	target	cells	by	binding	to	this	receptor.	He	demonstrated	that	there	is	a	strong	association	that	occurs	between	mucin	Lewis	X	and	the	DC-SIGN	receptor	of	dendritic	cells	that	subsequently	blocked	binding	of	the	viral	gp120	to	DC-	SIGN	resulting	in	the	inhibition	of	DC-SIGN-mediated	transmission	from	dendritic	cells	to	CD4+	T	 cells	 (Saeland	 et	 al.	 2009).	 It	 has	been	demonstrated	 that	 bile-salt	 stimulated	lipase	(BSSL)	from	breastmilk	and	MUC6	in	seminal	plasma	use	DC-SIGN	to	block	transfer	(Martijn	et	al.2009).	It	should	be	noted	that,	there	is	a	possibility	that	genetic	mutations	could	occur	in	the	lewis	X	content	of	MUC1	that	could	affect	the	level	of	protection	breast	
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milk	has	to	offer	against	HIV-1	which	could	explain	the	variable	transmission	of	HIV-1	via	breastfeeding	(Saeland	et	al.	2009).			 It	 seems	as	 if	 there	 are	 a	number	of	mechanisms	 through	which	HIV	 transmission	by	mucin	glycoproteins	occurs.	Currently,	viral	aggregation	between	the	mucin	glycans	and	the	viral	envelope	proteins	is	the	most	accepted	hypothesis.	This	hypothesis	is	supported	by	the	fact	that	mucins	have	a	high	proportion	of	carbohydrate	side	chains,	the	interaction	of	MUC7	with	gp120	envelope	protein	and	lastly	the	inhibition	that	is	specific	to	HIV-1	other	than	the	virus	(Malamud	et	al.	1993;	Bergey	et	al.	1994;	Wu,	Csako,	and	Herp	1994;	Nagashunmugam	 et	 al.	 1997;	 Habte	 et	 al.	 2006).	 Evidence	 is	 emerging	 that	 as	 with	variable	interaction	that	is	there	between	MUC5B	and	MUC7	with	bacteria,	the	inhibitory	mechanisms	of	these	mucins	might	also	be	different	due	to	their	physical	and	biochemical	characteristics.			 2.8 Anti-HIV	Microbicides		 The	idea	of	using	vaginal	microbicide	gels	was	first	thought	of	in	the	early	1900s	with	the	main	 aim	 of	 providing	 women	 with	 a	 tool	 that	 they	 could	 use	 to	 prevent	 sexually	transmitted	 infections	 (STIs)	 and	 also	 to	 protect	 them	 against	 the	 infection	 of	 HIV-1	(Stein,	1990;	Voelker,	2006).	In	addition,	this	would	allow	women	to	have	a	preventative	tool	that	they	could	use	without	their	partners’	consent	 especially	in	relationships	where	condom	use	 is	difficult	 (Doggett	et	al.	2015).	By	 the	end	of	2016,	UNAIDS	published	a	report	 stating	 that	 sixteen	million	women	 globally,	 aged	 between	15	 and	below	were	living	with	HIV.	South	Africa	was	residence	to	about	13	million	female	adolescents	and	young	 woman	 that	 were	 infected	 with	 this	 virus	 (UNAIDS,	 2014).	 UNAIDS	 further	reported	 that	 the	 main	 contributor	 of	 this	 infection	 among	 women	 was	 due	 to	heterosexual	 transmission	 (UNAIDS,	 2014).	 This	 then	 emphasized	 the	 need	 of	 a	microbicide	that	women	could	use	to	protect	themselves.	
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Microbicides	are	chemical	substances	in	the	form	of	gels	or	creams	that	are	applied	to	the	vagina	or	rectum	to	reduce	the	transmission	of	STIs	such	as	HIV	(Fichorova	et	al.	2001).	They	work	by	enhancing	the	natural	vaginal	defence	flora,	maintaining	the	acidic	pH	of	the	 vagina,	 by	 providing	 a	 physical	 barrier	 against	 HIV	 to	 target	 cells	 and	 lastly	 by	preventing	replication	of	 the	virus	once	 they	have	 infected	 targeted	cells(WHO	2009).	Vaginal	microbicides	 that	were	made	 initially	 (first	 generation),	were	 not	 effective	 at	providing	protection	against	HIV	infection	and	actually	induced	genital	inflammation	and	subsequent	cytokine	responses	that	enhanced	HIV-1	infection	in	women	that	used	them	(Fichorova	et	al.	2001;	Mesquita	et	al.	2009).	The	chemicals	and	formulations	that	were	used	in	early	microbicides	disrupted	the	cellular	and	microbial	membranes	and	altered	the	pore	size	of	the	mucus	coating	the	genital	mucosal	surfaces	subsequently	resulting	in	inflammation	and	allergic	response	(Lai	et	al.,	2010a).	Although	most	candidate	microbicides	have	shown	no	significant	protection	towards	HIV	transmission,	Karim	et	al.	(2010,	2012)	formulated	an	antiretroviral	microbicide	gel	that	contained	 a	 nucleotide	 reverse	 transcriptase	 inhibitor	 (NTRI)	 tenofovir	 (TFV),	 which	provided	a	39%	protection	against	heterosexual	transmission	of	HIV	(Karim	et	al.	2010;	Karim	et	al.	2012).	Originally	formulated	as	an	oral	antiretroviral	drug	(ARV),	Tenofovir	has	shown	high	reductions	in	HIV	infection	during	phase	III	clinical	trials	along	with	a	good	safety	profile	(Karim	et	al.	2012).	Unfortunately,	 the	specific	nature	and	mode	of	action	 of	 antiretroviral	 microbicides	 creates	 the	 potential	 for	 drug	 resistance	 on	recurrent	use,	which	is	a	noteworthy	concern	in	their	use	as	a	microbicidal	gels.	Other	microbicides	 have	 been	 shown	 to	 increase	 the	 risk	 of	 HIV	 acquisition	 when	 used	frequently	by	women	who	are	at	high	risk	remaining	an	option	for	woman	who	are	at	low	risk.	In	addition,	some	do	not	prevent	against	STIs	such	as	chlamydia	and	gonorrhoea	and	cannot	 be	 used	 rectally	 (WHO	 2009).	 This	 calls	 for	 safe,	 effective	 and	 affordable	microbicides	that	can	be	used	without	causing	side	effects	or	increasing	susceptibility	to	HIV.	
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2.9. Rationale	and	Research	Question		 Our	understanding	of	 the	specific	way	 through	which	mucin	glycosylation	 inhibits	 the	transmission	of	HIV-1	 is	 still	 superficial.	While	giving	some	 important	 insight	 into	 the	mechanism	 of	 HIV	 inhibition,	 we	 hope	 that	 this	 study	 will	 determine	 the	 minimum	peptide	 chain	 length	 and	 structure	 of	 a	 gel	 forming	 mucin	 that	 retains	 the	 anti-HIV	activity.	 This	 is	 the	 first	 time	 that	 our	 laboratory	 is	 testing	 crude	 saliva	 and	 purified	salivary	mucins	against	a	subtype	B	strain.			 By	 fully	 understanding	 how	 mucins	 protects	 the	 body	 against	 HIV-1	 entry,	 we	 can	potentially	reduce	viral	transmission	and	by	doing	so,	enhance	the	body’s	natural	innate	immune	defences.	If	able	to	distinguish	the	key	structural	variants	of	mucins	which	play	part	in	this	defence	mechanism,	we	could	use	this	as	the	core	component	of	a	vaginal	or	rectal	microbicide.			 2.9.1 Aims	and	Objectives			
● To	access	the	inhibitory	effect	of	salivary	mucins	(MUC5B	and	MUC7)	and	the	effect	of	reduction	and	trypsin	digestion	in	the	inhibition	of	HIV-1	in	vitro.	
● To	ascertain	the	role	of	salivary	oligosaccharides	/mucin	glycans	that	are	required	for	maximal	inhibition.	
● To	determine	the	minimum	peptide	chain	length	of	a	gel	forming	mucin	that	retains	the	anti-HIV-1activity	in	an	in-vitro	assay.	
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CHAPTER	THREE		 MATERIALS	AND	METHODS		 3.1 Ethics		 This	study	was	approved	by	the	University	of	Cape	Town	Research	and	Ethics	Committee.	(Ethics	approval	number	HREC;	REF	078/2010).		 3.2 Materials		 Guanidinium	hydrochloride	(GuHCl),	caesium	choride	(CsCl),	acrylamide,	Sepharose	CL-	4B,	 pararosaniline	 choride,	 N,N’-methylenebisacrylamide	 (Bis/Acrylamide),	 β-	mercaptoethanol,	 Thiazolyl	 blue	 trazolium	 bromide	 (MTT),	 N-Ethylmaleimide	 (NEM),	dialysis	 tubing,	Dulbecco’s	Modified	Eagle’s	Medium	 (DMEM),	Penicillin	 Streptomycin,	diethylaminoethyl	 (DEAE)	dextran	 ,	 Fetal	 bovine	 serum	 (FBS)	 Superior,	Non-essential	amino	acids	(NEAA)	(4-(2-hydroxyethyl)-1-piperazineethanesulfonic	acid)	HEPS	buffer,	Phosphate-buffered	saline(PBS)	without	Ca2+	or	Mg2+,	.Neuraminidase	proteomic	Grade	enzyme	 α(2→3,6,8,9)	 was	 purchased	 from	 Sigma-aldrich	 (St	 Louis,	 USA).	Phenylmethylsulfonylfluoride	 (PMSF),	 ethylenediaminetetraacetic	 acid	 (EDTA),	isopropanol,	 L-lysine,	 glycine,	 ammoniumpersulphate	 (AMPS),	 N,N,N,N,’-	tetramethylethylenediamine	 (TEMED),	 periodic	 acid	 and	 Tween	 20	 Detergent	 were	obtained	from	Merck	(Darmstadt,	Germany).	Tris(hydroxymethyl)-aminomethane	(Tris),	sodium	 dodecyl	 sulfate	 (SDS),	 sodium	 Metabisulphite,	 bromophenol	 blue	 and	nitrocellulose	 membrane	 were	 supplied	 by	 Kimix	 Chemical	 and	 Lab	 Suppliers	 (Cape	Town,	South	Africa).	Glycerol	and	activated	charcoal	were	from	BDH	Chemicals	(London,	UK).	Quick	StartTM	Bradford	dye	was	from	Bio-Rad	Laboratories	(Hercules,	California,	USA).	 Methyl	 orange	 was	 from	 Fluka	 Analytical	 (Seelze,	 Germany).	 The	 ChemiFast	Chemiluminescent	Substrate	Kit	was	from	SYNGENE	(Cambridge,	UK).	Hydrochloric	acid	(HCl)	was	obtained	from	Radchem	Products,	Inc	(Orland	Park,	Illinois,	USA).	Acetic	acid	was	 from	Associated	Chemical	Enterprises	(Johannesburg,	South	Africa).	Protein	Aqua	Stain	 was	 from	 Vacutec	 (Johannesburg,	 South	 Africa).	 Polyclonal	 rabbit	 anti-MUC7	primary	antibody	was	obtained	from	Santa	Cruz	Biotechnology	(Santa	Cruz,	California	
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USA).	Monoclonal	 rabbit	anti-MUC5B	primary	antibody	was	kindly	provided	by	Dallas	Swallow	 (University	 College	 London,	 UK).	 Polyclonal	 goat	 anti-rabbit	 and	 rabbit	 anti-	mouse	horse	radish	peroxidase	(HRPO)	 linked	secondary	antibodies	were	supplied	by	Dako	Cytomation	(Copenhagen,	Denmark).	Pre-stained	Protein	Ladder	and	trypsin-EDTA	solution	were	from	Thermo	Fisher	Scientific	(Cape	Town,	South	Africa).	Trypan	blue	was	obtained	from	Celtic	Diagnostics	(Dublin,	Ireland).	Bright	-Glo	Luciferase	Assay	Substrate	and	Bright-Glo	Luciferase	Assay	Buffer	were	from	Promega	(Madison,	Wisconsin,	USA)	and	the	Glycosylation	kit	was	purchased	from	sigma-aldrich	(Saint	Louise,USA).	The	cell	proliferation	 kit	 (MTT)	was	 purchased	 from	Roche	 (Mannheim,	 Germany).	 TZM-bl/JC	cells	 and	Du422.1	 pseudo	 virus	was	 provided	by	 the	 International	 Centre	 for	Genetic	Engineering	and	Biotechnology	(ICGEB)	(Cape	Town,	South	Africa.	
	 3.3 Collection	of	Samples		 Human	Saliva	was	collected	from	twenty-five	healthy	volunteers	who	declared	a	risk-free	lifestyle.	The	volunteers	had	abstained	from	eating	and	drinking	at	least	2	hours	prior	to	sample	collection	and	 immediately	before	collecting	the	saliva,	 the	participants	had	to	rinse	their	mouth	with	water.	Saliva	was	collected	at	 the	same	time	(10	O’clock)	 from	each	participant	to	allow	uniformity.			 The	production	of	saliva	was	stimulated	by	chewing	on	parafilm	and	was	collected	by	spitting	into	6M	Guanidine	hydrochloride	(GuHCl)	buffer	containing	a	cocktail	of	protease	inhibitors	(PI)	namely	5mM	NEM,	1mM	PMSF	and	10mM	EDTA.	The	ratio	of	GuHCl	 to	saliva	was	1:3.	The	samples	were	mixed	overnight	at	4°C	to	solubilise	the	mucins	and	they	were	centrifuged	at	105	000g	for	30	minutes	to	remove	insoluble	debris.	The	Supernatant	was	collected	and	stored	at	-20°C	until	further	purification.	
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3.4 Purification	of	Salivary	Mucins		 3.4.1 Caesium	Chloride	Ultracentrifugation.			 Mucins	 from	 saliva	 were	 purified	 and	 separated	 from	 other	 contaminants	 (proteins,	nucleic	 acids	 etc)	 using	 Caesium	 chloride	 (CsCl)	 isopycnic	 density	 ultracentrifugation.	This	method	separates	macromolecules	based	on	their	differences	in	densities.	Briefly,	CsCl	molecules	dissociates	into	heavy	Cs2+	and	Cl–	ions	and	because	of	their	heavy	nature,	the	force	of	centrifugation	pushes	them	downwards	and	the	same	time	this	is	opposed	by	the	force	of	diffusion	which	then	results	in	the	formation	of	a	shallow	density	gradient.	The	 lowest	density	 is	 formed	at	 the	 top	of	 the	 tube	which	gradually	 increase	until	 the	bottom.	Molecules	within	 the	 sample	 then	migrate	 to	where	 their	 buoyant	 density	 is	equal	to	that	of	their	surrounding	gradient.	Mucins	are	therefore	separated	based	on	their	densities	(Creeth	et	al.	,1970).			 Salivary	mucins	were	purified	in	accordance	with	the	methods	described	by	Creeth	and	Denborough	(1970).	Whole	saliva	supernatant	samples	were	prepared	in	4M	GuHCl	pH	6.5	containing	protease	inhibitors	and	were	adjusted	to	a	density	between	1.39	grams	per	millilitre	(g/ml)	and	1.42g/ml	(the	particle	buoyancy	of	mucins)	with	solid	caesium	chloride.	 50	ml	 Beckman	 tubes	were	 divided	 into	 9,	 1-centimetre	 (cm)	 fractions.	 The	adjusted	samples	were	transferred	and	sealed	in	Beckman	tubes	which	was	then	followed	with	density	gradient	ultracentrifugation	at	a	temperature	of	4°C	for	48	hours	at	105	000	g	in	a	Beckman	L45	ultra-centrifuge.			 The	resultant	fractions	were	fractionated	pipetted	into	10ml	glass	tubes	using	Pasteur	pipettes.	The	densities	of	each	fraction	were	measured	by	weighing	1	ml	of	the	respective	sample	on	an	analytical	balance.	The	fractions	were	analysed	for	glycoprotein	presence	using	the	Periodic	Acid	Schiff	(PAS)	assay	and	protein	detection	was	conducted	using	the	Bradford	 Assay.	 Fractions	 correlating	 with	 a	 positive	 PAS	 peak	 and	 a	 density	 of	approximately	1.42g/ml	(mucin	rich	fractions)	were	pooled	and	subjected	to	a	second	round	of	centrifugation.	The	resulting	gradients	were	fractionated,	their	densities	were	
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measured,	and	glycoprotein	and	protein	content	were	measured.	The	results	were	used	to	construct	a	profile	highlighting	the	glycoprotein	and	protein	rich	fractions.	Mucin	rich	fractions	(4	to	7)	were	pooled,	dialysed	against	three	changes	of	distilled	water	at	4°C	and	freeze	dried.				 3.4.2 Dialysis	of	Samples.		 In-order	to	remove	salts	and	small	contaminants	from	the	eluted	fractions	were	which	could		interference	in	subsequent	analytical	procedures,		dialysis	against	distilled	water	was	performed.		 Briefly,	a	25-millimetre	(mm)	wide	nitrocellulose	membrane	was	boiled	in	a	beaker	of	water	containing	1%	(w/v)	sodium	bicarbonate	and	1mM	EDTA	for	2	minutes	to	soften	it.	The	glycoprotein	rich	 fractions	were	pooled,	sealed	 in	 the	nitrocellulose	tubing	and	dialyzed	against	3	changes	of	distilled	water	(dH20)	with	continuous	stirring	on	a	Fried	Electric	 Magnetic	 Stirrer	 (Haifa,	 Israel),	 at	 4°C.	 Five	 hours	 was	 the	 minimum	 time	required	before	each	distilled	water	change.			 3.4.3 Freeze	Drying.			 This	method	concentrates	the	fractions	by	removing	water,	which	preserves	the	sample	in	a	stable	form	(Snowman	et	al.	1988).	During	this	process,	pooled	mucin	fraction		from	caesium	 chloride	 ultra-centrifugation	 were	 frozen	 at	 -80°C	 overnight	 which	 was	followed	 by	 lyophilization	 at	 50°C	 in	 a	 vacuum	 of	 0.021	 millibars	 (mbar)	 for	approximately	48	hours	or	until	completely	dehydrated	on	a	Freeze	Zone	6	Freeze	Dry	System	(Labconco,	Kansas	City,	USA).	
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3.4.4 Size	exclusion	chromatography.			 Salivary	Mucins	(MUC5B	and	MUC7)	were	purified	using	a	Sepharose	CL-4B	column	for	separation.	This	technique	separates	biological	materials	based	on	their	molecular	size.	The	 large	 molecules	 are	 excluded	 from	 the	 gel	 and	 move	 quickly	 down	 the	 column,	separating	 from	 smaller	 molecules	 which	 diffuse	 into	 the	 pores,	 restricting	 their	progress.	Sepharose	CL-4B	beads	have	a	fractionation	range	for	globular	proteins	of	60	to	20	000	kDa.	Before	the	sample	was	put	on	the	column,	oxygen	was	removed	from	sepharose	CL-4B	beads	by	bubbling	with	nitrogen	gas	to	prevent	air	bubbles	that	could	block	or	impede	the	flow	of	the	sample.	Following	this,	the	beads	were	packed	into	an	Amicon	Wright	gel	filtration	column	(30cm	x	2cm,	bed	volume	of	approximately	94cm)	as	described	by	the	manufacturer	(Sigma-Aldrich).	The	column	was	primed	by	washing	the	beads	with	a	4M	GuHCl	 solution	 for	 at	 least	 two	 hours	 to	 equilibrate	 the	 bed	 before	 use.	 Lyophilised	mucin	 samples	were	dissolved	 in	a	5ml	solution	of	4M	GuHCl	 that	contained	protease	inhibitors.	Approximately	0.1	mg	of	methyl	orange	was	added	to	the	sample	to	visualise	its	 movement	 through	 the	 column.	 The	 column	 was	 connected	 to	 a	 chromatography	fraction	collector	(FC	204	Fraction	Collector,	Gilson,	Inc.	USA)	that	eluted	each	fraction	at	1	ml	per	tube.	Fractions	of	l	ml	were	collected	per	tube	and	subjected	to	PAS	(Periodic	acid	Schiff)	for	glycoprotein	and	Bradford	Assay	for	protein	determination	using	the	method	illustrated	by	 Mantle	 et	 al.	 (1978)	 and	 Bradford	 (1977)	 respectively.	 The	 results	 were	 used	 to	construct	a	profile	highlighting	the	glycoprotein	and	protein	rich	fractions.	PAS	positive	peaks	eluting	in	the	void	volume	(V0)	and	included	volume	(Vi),	previously	identified	as	MUC5B	and	MUC7,	were	pooled	separately,	dialysed	against	3	changes	of	distilled	water	(dH20)	and	freeze	dried	for	further	analysis.	
38		
3.4.5 Periodic	acid	Schiff’s	(PAS)	assay	for	glycoprotein	detection.			 This	assay	was	used	to	detects	the	presence	of	glycoproteins	in	our	samples.	The	hydroxyl	group(-OH)	present	in	glycoprotein	is	oxidised	to	an	aldehyde	(-CHO)	in	the	presence	of	periodic	acid.	The	decolourised	schyffs	 reagent	 then	 reacts	with	 the	aldehyde	group(-	CHO)	resulting	in	a	colour	change	from	colourless	to	purple/red	(Thornton	et	al.	1996).			 20µl	 of	 each	 chromatographed	 sample	 fraction	was	pipetted	 into	 a	96	well	microtiter	plate.	 100	μl	of	Periodic	solution	(7%	acetic	acid	with	50%	Periodic	acid)	was	then	added	to	the	plate	and	the	reaction	was	incubated	at	37°C	for	1	hour.	After	incubation,	100μl	of	the	decolourised	schyffs	reagent	(0.1g	sodium	metabisulphite	in	6mls	schyffs	reagents)	was	added.	This	was	then	followed	by	a	further	incubation	period	of	30	minutes	at	room	temperature	before	the	absorbance	readings	were	taken	at	585	nm	on	an	Anthos	HTII	Plate	Reader	(GoIndustry	DoveBid,	Lancashire,	United	Kingdom).			 3.4.6 Bradford	assay	for	protein	detection.			 The	Bradford	protein	assay	was	used	to	measure	the	concentration	of	total	protein	in	our	samples.	The	principle	of	this	modified	assay	is	that	it	utilises	a	protein-binding	dye	that	exists	 in	 3	 forms;	 cationic,	 neutral	 and	 anionic	 (Compton	 et	 al.	 1985).	 Under	 acidic	conditions,	binding	of	the	protein	molecules	via	Van	der	Waals	forces	and	hydrophobic	interaction	to	the	Coomassie	dye	to	form	the	protein-dye	complex,	causes	a	colour	change	from	brown	to	blue.	Briefly,	10µl	of	our	fraction	sample	was	plated	on	a	96	well	plate.	200µl	of	the	Bradford	reagent	was	added	and	the	reaction	was	allowed	to	stand	at	room	temperature	 for	 5	minutes.	 Thereafter,	 the	 absorbance	was	 read	 at	 585	 nm	 using	 an	Anthos	HTII	Plate	Reader.	
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3.5 Chemical	Treatments	of	Samples		 Both	crude	and	purified	salivary	samples	were	treated	as	described	below.	Samples	were	reduced	and	digested	in	accordance	with	the	methods	described	by	Mall	(1988).			 3.5.1 Reduction	of	disulphide	bonds.		 Reduction	was	performed	by	incubating	15	ml	aliquots	of	crude	saliva	in	6M	GuHCL	with	10	mM	DL-dithiothreitol	(DTT)	at	37°C	for	5	hours.	Thereafter,	iodoacetamide	(IAA),	an	alkylating	 agent	 which	 prevents	 the	 formation	 of	 disulphide	 bonds	 was	 added.	 The	sample	 tubes	 were	 covered	 with	 foil	 paper	 and	 were	 incubated	 overnight	 at	 room	temperature	in	the	dark.	Samples	were	then	dialysed	against	6M	GuHCl	in	preparation	for	gel	filtration.			 3.5.2 Digestion	of	Proteins.			 Digestion	of	proteins	was	done	by	adding	0.125%	trypsin	with	EDTA	in	the	ratio	of	1:100	to	15	ml	aliquots	of	crude	saliva	in	6M	GuHCL.	This	was	then	followed	by	an	incubation	at	 37°C	 overnight.	 Samples	 were	 then	 dialysed	 against	 water	 and	 freeze	 dried	 in	preparation	 for	 gel	 filtration.	 It	 is	 important	 to	 note	 that	 the	 samples	 that	 were	undergoing	 trypsin	digestion	were	not	pH	controlled	so	 the	optimal	 trypsin	 treatment	may	not	have	occurred.				 3.6 Confirmation	of	Mucin	Size	and	Purity			 3.6.1 Gradient	(4-20%)	sodium	dodecyl	sulphate	polyacrylamide	gel	electrophoresis	(SDS-PAGE).	
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A	4-20%	SDS	Page	gradient	was	used	to	confirm	the	molecular	size	and	purity	of	salivary	mucins.	The	gradient	gels	were	made	as	described	by	Laemmli	et	al.	 (1970).	Briefly,	a	running	gel	solution	was	made	up	of	a	4%	light	solution	and	a	20%	heavy	solution.	The	light	solution	was	made	up	of	0.8	ml	30%	Bis/Acrylamide,	1.5	ml	1.5	M	Tris-buffer	with	0.1%	SDS,	pH	8.8,	3.7	ml	dH2O,	30	μl	10%	ammonium	persulphate	(AMPS)	and	5	μl	N,	N,	N,	N’-tetramethylethylenediamine	(TEMED)	while	the	20%	heavy	solution	was	made	up	of	4ml	30%	Bis/Acrylamide,	1.5	ml	1.5	M	Tris-buffer	with	0.1%	SDS,	pH	8.8,	0.5	ml	dH2O,	30	 μl	 10%	 AMPS	 and	 5	 μl	 TEMED.	 Using	 the	 same	 serological	 glass	 pipette,	 equal	volumes(2.3mls)	of	both	the	4%	light	solution	and	the	20%	heavy	solution	were	pipetted.	In	order	to	create	the	4-20%	gradient,	a	single	bubble	was	allowed	to	move	throughout	the	solution	by	letting	some	air	in	the	pipette.	Thereafter,	the	running	gel	was	poured	into	the	glass	plates	(biorad)	and	it	was	topped	up	with	methanol	to	promote	polymerisation.			 Thereafter,	the	stacking	gel	was	prepared	as	follows;	0.5	ml	Bis/Acrylamide,	2.8	ml	spacer	buffer,	73	μl	AMPS	and	5	μl	TEMED.	After	 the	gradient	gel	was	set,	 the	methanol	was	removed	by	tilting	the	glass	plates	on	a	piece	of	tissue	paper	and	the	stacking	gel	was	poured.	 Immediately	 the	 comb	 was	 then	 inserted	 to	 create	 wells.	 The	 freeze-dried	samples	(1mg/100µl)	were	reconstituted	in	sample	application	buffer	which	contained	2%	SDS,	10%	glycerol	and	0.01%	bromophenol	blue.	The	solution	was	left	overnight	at	room	temperature	for	the	samples	to	fully	dissolve.	Aliquots	of	the	sample	solution	(15	ul)	were	 loaded	onto	the	4-20%	gradient	gel	and	subjected	to	electrophoresis.	5ul	 the	protein	pre-stained	molecular	weight	marker	was	also	loaded.	The	gels	were	run	at	200V,	25mA	for	90	mins	in	tank	buffer	(0.025M	Tris,	0.19	Glycine,	0.1%	SDS).	The	gels	were	stained	 for	 glycoprotein	 and	protein	visualisation	using	PAS	and	aqua	 stain	 (Vacutec)	respectively.			 3.6.2 PAS	staining	of	4-20%	SDS-PAGE	gel.		 The	Periodic	Acid	Schiff	(PAS)	gel	staining	described	by	Dubray	and	Bezard	(1982)	was	used	to	visualise	glycoproteins	in	the	gels.	After	gel	electrophoresis,	the	gels	were	placed	in	50%	ethanol	for	30	minutes	which	was	followed	by	washing	with	distilled	water	for	
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10	minutes.	After	washing,	the	gels	were	then	placed	in	1%	Periodic	Acid	made	up	in	in	3%	Acetic	 acid	 for	 30	minutes.	 Thereafter,	 the	 gels	were	washed	with	distilled	water	overnight	 at	 4℃.	 The	 gels	 were	 washed	 twice	 in	 a	 solution	 containing	 0.1%	 Sodium	Metabisulphite	in	10mM	hydrochloric	acid.	Schiff’s	reagent	was	then	poured	over	the	gel	before	 being	 placed	 in	 the	 dark	 for	 1	 hour.	 This	 was	 followed	 by	 another	 one	 hour	incubation	of	the	gel	with	0.1%	Sodium	Metabisulphite	in	10mM	hydrochloric	acid	in	the	dark	 (Dubray	 et	 al.,	 1982).	 The	 Glycoprotein	 bands	 were	 visualized	 on	 the	 gel	 as	purple/pink	bands	and	the	gels	were	scanned	on	a	Hewlett	Packard	desktop	scanner	and	saved	to	a	computer.			 3.6.3 Protein	Staining	of	4-20%	SDS-PAGE	gel.			 ln	order	to	visualise	the	protein	bands,	we	stained	the	SDS-PAGE	gel	with	Vacutec	Acqua	Stain	Protein	Gel	for	10	mins	at	room	temperature	(as	per	manufacturer’s	instruction).	Thereafter	the	gels	were	scanned	on	a	Hewlett	Packard	desktop	scanner	and	saved	to	a	computer.				 3.7 Confirmation	of	Mucin	Identity			 3.7.1 Slot	Blot.		 We	used	slot	blots	to	identify	the	mucins	that	were	present	in	our	V0	and	Vi	fractionated	samples.	Briefly,	we	diluted	100μg	of	our	 fractionated	 lyophilized	mucin	samples	with	100ul	of	the	sample	application	buffer	(10%	v/v	glycerol,	0.01%	w/v	bromophenol	blue	in	1X	TAE).	The	nitrocellulose	membrane	was	soaked	in	4x	saline	sodium	citrate	buffer	(SSC)	(0.6M	NaCl,	0.06M	sodium	citrate,	pH	7)	and	it	was	treated	with	poly-L-lysine	(1:50	dilution	with	SSC	buffer)	to	allow	mucins	to	bind	to	the	membrane.	This	was	followed	by	vacuum	blotting	 for	an	hour	at	40	mBar	using	a	Pharmacia	LKB	Vacugene	XL	vacuum	blotter	(Kalamazoo,	United	States).	
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	 Following	the	one	hour	period,	the	membranes	were	probed	with	anti-MUC5B	and	anti-	MUC7	antibodies	and	to	visualise	the	mucins.	The	same	methods	described	in	the	western	blot	section	was	used	up	till	the	detection	point.	Instead	of	using	the	alkaline	phosphatase	secondary	 antibodies	 to	 detect	 the	 presence	 of	 the	 mucins,	 we	 used	 the	 ChemiFast	Chemiluminescent	Substrate	kit	(Vacutec).	Using	this	detection	method,	equal	amounts	of	reagent	A	and	reagent	B	were	mixed,	and	an	appropriate	amount	was	added	to	cover	the	membrane	before	being	dried	by	blotting	with	filter	paper.	The	membrane	was	then	viewed	in	a	Syngene	G-box	(Syngene,	Haryana,	India)			 3.8 HIV-1	Pseudo	virus	Neutralization	Assay		 The	anti-HIV	activity	of	MUC5B	and	MUC7	was	tested	using	a	pseudo	virus	neutralisation	assay	 developed	 by	Wei	 et	 al.	 (2002).	 This	 assay	was	 originally	 designed	 to	measure	neutralizing	antibodies	response	during	HIV	infection.	(Montefiori,	2009).	This	assay	was	later	modified	and	validated	by	the	Dorfman	laboratory	(from	the	International	Centre	for	 Genetic	 Engineering	 and	 Biotechnology	 (ICGEB),	 UCT)	 to	 test	mucins	 against	 HIV	infection.	The	viral	inhibition	potential	of	this	assay	was	determined	by	measuring	the	reduction	in	the	expression	of	the	luciferase	reporter	genes	of	TZM-bl	cells,	regulated	by	HIV	Tat	gene	after	a	single	round	of	infection	with	HIV-1	pseudo	virus	(Montefiori	2009).	This	assay	together	with	the	cytotoxicity	experiment	for	cell	viability	were	conducted	in	a	P2	Laboratory	at	the	ICGEB	unit	at	UCT.		 3.8.1 Pseudo	virus	constructs.		 The	Du422	HIV-1	env	pseudo	virus,	a	molecularly	cloned	subtype	C	virus	and	YU2	a	clade	B	virus	were	used	to	test	the	inhibitory	potential	of	salivary	mucins.	Although	both	the	viruses	are	HIV-1	subtypes,	the	origin	and	where	they	were	derived	from	differ.	These	pseudo	viruses	were	prepared	using	the	293T	cell	line	as	the	packaging	cells.	The	packaging	cells	were	transfected	with	an	envelope	plasmid	and	an	inactivated	envelope	backbone	(SG3-Δ	env)	which	contains	the	entire	genome	except	the	Env	protein	(Figure	3).	This	co-transfection	process	only	generates	pseudo	virus	particles	able	to	replicate	
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only	once	due	to	the	lack	of	the	envelope	gene	sequence	Montefiori	(2009)	and	Sarzotti-	Kelsoe	et	al.	(2014).					
		
Figure	3	An	 illustration	of	 how	Du422.1	and	YU2	pseudo	 viruses	were	produced	using	T293	 cells	 and	 SG3-	Δ	 env	 (an	
inactivated	envelope	gene)	as	the	plasmid	backbone.	
	
	
	
	 3.8.2 Maintenance	of	target	cells.			 A	Hela	cell	line,	(TZMB/JC)	cells	which	express	CCR5	and	CXCR4	co-	receptors	and	CD4	receptors	was	used	 for	 both	 the	MTT	assay	 for	 cell	 cytotoxicity	 and	 the	pseudo	virus	neutralisation	 assay.	These	 cells	 are	modified	with	 an	LTR	 (long	 translational	 repeat)	which	 promotes	 luciferase	 and	ß-galactosidase	 gene	 sequence.	 (Wei	 et	 al.	 2002).	 The	virus	is	made	from	plasmid	backbone	SG3*env	which	transcribes	all	viral	genes	except	for	a	dysfunctional	(Tat)	env	gene	and	a	plasmid	containing	a	functional	env	gene.	The	functional	 env	 is	 present	 in	 different	 viral	 strains	 (i.e.	 YU2	 and	 DU422).	 ln-order	 to	determine	the	viral	infection,	the	HIV-1	Tat	gene	(from	the	different	virus	strains)	
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initiates	the	LTR	promoter	which	causes	the	production	of	luciferase	and	ß-galactosidase	which	is	then	measured.			 TMZB/JC	cells	were	passaged	and	maintained	in	5%	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM),	 containing	 5%	 foetal	 bovine	 serum	 (FBS)	 and	 1%	 non-essential	 amino	 acid	(NEAA)	 25mM	 HEPS	 .	 These	 cells	 were	 passaged	 after	 every	 48	 hours	 when	 the	confluency	in	the	plate	was	between	80-90%.	Briefly,	2	mls	of	trypsin	(0.25%	trypsin-	EDTA)	 was	 added	 to	 a	 plate	 containing	 confluent	 cells	 and	 this	 was	 incubated	 for	 5	minutes	 at	 37℃.	 Thereafter,	 the	 cells	 were	 suspended	 in	 8	 mls	 of	 5%	 DMEM	 and	transferred	into	a	falcon	tube.	The	contents	of	the	tube	were	centrifuged	at	1	200	rpm	for	5	minutes	to	pellet	the	cells.	Following	this,	the	supernatant	was	discarded	and	5	mls	of	fresh	 5%	 DMEM	 was	 added	 to	 the	 pellet.	 The	 resuspended	 cells	 were	 counted	 on	 a	haemocytometer.10	μl	of	resuspended	cells	were	added	to	20	μl	of	trypan	blue	and	15	μl	of	trypan	blue	containing	stained	cells	were	counted	in	three	quadrants	to	obtain	the	total	X	x	104	cells/ml.	One	million	cells	from	the	suspension	were	then	returned	to	the	plate	and	5%	DMEM	was	topped	up	to	make	the	total	volume	13	mls.	The	cell	culture	plate	was	incubated	for	48	hours	in	a	37°C	incubator	(with	5%	CO2).					 3.8.3 Neutralization	assay	procedure.			 The	anti-HIV	activity	of	purified	treated	and	crude	salivary	mucins	was	tested	on	TZMB	/JC	cells	using	the	modified	HIV	neutralisation	assay	by	Montefiori	(2009).	Once	the	cells	were	 confluent	 as	 described	 above,	 they	 were	 resuspended	 in	 10%	 DMEM,	 with	Diethylamino	 ethyl-Dextran	 (DEAE-Dextran)	 at	 a	 concentration	 of	 16.4	 mg/ml.	 The	addition	of	DEAE-Dextran	was	to	remove	any	charge	repulsion	that	could	occur	between	the	virus	and	the	cells.	The	cells	were	then	adjusted	to	a	density	of	one	million	cells	per	ml	and	they	were	plated	in	a	96	well	plate	and	incubated	overnight	at	37°C.	
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On	the	second	day,	freeze	dried	samples	of	MUC5B,	MUC7,	crude	saliva,	trypsin	digested	saliva,	reduced	salivary	mucins,	deglycosylated	and	desialyated	mucins	were	prepared	in	10%	DMEM	at	a	concentration	of	1mg/ml.	The	samples	(run	in	triplicates)	were	serially	diluted	in	half	and	were	plated	on	a	separate	96	well	plate	(100µl	per	well).	The	starting	concentration	of	the	DU422	and	YU2	was	determined	using	the	virus	titration	method	described	 by	 Sarzotti-Kelsoe	 et	 al.	 (2014).	 This	method	determines	 the	 concentration	that	is	required	to	infect	50%	of	the	cells	with	the	virus.	This	is	also	known	as	the	50	000	relative	 light	 units	 (RLU)	 and	 this	 value	was	 0.03µl	 and	 0.002µl	 for	 DU422	 and	 YU2	respectively.	This	was	the	starting	concentration	used	to	infect	the	cells.	The	virus	was	then	added	to	the	mucin	samples	and	this	was	incubated	for	1	hour	at	37°C.	Thereafter,	the	virus-mucin	mixture	(100µl)	was	then	transfected	to	the	cell	culture	plate	which	was	plated	on	day	1	and	 it	was	 left	 to	 incubate	 for	48	hours.	Thereafter,	100	μl	of	 the	cell	media	 was	 removed	 from	 each	 well	 and	 100	 μl	 of	 Bright-Glo	 luciferase	 substrate	(Promega,	used	as	per	the	manufacturer’s	instructions)	was	added.	After	incubating	in	the	dark	for	2	minutes	at	room	temperature,	100μl	was	transferred	to	a	96-well	black	plate	 and	 luminescence	 was	 measured	 in	 relative	 light	 units	 (RLU)	 using	 a	 Victor	 2	luminometer	(Perkin-Elmer).	Cells	with	media	served	as	a	negative	control	while	cells	with	virus	but	no	mucins	served	as	a	positive	viral	control.			 3.8.4 Analysis	of	neutralization	data.			 In-order	for	the	data	to	be	reliable,	the	difference	between	replicates	needed	to	be	below	35%	 of	 the	 higher	 value.	 To	 include	 our	 samples	 for	 analysis,	 four	 data	 points	 with	different	concentrations	of	the	same	mucin	were	needed.	Viral	infectivity	was	measured	by	averaging	the	relative	light	units	(RLU)	of	the	(positive	control-negative	control).	The	percentage	inhibition	was	calculated	by	subtracting	viral	infectivity	from	100.	The	IC50	defined	 as	 the	 concentration	 at	which	50%	of	 the	 virus	was	 inhibited	 by	mucins	was	calculated	 using	 the	 Prism	 function;	 variable	 slope	 curve	 fit	 functions	 defined	 as	 log	(inhibitor)	vs	normalized	response	(GraphPad,	La	Jolla,	CA,	USA).	The	analysis	of	data	was	done	using	the	Mann-Whitney	U	tests.	
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3.8.5 MTT	assay	for	cell	viability.			 The	viability	of	the	cells	and	also	the	toxicity	of	our	mucin	samples,	was	tested	using	3-	(4,5-Dimethyl-2-thiazolyl)-2,	5-diphenyl-2H-tetrazolium	bromide)	(MTT)	assay.			 This	colorimetric	assay	mimics	the	neutralisation	assay	with	the	exclusion	of	any	virus	being	used.	Viable	cells	contain	mitochondrial	enzymes	that	have	the	ability	to	convert	the	MTT	tetrazolium	salt	into	a	purple	formazan	solution.	The	colour	change	determines	the	percentage	of	viable	cells	relative	to	the	control	cells.	This	was	read	on	a	microplate	reader	at	595nm.			 Briefly,	TZM-bl/JC	cells	(approximately	1	million)	were	plated	in	a	96	well	plate	(10000	cells	in	each	well)	and	100µl	of	10%	DMEM	media	was	added	in	each	well.	This	was	then	followed	by	incubation	at	37℃ for	24	hours.	Concurrently,	freeze	dried	samples	(starting	concentration	1mg/ml)	were	dissolved	in	10%	DMEM	media	overnight.	After	24	hours,	mucin	 samples	were	 serial	 diluted	 by	 half	 in	 a	 different	 plate	 done	 7	 times	 from	 the	starting	 concentration	 of	 1mg/ml).	 Thereafter,	 100ul	 from	 the	 cell	 culture	 plate	 was	discarded	from	each	well	and	100ul	of	mucin	sample	from	the	dilution	plate	was	added.	Samples	were	assayed	in	triplicates.	Cells	plated	without	mucins	were	used	as	a	positive	control,	and	media	was	plated	as	a	blank.	This	was	then	incubated	for	44	hours	in	a	37℃ incubator	 (5%	 CO2).	 Following	 this	 incubation	 period,	 10μl	 MTT	 (5mg/ml	 in	 10%	DMEM)	was	added	to	each	well	and	the	cell	culture	plate	was	incubated	for	a	further	4	hours.	 Thereafter,	 100μl	 of	wells	 contents	were	 removed	 and	 replaced	with	 100μl	 of	solubilizing	buffer	(10%	SDS	in	0.01	M	HCl).	The	plate	was	incubated	overnight	at	37℃ and	after	complete	solubilization	of	the	purple	formazan	crystals,	the	absorbance	of	the	samples	was	read	at	595nm.	
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3.8.6 Analysis	of	cell	viability	data.			 In-order	for	the	data	to	be	reliable,	the	difference	between	replicates	needed	to	be	below	35%	 of	 the	 higher	 value.	 To	 include	 our	 samples	 for	 analysis,	 four	 data	 points	 with	different	concentrations	of	the	same	mucin	were	needed.	The	percentage	viability	of	the	cells	was	imported	to	Microsoft	Excel	and	the	percentage	viability	was	calculated	as	the	difference	between	the	absorbance	of	the	mucin	samples	and	the	media	divided	by	the	average	difference	of	the	cell	control	absorbance	values	and	the	media.	This	value	was	multiplied	by	100	to	get	the	percentage.	Thereafter,	mucins	were	considered	non-toxic	if	 all	 the	 cell	 viability	 was	 above	 70%	 and	 no	 downward	 trend	 in	 cell	 viability	 with	increasing	mucin	concentration	was	observed.	A	50%	lethal	concentration	(LC50)	was	allocated	to	samples	that	had	a	trend	that	did	not	fit	the	above	statement.	This	(LC50)	defined	 as	 concentration	 at	 which	 50%	 of	 the	 cells	 die	 was	 calculated	 using	 the	log(inhibitor)	vs.	normalized	response	--	variable	slope	curve	fit	functions	in	GraphPad	Prism	(La	Jolla,	CA,	USA).	
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CHAPTER	FOUR:	COMPARISON	OF	THE	ANTI-HIV-1	POTENCY	OF	SALIVARY	GLYCOPROTEINS			 4.1 Purification	of	Salivary	Mucins		 Caesium	chloride	isopycnic	density	gradient	ultracentrifugation			 Salivary	mucins	were	separated	from	nucleic	acids	and	protein	contaminants	using	the	caesium	chloride	 isopycnic	density	 gradient	ultracentrifugation	method	of	Creeth	 and	Denborough	(1970).	Thereafter,	 the	 tubes	were	 fractionated	and	the	glycoprotein	and	protein	content	of	each	fraction	was	determined	using	the	PAS	and	Bradford	assay.	The	corresponding	density	was	also	measured	(g/ml).	After	the	first	ultra-centrifugation	round,	a	mucin	peak	detected	by	the	PAS	assay	was	observed	from	the	purification	profile	starting	from	fraction	4	to	fraction	7	(Figure	4a).	This	peak	correlated	with	the	expected	mucin	particle	buoyant	between	1.38g/ml	and	1.42g/ml.	Fractions	1-3	showed	high	protein	content	indicating	the	comparatively	low	density	of	 small	 glycoproteins	and	non-glycosylated	proteins.	 In	addition,	 there	was	a	clear	 separation	 of	 mucin	 and	 protein	 content	 after	 one	 ultracentrifugation	 spin.	However	due	to	the	comparatively	high	protein	 content	after	the	first	ultracentrifugation	spin,	mucin	 rich	 fractions	 from	 the	 first	 spin	were	 pooled	 and	 further	 subjected	 to	 a	second	round	of	caesium	chloride	ultracentrifugation.	Results	from	the	second	caesium	spin	(Figure	4b)	showed	a	low	protein	peak	and	a	corresponding	glycoprotein	peak	which	was	thought	to	be	the	protein	moiety	of	mucins.	
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a)																			 b)		
	 Figure	4	Purification	of	whole	saliva	using	isopycnic	caesium	chloride	density	gradient	ultracentrifugation.	(a)	Shows	the	gradient	profile	after	the	first	round	of	ultracentrifugation	and	(b)	shows	the	gradient	profile	following	the	second	round	of	ultracentrifugation.	Red	line	represents	mucin	content	,	blue	line	represents	protein	content	and	green	line	represents	density	of	mucins.	
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				 4.1.2.	Gel	Filtration			 Mucins	were	separated	according	to	their	molecular	sizes	using	the	Sepharose	CL-4B	gel	filtration	method.	The	Sepharose	CL-4B	gel	filtration	profile	(Figure	5)	showed	two	mucin	rich	macromolecules	 of	 different	molecular	weight	 sizes.	which	were	 detected	 by	 the	PAS	 assay	 .	 These	 two	 glycoproteins	were	 previously	 identified	 as	MUC5B	 and	MUC7	(Habte	 et	 al.	 2006).	MUC5B	 eluted	 first	 in	 the	 void	 volume	 (Vo)	 because	 of	 its	 larger	molecular	weight	 size	 of	 over	20000kda,	whilst	MUC7,	which	 is	 substantially	 smaller,	(150-200kda)	eluted	in	the	included	volume	(Vi)	(Figure	5).	The	Vi	and	Vo	samples	were	pooled	separately,	dialysed	and	freeze	dried	until	needed	for	further	analysis.	Salivary	mucins	from	all	participants	exhibited	the	same	profiles.	However,	It	is	worth	noting	that	inter-individual	variation	was	observed	in	some	samples	in	relation	to	the	sizes	of	the	mucin	peaks	of	MUC5B	and	MUC7.	
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			 Figure	5	Sepharose	CL-4B	gel	filtration	profile	of	purified	saliva.	This	was	used	to	separated	MUC5B	and	MUC7.	The	presence	of	mucins	was	detected	using	the	PAS	assay	by	testing	every	second	fraction	from	the	column.	
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4.1.3 Gel	Filtration	Graphs	of	Treated	Samples		 Crude	and	purified	salivary	samples	that	were	treated	with	either	DTT	or	trypsin	,	were	loaded	on	Sepharose	CL-4B	gel	filtration	column	in	order	to	monitor	the	changes	in	mucin	size.	Thereafter,	the	PAS	and	Bradford	assay	was	conducted	to	determine	the	mucin	and	protein	 concentration	 respectively	 in	 the	 eluted	material.	 Allen	 (1981)	 reported	 that	proteolytic	digestion	occurs	in	the	naked	regions	of	the	mucin	protein	core	resulting	in	subunits	while	 the	 reduction	of	mucins	by	DTT	breaks	 the	disulphide	bonds	 that	 join	mucin	subunits	to	one	another	via	cysteine	residues.	Treatment	 of	 crude	 saliva	 with	 0.25%	 trypsin	 yielded	 an	 elution	 profile	 that	 had	 a	smaller	Vo	peak	and	a	larger	distinct	Vi	peak	(Figure	6).	On	the	other	hand,	treatment	of	crude	saliva	by	DTT	followed	by	alkylation	with	IAA,	yielded	a	large	V0	peak	of	undigested	mucins	and	a	 relatively	 small	Vi	peak	 (Figure	7)	 suggesting	 the	possibility	of	a	partial	digestion	on	both	treatments.	Purified	trypsin	digested	mucin	samples	showed	a	 large	population	 of	 polymeric	 mucin	 which	 eluted	 in	 the	 V0,	 with	 smaller	 mucin	 subunits	eluting	as	a	broad	and	flat	peak	in	the	Vi	indicating	some	mucin	degradation	(Figure	8)	Treatment	with	DTT	reduced	the	size	of	the	V0	peak,	increasing	the	amount	of	material	eluting	in	the	Vi	peak	(Figure	9).	
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																																	 Figure	6	Sepharose	CL-4B	gel	filtration	profile	of	crude	saliva	that	was	treated	with	0.25%	trypsin.	Samples	were	eluted	with	guanidium	chloride	buffer	through	a	40ml	bed	volume	column	and	l	ml	fractions	were	collected,	subjected	to	PAS	and	Bradford	assay	to	measure	the	glycoprotein	and	protein	content	respectively.	Due	to	the	viscous	nature	of	saliva	the	samples	were	extracted	1:3	dilution	with	guanidium	chloride	buffer.	
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		 Figure	7	Sepharose	CL-4B	gel	 filtration	profile	of	 crude	 saliva	 that	was	 treated	with	DTT	and	alkylated	with	 IAA.	 .	Samples	were	 eluted	with	 guanidium	 chloride	 buffer	 through	 a	 40ml	 bed	 volume	 column	 and	 l	ml	 fractions	were	collected,	subjected	to	PAS	and	Bradford	assay	to	measure	the	glycoprotein	and	protein	content	respectively.	Due	to	the	viscous	nature	of	saliva	the	samples	were	extracted	in	1:3	dilution	with	guanidium	chloride	buffer.	
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		 Figure	8	Sepharose	CL-4B	gel	filtration	profile	of	purified	salivary	mucins	treated	with	0.25	%	Trypsin.	Samples	were	eluted	 with	 guanidium	 chloride	 buffer	 through	 a	 40ml	 bed	 volume	 column	 and	 l	 ml	 fractions	 were	 collected,	subjected	 to	 PAS	 and	 Bradford	 assay	 to	 measure	 the	 glycoprotein	 and	 protein	 content	 respectively.	 Due	 to	 the	viscous	nature	of	saliva	the	samples	were	extracted	1:3	dilution	with	guanidium	chloride	buffer	
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		 																													 Figure	9	Sepharose	CL-4B	gel	filtration	profile	of	purified	salivary	mucin	that	was	treated	with	DTT	and	alkylated	with	IAA.	Samples	were	eluted	with	guanidium	chloride	buffer	through	a	40ml	bed	volume	column	and	l	ml	fractions	were	collected,	subjected	to	PAS	and	Bradford	assay	to	measure	the	glycoprotein	and	protein	content	respectively.	Due	to	the	viscous	nature	of	saliva	the	samples	were	extracted	in	1:3	dilution	with	guanidium	chloride	buffer	.	
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4.1.4 Confirmation	of	Mucin	Identity			 Slot	Blot		 The	 identity	 of	 the	 Vo	 and	 Vi	 peaks	 from	 the	 Sepharose	 CL-4B	 column	 bed	 was	determined	by	the	slot	blot	analysis.	Briefly,	the	Vo	and	Vi	fractions	were	vacuum	blotted	on	 a	 nitrocellulose	 membrane	 and	 probed	 with	 anti-MUC5B	 monoclonal	 primary	antibody	(Dallas	Swallow,	University	College	London)	and	anti-MUC7	polyclonal	primary	antibody	 (Santa	 Cruz	 Biotechnology),	 respectively.	 The	 samples	 tested	 showed	immunoreactivity	 towards	 the	 primary	 antibodies	 indicating	 the	 presence	 of	 human	salivary	mucins	in	the	test	samples.	Furthermore,	our	results	revealed	the	identity	of	the	Vo	as	MUC5B	and	the	Vi	fraction	as	MUC7.	These	results	(Figure	10	a	&	b)	showed	that	mucins	were	successfully	separated	and	no	contamination	was	observed.	Previously	 it	 has	 been	 shown	 that	 salivary	mucins	 and	 the	 salivary	 glycoprotein	 SAG	usually	coprecipitates	and	elutes	together	as	a	complex	hence	the	purification	of	salivary	mucins	has	been	of	concern	(Thornton	et	al.	2001).	We	investigated	if	no	co-purification	had	 occurred	 between	 our	 salivary	 mucins	 and	 SAG	 by	 probing	 with	 anti-gp340	monoclonal	antibody	(BioPorto	Diagnostics)	in	all	of	the	MUC5B	and	MUC7	samples.	Our	results	 (data	 not	 shown),	 showed	 no	 immunoreactivity	 in	 all	 the	 samples	 tested		indicating	that	no	co-purification	had	occurred.	
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V0	 V0	
a) Monoclonal	Ab	MUC5B	 b)	 Polyclonal	Ab	MUC7		
Figure	10	Slot	blots	of	the	PAS	positive	fractions	(Vo	and	Vi)	from	the	Sepharose	CL-4B	gel	filtration	column.	The	Vo	(4a)	and	(	4b)	Vi	samples	represent	MUC5B	and	MUC7	respectively.					 4.1.5 Confirmation	of	Mucin	Purity	and	Size	Using	Sodium	Dodecyl	Sulfate	Polyacrylamide	Gel	Electrophoresis	(SDS-PAGE).			 In	order	to	visualize	the	mucin	content	in	our	crude	and	purified	samples,	the	Vo	and	Vi	fractions	were	 subjected	 to	 SDS-PAGE	 analysis	 and	 stained	with	PAS.	A	 characteristic	feature	of	mucins	is	that	it	usually	retains	at	the	top	 the	stacking	gel	due	to	their	extensive	carbohydrate	side	chains	that	accounts	for	85%	of	mucins	total	molecular	weight	(Wu,	Csako,	and	Herp	1994).	This	was	observed	in	our	crude	sample	(Figure	11).	In	addition,	there	was	a	smearing	effect	that	was	distinctly	observed	in	crude	saliva	(Figure	11).	PAS	staining	 of	 crude	 saliva	 (Figure	 11)	 showed	 two	 populations	 of	 different	 molecular	weight	 sizes	 at	 approximately	 250kDa	 and	 180kDa,	 which	 were	 later,	 identified	 as	MUC5B	and	MUC7	respectively.	MUC5B	mobility	 was	 restricted	 at	 the	 top	 of	 the	 gel	 (Figure	 12).	We	 attributed	 this	finding	to	its	large	molecular	weight	size	and	its	extensive	glycosylation.	MUC7	(Figure	13)	had	 faint	bands	of	PAS	staining	as	compared	to	MUC5B	suggesting	the	possibility	that	the	exposed	regions	of	the	mucin	core	were	not	highly	glycosylated.	Its	molecular	weight	size	 was	 detected	 at	 180kDa	 further	 supporting	 the	 theory	 that	 MUC7	 is	 smaller	compared	to	MUC5B	(Thomsson	2002).	In	addition	,	more	mobility	was	shown	by	MUC7	as	more	material	entered	the	running	gel	(Figure	13).	No	 other	 bands	were	 detected	 during	 the	 purification	 process	 confirming	 that	mucin	purification	 was	 successful	 and	 no	 contaminants	 were	 present.	 We	 observed	 slight	variation	in	the	mobility	of	the	MUC7	among	different	samples.	It	is	important	to	note	
Vi 
Vi	
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that	due	to	the	unavailability	of	aqua	stain	from	our	manufacturers,	we	did	not	conduct	any	aqua	staining	of	our	gels	to	visualize	the	protein	content.										 Lane			1	 2	 3	 4	 5	 6													 Figure	11	The	presence	of	crude	saliva	proteins		was	detected	using	a	4-20%	gradient	SDS-PAGE	gel	followed	by	PAS	staining	 of	 glycoproteins.	 The	 size	 of	 the	 salivary	mucins	was	 estimated	using	 a	molecular	weight	marker.	Briefly,	1mg	of	 lyophilized	aliquots	were	dissolved	in	100μl	of	2%	SDS,	1%	glycerol	and	0.01%	bromophenol	blue	for	SDS-PAGE	gel	investigation.	Lane	1	represents	10μl	of	Thermo	Scientific	Page	Ruler	Pre-stained	Protein	Ladder	while	Lane	2-6	shows	crude	saliva	material.	
180kDa	
250kDa	
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250kDa	
						 Lane	 1	 2	 3	 4		
	 Figure	12	Estimation	of	mucin	size	and	confirmation	of	the	purity	of	MUC5B	samples	by	4-20	%	gradient	gel	SDS-PAGE	followed	by	PAS	staining	of	mucin	glycoprotein.	Briefly,	1mg	of	purified	lyophilized	aliquots	were	dissolved	in	100μl	of	2%	SDS,	1%	glycerol	and	0.01%	bromophenol	blue	for	SDS-PAGE	gel	investigation.	Lane	1	represents	10μl	of	Thermo	Scientific	Page	Ruler	Pre-stained	Protein	Ladder	while	Lane	2-4	shows	10	μl	of	purified	V0	material.	The	first	arrow	represents	the	start	of	 the	running	gel	and	Lane	3	shows	a	dark	band	that	could	not	penetrate	the	running	gel	and	remained	at	the	top	of	the	well.	
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180kDa	
						 Lane		1	 2	 3	 4		
	 Figure	13	Estimation	of	mucin	size	and	confirmation	of	the	purity	of	MUC7	samples	by	4-10	%	gradient	gel	SDS-PAGE	followed	by	PAS	staining	of	mucin	glycoprotein.	Briefly,	1mg	of	purified	lyophilized	aliquots	were	dissolved	in	100μl	of	2%	SDS,	1%	glycerol	and	0.01%	bromophenol	blue	for	SDS-PAGE	gel	investigation.	Lane	1	represents	10μl	of	Thermo	Scientific	Page	Ruler	Pre-stained	Protein	Ladder	while	Lane	2-4	shows	10	μl	 of	 the	purified	Vi	material.	The	first	arrow	represents	the	start	of	the	running	gel	.	
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		 4.1.6 Confirmation	Of	Treated	Mucins	Using	Sodium	Dodecyl	Sulfate	Polyacrylamide	Gel	Electrophoresis	(SDS-PAGE).		 Crude	saliva	and	purified	salivary	mucins	that	were	treated	with	either	DTT	or	digested	with	trypsin	were	analysed	by	SDS-PAGE.	Crude	saliva	that	was	treated	with	DTT	showed	degraded	 subunits	 of	 molecular	 size	 130kDa	 and	 55kDa	 while	 treatment	 of	 trypsin	resulted	in	one	distinct	band	of	molecular	size	250kDa	(Figure	14	a	&b)	We	concluded	that	treatment	of	crude	saliva	with	DTT	was	effective	as	it	 led	to	an	increase	in	mucin	mobility	indicative	of	degraded	mucin	subunits.	Purified	 samples	 that	 were	 treated	 with	 DTT	 (	 Figure	 15a)	 or	 trypsin	 (Figure	 15b)	showed	distinct	bands	of	degraded	subunits.	DTT	treated	samples	showed	subunits	that	had	molecular	weights	of	130kDa	and	72kDa.	These	bands	were	distinct	and	the	subunits	showed	 polydispersity	 a	 characteristic	 of	 mucins.	 Treatment	 with	 trypsin	 showed	distinct	 subunit	 bands	 of	 250kDa	 and	 130kDa.	 Most	 of	 the	 treated	 samples	 were	restricted	at	the	top	of	the	gel	and	did	not	penetrate	the	running	 gel	(Figure	15a	&	Figure	15b).	In	addition	,	very	faint	subunits	of	72kDa	in	size	were	observed	from	DTT	treated	samples	(Figure	15a)	
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Figure	14	Estimation	of	mucin	size	and	purity	of	crude	that	were	treated	with	a)	DTT	and	b)	Trypsin	on	a	4-10	%	gradient	gel	SDS-PAGE	followed	by	PAS	staining	of	mucin	glycoprotein.	Briefly,	1mg	of	purified	lyophilized	aliquots	were	dissolved	in	100μl	of	2%	SDS,	1%	glycerol	and	0.01%	bromophenol	blue	for	SDS-PAGE	gel	investigation.	Lane	1	represents	10μl	of	Thermo	Scientific	Page	Ruler	Pre-stained	Protein	Ladder	while	Lane	2-6	shows	10	μl	mucins	that	were	treated	with	either	a)	DTT	or	b)	Trypsin.	The	first	arrow	represents	the	start	of	the	running	gel	on	both	pictures.				 a)Lane	 1	 2	 3	 4	 5	 6	 b)Lane	 1	 2	 3	 4	 5	 6		
	 Figure	15	Estimation	of	mucin	size	and	purity	of	purified	 salivary	mucins	 that	were	treated	with	a)	DTT	and	b)	Trypsin	on	a	4-10	%	gradient	gel	SDS-PAGE	followed	by	PAS	staining	of	mucin	glycoprotein.	Briefly,	1mg	of	purified	lyophilized	aliquots	were	dissolved	in	100μl	of	2%	SDS,	1%	glycerol	and	0.01%	bromophenol	blue	for	SDS-PAGE	gel	investigation.	Lane	1	represents	10μl	of	Thermo	Scientific	Page	Ruler	Pre-stained	Protein	Ladder	while	Lane	2-6	shows	10	μl	mucins	that	were	treated	with	either	a)	DTT	or	b)	Trypsin.	The	 first	arrow	represents	 the	start	of	 the	running	gel	on	both	pictures.	
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4.1.7 HIV-1	Neutralisation	Assay		 The	anti-HIV-1	activity	of	crude	saliva,	MUC5B,	MUC7,	as	well	as	trypsin	digested	and	DTT	reduced	salivary	samples	was	tested	against	the	YU2	and	DU422.1	pseudo	virus	strains.	The	inhibitory	potential	of	these	samples	were	calculated	by	measuring	the	IC50	defined	as	the	concentration	at	which	50%	of	the	virus	is	inhibited.	The	samples	were	considered	non-inhibitory	at	the	tested	concentrations	in	cases	where	the	neutralisation	value	was	less	than	30%,	or	the	values	were	negative	(regarded	as	artefacts)	or	where	an	increase	in	 mucin	 concentration	 did	 not	 increase	 the	 inhibitory	 activity.	 These	 samples	 were	assigned	 an	 arbitrary	 IC50	 value	 of	 2000ug/ml	 (triple	 the	 highest	 concentration	 used	during	these	experiments)	which	was	log	transformed	as	it	was	impossible	to	extrapolate	an	 IC50.	This	 value	did	not	 interfere	with	our	 statistical	 analysis	 as	 the	data	was	non-	parametric.	 Statistical	 analysis	was	 done	using	 the	Kruskal	Wallis	 test	 and	 the	Mann-	Whitney	U	test	on	all	our	samples.			 Crude	saliva,	MUC5B	and	MUC7		 From	the	cytotoxicity	results	(Table	1),	crude	saliva	samples	had	IC50	that	were	as	high	as	1987	μg/ml	to	as	low	as	500	μg/ml.	Most	of	the	crude	samples	ranged	between	500	μg/ml-	687	μg/ml.	MUC5B	had	lower	IC50	throughout	all	the	samples	with	IC50	as	low	as	68	μg/ml	and	high	as	710	μg/ml.	MUC7	had	three	samples	with	IC50	that	were	>2000	and	the	remaining	samples	ranged	between	65	μg/ml	to	982	μg/ml.	There	was	a	high	inter-individual	variability	shown	from	our	samples	in	their	ability	to	neutralize	the	DU422	virus	(Figure	16).	A	significant	difference	was	detected	by	the	non-	parametric	t	test	between	crude	saliva,	MUC5B	and	MUC7	(Kruskal-Wallis,	p=0.00025).	Furthermore,	pair	wise	analysis	showed	that	MUC5B	was	more	potent	in	inhibiting	the	DU422	virus	as	compared	 to	crude	saliva	and	MUC7	(Mann-Whitney	U,	p=0.0227	and	p=0.0195	 respectively).	 Furthermore,	 no	 difference	 was	 observed	 in	 inhibiting	 the	DU422	virus	by	MUC7	and	crude	saliva	(Mann-Whitney	U,	p=0.128).			 Interestingly,	the	three	cohorts	of	samples	showed	a	significant	difference	in	their	anti-	HIV	activity	against	YU2	virus	(Kruskal-Wallis,	p=0.0078)	(Figure	17).	MUC7	showed	a	
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higher	inhibition	compared	to	MUC5B	and	crude	saliva	(Mann-Whitney	U,	p=0.0341	and	p=0.176	 respectively).	 A	 significant	 difference	 in	 the	 inhibition	 of	 the	 YU2	 virus	 was	detected	between	MUC7	and	crude	saliva	(Mann-Whitney	U,	p=0.0031).					
Figure	16	Comparison	of	the	anti-HIV	activity	of	crude	saliva,	MUC5B	and	MUC7	against	the	DU422	virus	(Kruskal-Wallis,	
p=0.00025).	MUC5B	was	more	potent	in	inhibiting	the	DU422	virus	 as	compared	to	crude	saliva	and	MUC7	(Mann-Whitney	
U,	p=0.0227	and	p=0.0195	respectively).	Furthermore,	no	difference	was	observed	in	inhibiting	the	DU422	virus	by	MUC7	
and	crude	saliva	(Mann-Whitney	U,	p=0.128).	
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Figure	17	Comparison	of	the	anti-HIV	activity	of	crude	saliva,	MUC5B	and	MUC7	against	the	YU2	virus	(Kruskal-Wallis,	
p=0.0078).	MUC7	 showed	 a	 higher	 inhibition	 compared	 to	MUC5B	 and	 crude	 saliva	 (Mann-Whitney	 U,	 p=0.0341	 and	
p=0.176	respectively).	A	significant	difference	in	the	inhibition	of	the	YU2	virus	was	detected	between	MUC7	and	crude	
saliva	(Mann-Whitney	U,	p=0.0031)	
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DTT	Treated	saliva	and	DTT	treated	purified	mucin	
	 A	significant	difference	was	observed	in	the	anti-HIV	activity	of	the	DU422	virus	by	DTT	treated	crude	saliva	and	purified	DTT	treated	salivary	mucins(Figure	18)	(Mann-Whitney	U,	p=0.006).	Purified	DTT	treated	samples	showed	a	higher	inhibitory	activity	compared	to	the	DTT	crude	samples.	The	IC50	for	both	samples	showed	high	variability	against	the	DU422	virus.	They	ranged	between	89	μg/ml	to	956	μg/ml	(	Table	3)	However,	despite	the	differences	in	IC50	between	the	DTT	treated	crude	saliva	and	DTT	purified	mucin	which	ranged	as	low	as	267	μg/ml	to	IC50	of	1000	μg/ml	between	the	two	cohorts,	no	significant	difference	in	the	inhibition	of	the	YU2	virus	by	either	sample	was	observed	(Mann-Whitney	U,	p=0.06)(Figure	19).				
	
Figure	18	Comparison	of	the	anti-HIV	activity	of	DTT	treated	crude	saliva	and	DTT	treated	purified	mucins	against	the	DU422	
pseudo	virus	(Mann-Whitney	U,	p=0.006).	Purified	DTT	treated	samples	showed	a	higher	inhibitory	activity	compared	to	the	
DTT	crude	samples	
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Figure	19	Comparison	of	the	anti-HIV	activity	of	DTT	treated	crude	saliva	and	DTT	treated	purified	mucins	against	the	YU2	
pseudo	virus	using	TZMB/J	cells	(Mann-Whitney	U,	p=0.06).	No	significant	difference	was	observed	in	the	inhibition	of	YU2	
pseudo	virus	by	DTT	treated	crude	saliva	and	DTT	treated	mucins.	
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Trypsin	digested	Saliva	and	trypsin	digested	purified	mucins	
	
	 Although	purified	mucins	had	better	 IC50s	as	compared	 to	crude	saliva,	 there	was	no	significant	 difference	 observed	 in	 the	 anti-HIV	 activity	 of	 the	DU422	 virus	 by	 trypsin	digested	crude	saliva	and	purified	 trypsin	digested	salivary	mucins	 (Mann-Whitney	U,	p=0.08)(Figure	 20).	 The	 IC50	 for	 trypsin	 digested	 crude	 saliva	 samples	 showed	 high	variability	 against	 the	 DU422	 virus.	 They	 ranged	 between	 900	 μg/ml	 to	 1610	 μg/ml	(Table	5).	Purified	digested	samples	had	IC50	with	less	variation	ranging	from	800	μg/ml	to	1400	μg/ml.	Despite	 the	 differences	 in	 IC50	 between	 trypsin	 treated	 samples	 of	 crude	 saliva	 and	purified	 mucin,	 no	 significant	 difference	 in	 the	 inhibition	 of	 the	 YU2	 virus	 by	 either	sample	was	observed	(Mann-Whitney	U,	p=0.06)	(Figure	21).	The	IC50	of	purified	mucins	showed	 large	 variation	 ranging	 from	 810	 μg/ml	 to1653	 μg/ml.	 Crude	 saliva	 that	was	digested	 with	 trypsin	 had	 IC50	 ranging	 from	 889	 μg/ml	 to	 1632	 μg/ml(Table4.1	 in	appendix).	
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	Figure	20	Comparison	of	the	anti-HIV	activity	of	trypsin	digested	samples	between	crude	saliva	and	purified	mucins	.	No	 significant	difference	observed	 in	 the	 anti-HIV	 activity	 of	 the	DU422	virus	by	 trypsin	digested	 crude	 saliva	 and	purified	trypsin	digested	salivary	mucins	(Mann-Whitney	U,	p=0.08).	
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	Figure	21	Comparison	of	the	anti-HIV	activity	of	trypsin	digested	samples	between	crude	saliva	and	purified	mucins	.	No	significant	difference	observed	in	the	anti-HIV	activity	of	the	YU2	virus	by	trypsin	digested	crude	saliva	and	purified	trypsin	digested	salivary	mucins	(Mann-Whitney	U,	p=0.06).	
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4.1.8 Cell	Viability	Assay		 Crude	and	purified	 salivary	 samples	 that	were	used	 for	 the	neutralization	assay	were	tested	or	cytotoxicity	using	the	MTT	assay.	If	the	cell	viability	remained	above	70%	and	there	was	no	increase	in	cell	death	with	increase	in	sample	concentration,	mucins	were	considered	non-toxic.	 In	cases	where	 the	above	condition	was	not	met,	 the	LC50	(50%	Lethal	dose)	was	calculated	using	the	variable	slope	curve	fit	function	in	GraphPad	Prism	(La	Jolla,	CA,	USA)	which	calculates	the	log(inhibitor)	vs.	normalized	response	(Table	1	&	2)							
	 Figure	22	This	graph	demonstrates	the	criteria	that	was	used	to	determine	the	cytotoxicity	of	TZM-bl/JC	cells	where	an	increase	in	mucin	concentration	resulted	in	an	increase	in	cell	death.	
73		
	
Crude,	MUC5B	and	MUC7	
	 In	all	the	fifteen	samples	of	crude	saliva,	eleven	samples	showed	no	detectable	toxicity	with	an	increase	in	crude	saliva	concentration	(Table	1	&	2).	The	remaining	four	samples	had	LC50	ranging	from	535µg/ml	and	as	high	as	1490µg/ml.	Most	samples	of	MUC5B	and	MUC7	showed	no	detectable	cytotoxicity	at	the	different	concentrations	that	were	being	tested.	The	remaining	samples	of	both	MUC5B	and	MUC7	showed	a	high	variation	in	LC50	that	were	high	as	>1287µg/ml	and	LC50	that	were	low	as	167µg/ml.	MUC7	in	particular,	showed	more	cell	death	as	compared	to	MUC5B	(Mann-Whitney	U	,p-value=0.03)(Table	1	&	 2).			
Reduced	Crude	saliva	and	Reduced	Purified	Mucins	
	
	 Initially,	cell	toxicity	was	detected	across	all	the	sample	cohort	of	crude	reduced	saliva	and	purified	reduced	mucins.	We	hypothesised	that	the	cytotoxicity	of	these	samples	was	caused	by	DTT	and	IAA	that	was	not	completely	removed	during	dialysis	and	that	it	could	be	alleviated	if	we	dialysed	our	samples	again	against	PBS.	To	test	this,	we	cultured	TZM-	bl/J	cells	and	tested	our	dialysed	samples	at	different	concentrations.	Four	out	of	nine	of	our	 samples	 showed	 detectable	 toxicity	while	 the	 remaining	 samples	 showed	 a	 large	variation	ranging	from	LC50	high	as	39	876	µg/ml	and	LC50	low	as	385µg/ml	(Table	5	in	appendix).	We	 therefore	 dialysed	 all	 our	 samples	with	 PBS	 to	 exclude	 interference	 of	cytotoxicity	in	our	analysis.			
Trypsin	digested	saliva	and	Trypsin	digested	Purified	Mucins	
	
	 The	majority	of	the	trypsin	digested	saliva	and	trypsin	digested	purified	salivary	mucin	samples	 showed	 no	 detectable	 toxicity	 while	 the	 remaining	 samples	 showed	 a	 huge	variation	with	 the	 LC50	 values	 ranging	 from	 1870µg/ml	 to	 20432µg/ml	 (Table	 5.1	 in	appendix)	
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Table	1	Cytotoxicity	(LC50)	and	HIV-1	neutralization	values	of	DU422	virus	(IC50)	by	
crude	saliva	and	purified	MUC5B	and	MUC7	mucin	samples	
	
	
	 Samples	
CRUDE	 MUC5B	 MUC7	LC50	(µg/ml)	 IC50	µg/ml	 LC50	(µg/ml)	 IC50	µg/ml	 LC50	(µg/ml)	 IC50	µg/ml	1	 No	toxicity	 687	 No	toxicity	 128	 538	 455	2	 No	toxicity	 643	 No	toxicity	 321	 769	 354	3	 No	toxicity	 687	 No	toxicity	 189	 No	toxicity	 >2000	4	 No	toxicity	 566	 No	toxicity	 68	 No	toxicity	 >2000	5	 No	toxicity	 500	 1209	 322	 No	toxicity	 >2000	6	 No	toxicity	 345	 567	 132	 No	toxicity	 982	7	 No	toxicity	 875	 No	toxicity	 421	 1287	 438	8	 758	 987	 No	toxicity	 531	 605	 321	9	 No	toxicity	 656	 No	toxicity	 332	 465	 476	10	 No	toxicity	 527	 No	toxicity	 585	 167	 656	11	 No	toxicity	 1345	 No	toxicity	 315	 534	 564	12	 No	toxicity	 1987	 No	toxicity	 710	 715	 641	13	 535	 897	 No	toxicity	 432	 No	toxicity	 734	14	 625	 1308	 No	toxicity	 68	 No	toxicity	 245	15	 1490	 888	 No	toxicity	 178	 239	 811	
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Table	2	Cytotoxicity	(LC50)	and	HIV-1	neutralization	values	of	YU2	virus	(IC50)	by	Crude	
saliva	and	purified	MUC5B	and	MUC7	mucin	samples	
	
	
	 Samples	
CRUDE	 MUC5B	 MUC7	LC50	(µg/ml)	 IC50	µg/ml	 LC50	(µg/ml)	 IC50	µg/ml	 LC50	(µg/ml)	 IC50	µg/ml	1	 No	toxicity	 629	 No	toxicity	 185	 538	 267	2	 No	toxicity	 No	inhibitio	n	
No	toxicity	 333	 769	 138	
3	 No	toxicity	 678	 No	toxicity	 411	 No	toxicity	 198	4	 No	toxicity	 782	 No	toxicity	 439	 No	toxicity	 65	5	 No	toxicity	 651	 1209	 178	 No	toxicity	 57	6	 No	toxicity	 433	 567	 410	 No	toxicity	 324	7	 No	toxicity	 529	 No	toxicity	 611	 1287	 115	8	 758	 342	 No	toxicity	 484	 605	 778	9	 No	toxicity	 744	 No	toxicity	 382	 465	 607	10	 No	toxicity	 880	 No	toxicity	 102	 167	 213	11	 No	toxicity	 761	 No	toxicity	 1091	 534	 879	12	 No	toxicity	 907	 No	toxicity	 381	 715	 221	13	 535	 767	 No	toxicity	 32	 No	toxicity	 111	14	 625	 1809	 No	toxicity	 648	 No	toxicity	 84	15	 1490	 668	 No	toxicity	 478	 239	 216	
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Table	3	Cytotoxicity	(LC50)	and	HIV-1	neutralization	values	of	DU422	virus	(IC50)	by	DTT	
treated	crude	saliva	and	DTT	treated	purified	mucins.	
	
	
	
	 Samples	
DTT	Treated	crude	saliva	 DTT	Treated	Purified	Mucins	LC50	(µg/ml)	 IC50	(µg/ml)	 LC50	(µg/ml)	 IC50	(µg/ml)	1	 No	toxicity	 	 1000	 No	toxicity	 	 448	2	 No	toxicity	 	 278	 No	toxicity	 	 567	3	 No	toxicity	 	 622	 No	toxicity	 	 109	4	 No	toxicity	 	 776	 No	toxicity	 	 250	5	 No	  1209	  
 toxicity	 333	  411	6	 No	  567	  
 toxicity	 500	  109	7	 No	toxicity	 	 846	 No	toxicity	 	 522	8	 758	  No	  
  267	 toxicity	 355	9	 No	toxicity	 	 667	 No	toxicity	 	 189	
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Table	4	Cytotoxicity	(LC50)	and	HIV-1	neutralization	values	of	YU2	virus	(IC50)	by	DTT	
treated	crude	saliva	and	DTT	treated	purified	mucins.	
	
	
	
	
	
	 Samples	
DTT	Treated	crude	saliva	 DTT	Treated	Purified	Mucins	LC50	(µg/ml)	 IC50	(µg/ml)	 LC50	(µg/ml)	 IC50	(µg/ml)	1	 No	toxicity	 	 956	 No	toxicity	 	 500	2	 No	toxicity	 	 564	 No	toxicity	 	 544	3	 No	toxicity	 	 841	 No	toxicity	 	 299	4	 No	toxicity	 	 734	 No	toxicity	 	 225	5	 No	  1209	  
 toxicity	 567	  125	6	 No	  567	  
 toxicity	 650	  335	7	 No	toxicity	 	 411	 No	toxicity	 	 433	8	 758	  No	  
  333	 toxicity	 689	9	 No	toxicity	 	 217	 No	toxicity	 	 250	
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Table	5	Cytotoxicity	(LC50)	and	HIV-1	neutralization	values	of	YU2	virus	(IC50)	by	trypsin	
digested	crude	saliva	and	trypsin	digested	purified	mucins.	
	
	
	
	
	
	 Samples	
Trypsin	digested	crude	saliva	 Trypsin	digested	purified	mucins	LC50	(µg/ml)	 IC50	(µg/ml)	 LC50	(µg/ml)	 IC50	(µg/ml)	1	 No	toxicity	 	 1190	 No	toxicity	 	 900	2	 No	toxicity	 	 1087	 No	toxicity	 	 1632	3	 No	toxicity	 	 1233	 No	toxicity	 	 917	4	 No	toxicity	 	 1467	 No	toxicity	 	 1021	5	 No	  1209	  
 toxicity	 1306	  1161	6	 No	  567	  
 toxicity	 889	  1332	7	 No	toxicity	 	 1312	 No	toxicity	 	 1421	8	 758	  No	  
  1653	 toxicity	 810	9	 No	toxicity	 	 1085	 No	toxicity	 	 1332	
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Table	6	Cytotoxicity	(LC50)	and	HIV-1	neutralization	values	of	DU422	virus	(IC50)	by	
trypsin	digested	crude	saliva	and	trypsin	digested	purified	mucins.	
	
	
	
	
	
	 Samples	
Trypsin	digested	crude	saliva	 Trypsin	digested	Purified	mucins	LC50	(µg/ml)	 IC50	(µg/ml)	 LC50	(µg/ml)	 IC50	(µg/ml)	1	 No	toxicity	 	 1610	 No	toxicity	 	 1221	2	 No	toxicity	 	 1161	 No	toxicity	 	 999	3	 No	toxicity	 	 1100	 No	toxicity	 	 917	4	 No	toxicity	 	 1421	 No	toxicity	 	 1100	5	 No	  1209	  
 toxicity	 1321	  1400	6	 No	  567	  
 toxicity	 1121	  800	7	 No	toxicity	 	 1543	 No	toxicity	 	 1099	8	 758	  No	  
  1332	 toxicity	 1332	9	 No	toxicity	 	 917	 No	toxicity	 	 1111	
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	 4.2 DISCUSSION		 Previous	studies	in	our	laboratory	has	shown	that	crude	saliva,	purified	salivary	mucins	together	with	purified	mucins	from	breast	milk	and	the	cervix	inhibits	HIV-1,	whereas	crude	breastmilk	and	cervical	mucus	showed	no	inhibition	(Habte	et	al.	2006:Habte	et	al.	2008;	Peacocke	2011;	Peacocke	et	al.	2012;	Mthembu	et	al.	2014).This	study	aimed	to	determine	the	minimum	peptide	chain	length	and	structure	of	a	gel	forming	mucin	that	retains	the	anti-HIV-1	activity.	Furthermore,	this	study	aimed	to	investigate	the	role	of	glycans	in	the	inhibition	of	HIV-1.	Salivary	samples	used	in	this	study	were	obtained	from	HIV-negative	individuals	who	declared	a	risk	free	lifestyle.	Saliva	was	collected	in	6M	GuHCL	with	PI	and	was	successfully	purified	using	caesium	chloride	 gradient	 ultracentrifugation	 a	 well-established	 method	 for	 purifying	 mucins	(Creeth	and	Denborough	1970;	Mall	1987;	Mall	1988).	These	samples	underwent	 two	caesium	 chloride	 gradient	 ultracentrifugation	 spins	 in-order	 to	 remove	 the	 excess	proteins	 and	 contaminates	 before	 yielding	mucins	 (Figure	 4).	 Thereafter,	 the	 salivary	glycoproteins	were	successfully	separated	on	a	Sepharose	CL-4B	bead	(Figure	5).	The	Vo	fraction	which	was	 later	identified	as	MUC5B	eluted	in	the	first	peak	whilst	the	Vi	fraction	identified	as	MUC7	eluted	second	and	had	a	smaller	peak	compared	to	the	V0	peak	(Figure	5).	Crude	and	purified	samples	that	were	treated	with	DTT	or	digested	with	trypsin	were	subjected	 to	gel	 filtration	 to	monitor	 the	 changes	 in	mucin	 size.	 In	both	 treatments	of	crude	and	purified	salivary	samples,	there	was	 incomplete	digestion	and	reduction	of	the	samples	with	trypsin	and	DTT	respectively	(Figure	6,7,	8	&	9).	A	rightward	shift	in	mucin	peak	is	an	indicator	for	reduction	in	mucin	size	(Allen	1989).	Our	gel	filtration	profiles	did	not	shift	to	the	right	and	the	size	of	peaks	did	not	decrease	as	expected	(Figure	6,	7,	8	&	9).	We	attributed	this	to	GuHCl,	a	denaturant	that	was	used	as	the	extraction	buffer.	The	presence	of	protease	inhibitors	in	the	buffer	could	have	prevented	any	endogenous	proteolysis	 to	 take	place.	 In	addition,	 the	aggregatory	properties	of	GuHCl	could	have	
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masked	 the	 protein	 naked	 regions	 or	 the	 disulphide	 bridges	 within	 the	 mucins	 thus	making	 it	 difficult	 for	 digestion	 and	 reduction	 to	 occur	 (Mall	 1984).	 Moreover,	 the	digestion	of	saliva	using	trypsin	was	not	pH	controlled	and	this	could	have	affected	the	optimal	rate	at	which	proteolytic	digestion	occurred.			 Antibodies	raised	against	the	human	mucin	MUC5B	and	MUC7	were	used	during	slot	blot	analysis.	 The	 purification	 of	 salivary	 mucins	 has	 raised	 some	 concern	 since	 it	 was	previously	identified	by	Thornton	et	al.	(2001)	that	salivary	mucins	and	SAG	precipitates	together	 and	 elutes	 during	 purification	 as	 a	 complex.	 To	 solve	 this,	we	 tested	 all	 our	samples	with	a	monoclonal	antibody	anti-gp340	and	no	immunoreactivity	was	detected.	These	results	(Figure	10)	showed	that	our	mucins	were	successfully	separated	when	the	V0	 and	Vi	 fractions	were	 tested	 against	 their	 respective	 antibodies.	 SDS	Page	 analysis	followed	by	PAS	staining	of	crude	saliva	showed	two	population	of	mucins	of	molecular	weights	size	250kDa	and	180kDa	(Figure	11).	The	smear	effect	observed	in	all	the	lanes	in	figure	11	attributed	to	the	heterogeneity	and	polydispersity	of	glycoproteins	(Harding,	1984).	 Briefly,	 heterogeneity	 is	 a	 feature	 that	 results	 when	molecules	 do	 not	 have	 a	distinct	 single	 molecular	 weight	 while	 polydispersity	 occurs	 when	 a	 molecule	 has	different	densities	which	results	in	different	molecular	weights	(Harding,	1984).			 Regardless	 of	 mucin	 samples	 showing	 the	 same	 purification	 profiles,	 there	 were	differences	in	electrophoretic	mobility	of	MUC5B	and	MUC7	(Figure	12	&	13).	In	addition,	the	mucin	yield	that	was	obtained	after	the	purification	process	differed	from	individual	to	individual.	The	difficulty	in	getting	volunteers	to	consistently	spit	saliva	at	specific	time	intervals	and	diurnal	variations	in	salivary	glands	could	contribute	to	the	differences	in	mucin	yield	and	mobility.			 Subtype	C	is	the	most	prevalent	strain	in	South	Africa	and	has	a	high	global	predominance	whereas	the	subtype	B	virus	 is	not	as	common	in	Africa.	The	subtype	B	strain	 is	most	common	and	prevalent	in	Europe	and	Asia	(Junqueira	et	al.	2016).	The	YU2	virus	and	the	DU422	virus	which	are	both	 laboratory	adopted	subtype	B	and	C	strains	 respectively,	were	used	 for	 the	neutralization	assays	 in	 this	study	to	determine	the	role	of	salivary	
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mucins	in	the	inhibition	of	HIV-1.	To	the	best	of	my	knowledge,	this	was	the	first	time	that	our	laboratory	conducted	neutralization	assays	on	a	subtype	B	strain.	The	results	of	this	present	 study	 and	 that	 of	 Peacocke	 et	 al.	 (2012)	 agree	 that	 both	 crude	 and	 purified	salivary	mucins	from	HIV-negative	individuals	inhibit	HIV-1	in	vitro.	While	successfully	demonstrating	this,	the	study	by	Peacocke	et	al.	(2012)	did	not	quantitatively	compare	the	inhibitory	potential	of	the	mucin	samples.	Therefore,	this	present	study	used	a	more	advanced	 neutralisation	 assay.to	 calculate	 dose	 response	 curves	which	measured	 the	potency	(IC50s)	of	the	mucin	samples.			 The	traditional	neutralization	method	used	by	Habte	et	al.	(2006;	2010)	and	Peacocke	et	al.	 (2012)	 involved	 the	use	of	mitogen-stimulated	peripheral	blood	mononuclear	 cells	(PBMCs)	and	a	p24	antigen	to	detect	the	replication	of	the	HIV-1	virus.	While	this	assay	was	 considered	 to	 be	 of	 physiological	 value,	 there	 was	 a	 major	 concern	 regarding	reproducibility	(Polonis	et	al.	2008).	The	producibility	of	the	p24	assay	was	affected	by	using	PBMCS	 from	different	donors.	This	 is	 the	reason	 for	 the	considerable	variability	detected	with	 using	 this	 assay	 during	 experiments	 (Montefiori	 and	 Evans	 1999).	 The	differences	in	the	number	of	CD4+	cells	and	CD4+	surface	cell	receptors	on	PBMC	cells	,	from	different	 individuals	 could	 affect	 their	 susceptibility	 to	HIV-1.	Moreover,	 genetic	polymorphism	in	chemokine	receptors	as	well	as	host	cell	surface	receptors	could	also	account	for	the	variation	that	this	assay	has	(Polonis	et	al.	2008).			 In	this	present	study	we	used	the	luciferase	reporter	assay	as	described	by	Montefiori	(2009).	This	assay	involved	the	infection	of	a	pseudoviral	strain	to	a	transformed	cell	line	such	as	the	TZM-bl/JC	cells.	This	cell	line	express	the	CD4,	CXCR4,	ICAM	3	and	MHC	class	ll	 receptors	 making	 them	 suitable	 host	 cells	 for	 HIV	 infection	 (Nara	 et	 al.	 1987).	 In	addition,	these	cells	are	modified	and	contain	reporter	genes	for	luciferase	and	E.	coli	β-	galactosidase	 which	 are	 initiated	 in	 the	 presence	 of	 the	 HIV	 Tat.	 Viral	 infection	 is	indicated	by	the	activity	of	the	luciferase	(Montefiori	2009).	The	envelope	protein	was	cloned	 and	 incoperated	 into	 a	 plasmid	 that	 contained	 a	 dysfunctional	 env	 gene	sequence.	The	advantage	of	using	this	dysfunctional	env	gene	is	that	it	allows	for	the	host	cells	to	be	infected	only	once	 thereby	making	it	a	good	alternative	to	use	in	the	laboratory	
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than	a	wildtype	virus	(Montefiori	2009).	Moreover,	 the	env	plasmids	were	engineered	with	 viruses	 from	 different	 clades	 making	 it	 easier	 to	 test	 the	 anti-HIV-1	 activity	 of	different	strains.	This	assay	is	safe,	needs	less	time	to	be	conducted	and	is	reproducible.	Moreover,	 inter-experimental	 comparisons	are	 easier	because	of	 the	platform	used	 to	give	standardized	results	(Montefiori	2005;	Montefiori	2009;	Sarzotti-Kelsoe	et	al.	2014).	Although	the	TZM-bl/JC	cell	line	has	a	high	expression	of	the	CCR5	co-surface	receptors	,	this	may	not	be	a	true	representation	of	the	cellular	environment	 in-vivo.	Nonetheless,	this	assay	closely	mimics	the	natural	physiological	conditions.			 The	results	of	 this	present	study	showed	 that	crude	saliva,	MUC5B	and	MUC7	has	 the	ability	to	inhibit	the	transmission	of	HIV-1	to	TZM-bl/JC	cells	by	HIV-1	DU422.1	and	YU2	pseudo-virus	 strain.	 While	 MUC5B	 showed	 a	 higher	 inhibitory	 potential	 against	 the	DU422	virus,	MUC7	had	a	greater	anti-HIV-1	activity	against	the	YU2	pseudo-virus	strain.	This	 finding	 requires	 further	 investigation.	 Furthermore,	 crude	 saliva	 showed	comparable	HIV-1	inhibition	against	both	the	DU422	virus	and	the	YU2	virus.			 As	shown	in	figure	16	&	17	crude	saliva	inhibited	the	infection	of	TZM-bl/JC	cells	against	the	 DU422	 and	 YU2	 pseudo-virus	 strains	 (Kruskal-Wallis,	 p=0.00025).	 This	 is	 in	agreement	with	the	initial	findings	of	Fultz	(1986)	and	Fox	et	al	(1990)	in	which	saliva	inhibits	 the	 activity	 of	 HIV-1	 in-vitro.	The	 isotonic	 nature	 of	 saliva	 together	 with	 the	presence	 of	 immunological	 factors	 and	 non-immunological	 proteins	 in	 the	 oral	 cavity	accounts	 for	 the	 inhibitory	 potential	 of	 saliva	 towards	 HIV-1	 pseudo-virus	 strains	(Matsuda	et	al.	1993;	Artenstein	et	al.	1997;	Yasida	et	al.	1998).	This	also	explains	why	the	transmission	of	HIV	via	 the	oral	cavity	 is	rare.	 In	addition,	 the	presence	of	soluble	factors	 such	 as	 SPL1	 and	 lactoferrin	 in	 saliva	 are	 known	 to	 play	 a	 crucial	 role	 in	 the	inhibition	of	HIV-1.	While	SLPI	interacts	with	host	cells	thereby	preventing	viral	binding	and	 subsequent	 infection	 (McNeely	 et	 al.	 1995;	McNeely	 et	 al.	 1997;	Ma	 et	 al.	 2004),	lactoferrin	 is	 known	 to	 inhibit	 one	 of	 the	 HIV-1	 infection	 cycle	 enzymes,	 reverse	transcriptase	 (Ng	 et	 al.	 2001).	 These	 proteins	 in	 saliva	 provide	 Synergistic	 effects	 in	their	role	as	 inhibitors	against	the	transmission	of	HIV-1	(Yeh	et	al.	1992;	Kazmi	et	al.	2006).	
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MUC5B	 showed	 the	 highest	 anti-HIV-1	 potency	 against	 the	DU422	 virus	 between	 the	three	cohorts.	These	results	agree	with	the	initial	findings	of	Habte	et	al.	(2008;	2010)	;	Peacocke	et	al.	(2012)	and	McQuaid	2017	(manuscript	under	review)	in	which	MUC5B	showed	a	higher	potency	against	the	DU422	pseudo	virus	compared	to	MUC7.	The	finding	that	MUC5B	shows	greater	potency	compared	 to	MUC7	 is	 in	 line	with	 the	 theory	 that	carbohydrate	side	chains	play	a	vital	role	in	their	anti-HIV-1	activity.	The	carbohydrates	moieties	on	MUC5B	are	 large,	many	and	extensive	as	compared	 to	MUC7	which	could	account	for	an	effective	aggregatory	activity	(Thornton	et	al.	1999;	Levine	et	al.	1987).	They	account	for	78%	of	the	total	molecular	weight	of	MUC5B	(Levine	et	al.	1987).	The	threonine	and	serine	residues	that	form	the	tandem	repeat	sites	of	MUC5B	 contain	many	potential	sites	for	O-linked	glycosylation	(Zalewska	et	al.	2000).	The	higher	glycosylation	seen	on	MUC5B	could	increase	the	glycan	/viral	binding	sites	or	could	increase	the	net	negative	 charge	 of	mucins	which	 in-turn	 could	 increase	 its	 aggregatory	 function.	 The	different	glycosylation	profiles	shown	by	both	mucins	(MUC5B	and	MUC7)	may	account	for	the	differences	observed	during	viral	inhibition	(Thomsson	et	al.	2002).	In	 addition,	MUC5B	 consists	 of	many	 subunits	 that	 are	 joined	 together	 via	 disulphide	bonds.	 These	 subunits	 add	 to	 the	 polymeric	 nature	 and	 the	 gel	 forming	 abilities	 of	MUC5B.	Furthermore,	 these	 subunits	physically	block	 the	HIV-1	particles	 ensuring	no	infection	of	target	cells	occur	(Zalewska	et	al.	2000;	Sellers	et	al.	1988).	MUC7	on	the	other	hand,	primarily	consists	of	monomeric	subunits	with	less	sugar	side	chains	(Mehrotra,	Thornton	 and	 Sheehan	1998).	 This	 could	 account	 for	 the	 lower	 aggregatory	potential	towards	the	DU422	pseudo-viral	strain.	While	this	is	based	on	the	understanding	that	the	inhibition	of	HIV-1	by	saliva	and	salivary	mucins	is	thought	to	be	primarily	by	aggregation	(Archibald	and	Cole	1990;	Malamud	et	al.1993;	Bergey	at	al.	1994),	 the	limited	inhibitory	activity	 of	 MUC7	 contradicts	 earlier	 studies	 which	 demonstrated	 MUC7	 as	 the	 most	dominant	 glycoprotein	 in	 the	 inhibition	of	HIV-1	via	 salivary	 secretions	 (Bergey	et	 al.	1994;	Nagashunmugan	et	al.	1998).	Perhaps	In	vivo,	MUC7	form	complexes	with	other	soluble	 proteins	 to	 elicit	 an	 efficient	 anti-HIV-1	 response.	 It	 is	 possible	 that	 the	purification	of	MUC7	diminishes	this	response.	Future	experiments	should	use	electron	microscopy	work	to	determine	the	mucin/virus	interaction	as	well	as	the	mucin/cell	and	virus	interactions	of	MUC5B	and	MUC7	to	account	for	these	inhibitory	differences.	
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There	has	been	a	major	debate	as	to	whether	the	aggregatory	activity	of	salivary	mucins	is	specific	or	non-specific.	The	presence	of	infectious	viral	and	bacterial	agents	in	saliva	such	as	hepatitis	B	virus,	herpes	simplex	virus	(HSV),	HIV-2	(Tabak	1995;	Bosch	et	al.	2000;	Crombie	et	al.	1998)	in	saliva	suggests	the	possibility	that	the	aggregatory	activity	could	be	specific.	In	addition,	Bobek	and	Situ	(2003)	reported	that	the	binding	of	salivary	mucins	to	pathogens	prevents	them	from	binding	to	targeted	host	cells	and	subsequently	causing	infection.	Furthermore,	saliva	was	demonstrated	to	selectively	bind	to	and	clear	both	viral	and	bacterial	microorganisms	from	the	oral	cavity	(Prakobphol	et	al.	2005).	The	interaction	of	MUC5B	and	MUC7	towards	viruses	and	bacteria	differs	which	suggests	the	 possibility	 that	 they	 have	 different	mechanisms	 through	which	 they	 interact	 and	inhibit	HIV-1	 (Frenkel	 and	Ribbeck	2015a).	 It	 is	 also	known	 that	MUC7	demonstrates	better	bacterial	binding	while	MUC5B	shows	effective	viral	binding	properties	(Frenkel	and	Ribbeck	2015a).	This	current	study	showed	that	mucins	interact	with	viral	strains	differently.	 MUC7	 showed	 a	 better	 anti-HIV	 activity	 against	 the	 YU2	 pseudo-virus	 as	compared	 to	 DU422	 virus	 (Mann-Whitney	 U,	 p=0.0031)	 Although	 the	 mechanism	through	which	MUC7	inhibits	the	YU2	pseudo-virus	is	unknown,	we	speculate	that	the	observation	by	Bobek	and	Situ	(2003);	Smith	and	Bobek	(2001)	could	account	for	this.	The	 authors	 found	 that	 the	presence	 of	 cationic	 peptides	 together	with	 the	histatin	 5	peptides	 that	 were	 present	 on	 the	 N-terminal	 residues	 of	 MUC7	 offered	 an	 added	advantage	 that	 specifically	 allowed	 MUC7	 to	 entrap	 viruses	 causing	 an	 effective	inhibitory	activity.	Furthermore,	MUC7	has	been	associated	with	specific	bacterial	strains	such	as	streptococci	strain	(Murray	et	al.	1982;	Ligtenberg	et	al.1992;	Murray	et	al.	1992).	Tabak	(1990)	demonstrated	that	saliva	that	was	depleted	of	MUC7	and	not	MUC5B	could	cause	agglutination	and	subsequently	abolish	the	activity	of	certain	streptococci	strains.	Moreover,	he	demonstrated	that	sialic	acids	present	on	the	MUC7	glycans	were	involved	in	the	binding	of	different	bacteria	including	Streptococcus	gordonii	and	Streptococcus	sanguis	strains	(Murray	et	al.	1992;	Levine	et	al.	1978).	Thus,	the	structural	difference	between	MUC5B	and	MUC7	could	account	for	the	differences	observed	during	inhibition.	MUC7	could	be	involved	in	different	mucin/	virus	interactions	with	different	strains	and	this	could	account	for	the	differences	observed	inhibition.	
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In-order	to	assess	the	minimum	size	that	is	required	for	mucins	to	retain	their	anti-HIV-	1	activity,	crude	saliva	together	with	purified	mucins	were	treated	with	either	DTT	or	0.25%	trypsin	and	tested	against	the	two	different	pseudo-virus	strains.	DTT	treatment	breaks	down	the	disulphide	bonds	 that	 links	mucin	subunits	 together	via	 the	cysteine	residues	(Carlstedt	et	al.	1983a).	Purified	salivary	mucins	that	were	treated	with	DTT	had	the	highest	anti-HIV-1	activity	towards	both	strains	compared	to	crude	saliva	that	was	treated	 with	 DTT	 (Mann-Whitney	 U,	 p=0.006)	 (Figure	 18	 &	 19).	 This	 observation	suggests	that	even	when	the	gel	forming	properties	of	mucins	are	compromised,	mucins	still	retain	their	ability	to	inhibit	viruses	(Carlstedt	et	al.	1983a).	However,	the	reduced	inhibitory	potential	 in	 samples	 that	were	 treated	with	DTT	compared	 to	 samples	 that	were	not	treated(both	crude	and	purified	saliva)	suggests	the	possibility	that	disulphide	bonds	may	play	a	role	in	recognizing	viral	epitopes	(Pillay	2017	thesis).	Trypsin	 digestion	 of	 both	 crude	 saliva	 and	 purified	 salivary	 mucins	 yielded	 minimal	inhibition	 of	 both	DU422	 and	 YU2	 pseudo-viral	 strain	 compared	 to	 reduced	 subunits	(Figure	20	&	21).	While	it	is	possible	that	extensive	glycosylation	of	mucins	could	have	masked	the	interaction	of	the	trypsin	enzymes	to	the	underlying	protein	core	,	it	is	highly	likely	that	this	could	have	affected	any	interactions	between	the	peptides	and	the	viral	particles	thereby	influencing	 the	potency	of	these	samples	towards	the	different	pseudo-	strains	(Wu,	Csaka	and	Herp	1994).	 Furthermore,	given	that	our	extraction	buffer,	GuHCl	is	known	to	cause	aggregation	(Mall	1984),	the	peptide	fragments	could	have	aggregated	masking	the	viral	binding	sites	which	subsequently	lead	to	a	reduced	inhibitory	activity.	However,	the	inhibition	shown	by	these	peptide	fragments	suggests	the	possibility	that	mucins	do	not	have	to	be	large	or	polymeric,	they	just	need	to	have	the	required	number	of	oligosaccharides	or	the	specific	sugar	side	chain	sequence	and	composition	to	inhibit	HIV-1	via	aggregation.	The	average	concentration	of	MUC5B	and	MUC7	in	saliva	under	mastication	conditions	as	 reported	by	Rayment	et	al.	 (2000)	 is	233ug/ml	and	133ug/ml	 respectively.	During	stimulation,	parotid	secretions	increase	considerably	(Humphrey	and	Williamson	2001).	However,	since	parotid	secretions	are	devoid	of	mucins,	the	above	concentrations	are	less	likely	to	represent	the	total	mucin	concentration	in	whole	saliva.	Ten	of	the	30	Purified	MUC5B	(Table	1	&	2)	had	IC50	below	the	reported	physiological	concentrations.	Only	5	purified	samples	of	MUC7	(Table	1	&	2)	had	IC50	at	or	below	the	reported	values.	The	
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values	reported	by	Rayment	et	al.	(2000)	had	high	standard	deviations	these	values	were	used	to	give	context	rather	than	being	used	as	absolute	values.	The	cytotoxicity	of	crude	saliva	and	purified	salivary	mucins	were	tested	against	the	TZM-	bl/JC	cells	using	the	MTT	assay.	If	the	cell	viability	remained	above	70%	and	there	was	no	increase	in	cell	death	with	increase	in	sample	concentration,	mucins	were	considered	non-toxic.	In	cases	where	the	above	condition	was	not	met,	the	LC50	(50%	Lethal	dose)	was	calculated	using	the	variable	slope	curve	fit	function	in	GraphPad	Prism	(La	Jolla,	CA,	USA)	which	calculates	the	log(inhibitor)	vs.	normalized	response	(Figure	6).	Our	samples	showed	that	mucins	were	not	toxic	hence	we	ruled	out	the	possibility	that	salivary	mucin	samples	could	cause	cell	death.	Overall,	most	of	the	crude	saliva	samples	together	with	purified	 MUC5B	 samples	 were	 non-toxic	 and	 gave	 IC50	 values	 that	 validated	 the	neutralisation	 assay	 (Table	 1	 &	 2).	 The	majority	 of	MUC7	 and	 DTT	 reduced	 samples	showed	 cytotoxicity	 and	 while	 it	 is	 possible	 that	 residual	 traces	 of	 DTT	 and	 mucin	extraction	buffer	GuHCl	caused	cell	death,	this	is	unlikely	since	all	samples	were	subjected	to	extensive	dialysis.	Therefore,	using	a	different	cell	line	in	future	experiments	might	be	valuable	in	this	regard.			 There	is	a	significant	decline	in	the	amount	and	concentration	of	salivary	mucins	in	older	people	 as	 compared	 to	 younger	 individuals	 (Bolscher	 et	 al.	 1999;	Denny	 et	 al.	 1991).	Furthermore,	 the	sugar	content	between	the	two-age	group	also	differs.	Tabak	(1982)	demonstrated	that	the	amount	of	sugar	content	of	salivary	mucins	present	in	adults	 is	twice	 as	 much	 as	 compared	 to	 the	 younger	 group.	 In	 addition,	 the	 frequent	 use	 of	medication	and	the	loss	of	function	of	the	submandibular	parenchyma	is	argued	to	cause	a	decrease	in	the	amount,	concentration	and	potency	of	these	mucins	in	the	older	aged	group	 (Denny	 et	 al.	 1991).	 Therefore,	 future	 studies	 should	 put	 to	 account	 the	 age	difference	when	testing	the	anti-HIV	activity	of	crude	saliva	and	purified	salivary	mucins	against	the	different	viral	strains.			 The	 results	 of	 this	 study	 shows	 that	 salivary	 mucins	 inhibit	 the	 activity	 of	 HIV-1.	 In	addition,	MUC5B	a	 gel	 forming	mucin	 showed	greater	 anti-HIV-1	 activity	 towards	 the	DU422	virus,	a	subtype	C	strain	than	MUC7.	Furthermore,	MUC7	had	a	significantly	
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higher	inhibitory	potency	towards	the	YU2	virus,	a	subtype	B	strain.	However,	it	should	be	 noted	 that	 this	 present	 study	 did	 not	 test	 the	 anti-HIV	 activity	 of	 salivary	mucins	against	 a	 wide	 range	 of	 subtype	 B	 strains	 hence	 we	 cannot	 conclude	 if	 this	 is	 a	characteristic	of	the	YU2	virus	or	of	all	subtype	B	strains.	Thus,	future	studies	with	large	sample	sizes	need	to	investigate	if	MUC7	display	such	potency	towards	different	strains	of	the	subtype	B	virus.	
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CHAPTER	FIVE:	A	COMPARISON	OF	THE	ANTI-HIV-1	INHIBITORY	ACTIVITY	OF	DEGLYCOSYLATED	MUC5B	AND	MUC7	5.1 Introduction		 The	addition	of	sugar	chains	to	a	protein	core	(glycosylation)	is	a	highly	conserved	type	of	protein	modification	and	requires	a	lot	of	enzymes	(Hagen	et	al.	2013).	To	date,	two	forms	of	mucin	glycosylation,	N-linked	and	O-linked	occur	on	most	secreted	or	membrane	bound	 proteins.	 O-	 linked	mucin	 glycosylation	 is	 an	 evolutionarily	 conserved	 protein	modification	that	is	found	in	most	mammals,	worms	and	in	certain	insects	(Hagen	et	al	2013).	 This	 modification	 is	 characterised	 by	 the	 addition	 of	 N-acetylglucosamine	(GALNAc)	 to	 the	 hydroxyl	 group	 of	 serine	 or	 threonine	 residues	 (Rose	 and	 Voynow	2005).	N-linked	oligosaccharides	are	usually	attached	via	N-Acetylglucosamine	linkage	to	asparagine	(Jansen	et	al.	2009).	In	addition	to	N-acetyl	galactosamine	(GalNAc),	N-acetyl	glucosamine	(GlcNAc),	N-acetyl	neuraminic	 acid,	 fucose	 and	 galactose	 are	 the	 sugars	 that	make	 up	 the	 carbohydrate	moiety	of	O-linked	mucins.	This	moiety	accounts	for	85%	of	their	molecular	weight	(Wu,	Csako,	and	Herp	1994)	and	serves	to	protect	the	mucin	protein	core	(apomucin)	 from	proteolysis	 and	 degradation	 (Wu,	 Csako,	 and	 Herp	 1994).	 Moreover,	 the	 extensive	glycosylation	 serves	 to	 extend	 the	 protein	 backbone	 transforming	 it	 into	 a	 globular	structure	(Shogren	et	al	1989).	The	sequence	and	extent	of	glycosylation	depends	on	the	type,	function	and	localisation	of	the	mucin	(Sellers	et	al.	1988).	In	addition,	the	length	of	these	glycan	chains	also	varies.	The	 terminal	 residues	of	mucins	are	made	up	of	sialic	acids,	fucose	and	sulphated	GlcNAc	or	blood	group	determinants	that	give	mucins	their	hydrophobic	 and	hydrophilic	properties	 (Rose	and	Voynow	2005).	Table	7	 shows	 the	structures	of	O-glycan	cores	and	antigenic	epitopes	found	in	mucins.	
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Table	7	The	O-glycan	core	structures	and	antigenic	epitopes	found	in	mucins	(taken	from	
Brockhausen	et	al.	2009).	
	
O-Glycan	 Structure	Core	Tn	antigen	 GalNAcαSer/Thr	Sialyl-Tn	antigen	 Siaα2-6GalNAcαSer/Thr	Core	1	or	T	antigen	 Galβ1-3GalNAcαSer/Thr	Core	2	 GlcNAcβ1-6(Galβ1-3)GalNAcαSer/Thr	Core	3	 GlcNAcβ1-3GalNAcαSer/Thr	Core	4	 GlcNAcβ1-6(GlcNAcβ1-3)GalNAcαSer/Thr	Core	5	 GalNAcα1-3GalNAcαSer/Thr	Core	6	 GlcNAcβ1-6GalNAcαSer/Thr	Core	7	 GalNAcα1-6GalNAcαSer/Thr	Core	8	 Galα1-3GalNAcαSer/Thr	Epitope	Blood	groups	O,	H	 Fucα1-2Gal-	Blood	group	A	 GalNAcα1-3(Fucα1-2)Gal-	Blood	group	B	 Galα1-3(Fucα1-2)	Gal-	Linear	B	 Galα1-3Gal-	Blood	group	i	 Galβ1-4GlcNAcβ1-3Gal-	Blood	group	I	 Galβ1-4GlcNAcβ1-6(Galβ1-4GlcNAcβ13)	Gal-	Blood	group	Sd(a),	Cad	 GalNAcβ1-4(Siaα2-3)Gal-	Blood	group	Lewisa	 Galβ1-3(Fucα1-4)GlcNAc-	Blood	group	Lewisx	 Galβ1-4(Fucα1-3)GlcNAc-	
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	 5.2 Analysis	of	O-linked	Glycosylation		 For	 a	while	now,	O-linked	glycosylation	has	been	overlooked	by	 researchers	due	 to	 a	variety	of	reasons.	Firstly,	O-glycosylation	lacks	a	known	amino	acid	consensus	sequence.	In	contrast	to	N-linked	glycosylation,	the	sites	for	O-	linked	glycosylation	are	not	found	in	any	known	amino	acid	sequence	making	it	difficult	for	the	development	of	any	tools	that	can	be	used	as	predictors	(Jensen	et	al.	2009).	Secondly,	the	analysis	of	O-glycans	remain	a	challenge	because	of	the	structural	heterogeneity	of	mucins.	This	has	made	system	wide	analysis	of	mucin	difficult	because	there	is	no	universal	enzyme	for	the	removal	of	glycans	from	 mucins	 (lwase	 et	 al.	 1993).	 Furthermore,	 O-type	 glycosylation	 of	 mucin	 is	heterogenous	thus	there	 is	no	general	 isolation	and	detection	method.	There	has	been	many	attempts	to	use	tags	on	glycans	and	although	this	has	been	successful,	it	has	been	limited	 to	 cell	 culture	 and	 animal	 studies	 (Agard	 et	 al.	 2006;	Hang	 et	 al.	 2003).	 In	 an	attempt	to	identify	the	different	approaches	of	characterizing	glycoproteins,	Dodds	et	al.	(2009)	 divided	 the	 field	 of	 glycosylation	 into	 three	 parts	 namely	 the	 proteocentric,	glycocentric	and	reductionist	glycoproteomic.	The	branch	of	proteocentric	deals	with	the	removal	 of	 glycans	 to	 identify	 the	underlying	proteins	while	 glycocentric	 involves	 the	analysis	of	glycans	removed	from	a	subset	of	proteins	and	reductionist	glycoproteomic	analyses	 both	 the	 glycans	 and	 proteins	 (Dodds	 et	 al.	 2009).	 However,	 due	 to	 the	complexity	 of	 glycoproteins,	 the	 authors	 stressed	 the	 need	 of	 developing	 real	 global	glycoproteomic	 analysing	 tools	 that	 can	 differentiate	 and	 characterize	 both	 N	 and	 O-	linked	glycosylation.	
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5.3 Alterations	in	Mucin	Glycosylation	and	The	Role	of	Glycosylation	in	HIV	Inhibition.		 Alterations	 and	 regulation	 in	 mucin	 glycosylation	 has	 been	 associated	 with	 certain	diseases.	For	example,	the	under-glycosylation	of	mucins	has	resulted	in	the	formation	of	cancer	 associated	 antigens	 that	 are	 expressed	 in	most	 carcinomas	 (Iwata	 et	 al.	 1993;	Vinall	 et	 al.	 1998;	 Fowler,	 Vinall,	 and	 Swallow	 2001).	 It	 has	 been	 shown	 that	 during	oncogenic	 transformation,	 mucins	 tend	 to	 be	 susceptible	 to	 aberrant	 glycosylation	patterns.	This	has	been	recognized	as	one	of	the	hallmarks	of	cancer	(Tuccillo	et	al.	2014).	The	highly	polymorphic	nature	of	mucin	genes	as	a	result	of	the	tandem	repeats	which	are	variable	in	number	makes	them	susceptible	to	alterations	in	the	apomucin	core	and	in	the	number	of	O-linked	sites	that	can	be	available	for	glycosylation	(Vinall	et	al.	1998;	Fowler,	Vinall,	 and	Swallow	2001).	 In	 addition,	mutations	 that	directly	 affect	O-linked		glycosylation,	either	by	changing	the	glycosylation	sites	or	 inhibiting	 the	glycosylation	processes	 has	 been	 associated	 with	 familial	 tumoral	 calcinosis,	 Tn	 syndrome,	 IgA	neuropathy	 and	 thrombocytopenia	 among	 other	 diseases	 (Jensen	 et	 al.	 2009).	 While	there	 is	 a	 lot	 of	 research	 showing	 the	 relationship	 between	 mucins	 and	 disease	progression	especially	in	the	field	of	cancer,	the	above	shows	that	mucin	glycans	can	be	altered	in	structure	and	subsequently	affect	function.			 It	 is	therefore	plausible	to	think	that	infection	with	HIV	can	alter	mucin	glycans	which	subsequently	compromise	their	binding	ability	to	HIV.	Habte	et	al.	(2010)	showed	that	purified	salivary	mucins	from	HIV	negative	individuals	inhibited	HIV-1	infection	in	vitro	but	this	inhibitory	activity	was	not	observed	from	individuals	who	were	HIV	positive	and	had	 different	 CD4	 counts.	 He	 postulated	 that	 there	 could	 be	 an	 alteration	 in	 the	glycosylation	pattern	of	mucins	in	patients	that	are	HIV	positive	which	could	result	in	the	in-ability	to	inhibit	the	virus	by	aggregation.	Interestingly,	these	results	contradicted	the	findings	of	Peacocke	et	al.	(2012)	in	which	she	demonstrated	that	salivary	mucins	from	both	HIV	negative	and	positive	individuals	inhibited	HIV	 in	vitro.	Furthermore,	a	study	conducted	in	our	laboratory	showed	that	taking	into	account	inter-individual	variation,	salivary	mucins	from	both	HIV	negative	and	positive	individuals	inhibited	HIV-1	activity	
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in	vitro	and	there	was	no	significant	difference	in	their	inhibitory	potential	towards	HIV-	1	(McLeod	2017).			 During	infection,	the	envelope	spike	(gp120)	binds	to	the	host	CD4	co-receptors	(CCR5	or	CXCR4)	and	activates	 the	 trimerization	process	 in	 the	endoplasmic	 reticulum	(ER).	This	trimerization	process	results	in	protein	fold	called	gp160	which	has	ten	disulphides	added	to	it	and	approximately	30	N-linked	glycans	depending	on	the	viral	isolate	(Land	et	al.	2003).		It	is	important	to	note	that	(HIV-1)	envelope	glycoprotein	is	synthesized	as	a	 precursor	 glycoprotein,	 gp160	 (Koga	 et	 al.	 1994).	 Thereafter,	 the	 cellular	 enzyme,	protease	cleaves	the	gp160	into	gp120	and	a	trans	membrane	subunit	gp41	(Zhu	et	al.	2000).	The	N	glycosylated	region	of	the	gp120	is	the	site	where	viral	binding	to	the	cell	surface	receptors	occurs	suggesting	a	possible	role	of	the	sugar	glycans	in	non-covalent	viral	interactions	(Zhu	et	al.	2000).			 The	N-glycosylation	of	the	viral	capsid	protein	has	been	area	of	much	research	(Zhu	et	al.	2000:	 Pantophlet	 et	 al.	 2003).	 The	 outer	 domain	 of	 the	 gp120	 has	 oligo-mannose	glycans	 are	 highly	 glycosylated	 (Zhu	 et	 al.	 2000)	 Furthermore,	 mass	 spectrometry	analysis	of	viral	proteins	showed	highly	conserved	virus	specific	glycan	profiles	across	different	 primary	 isolates	 of	 geographically	 divergent	 clades	 (Doores	 et	 al.	 2010).	 In	addition,	the	glycosylation	pattern	of	HIV	was	shown	to	be	uniquely	conserved	across	all	isolates	of	HIV	-1	from	clade	A,B	and	C	(Doores	et	al.	2010).	Thus,	there	is	a	possibility	that	mucin	 glycans	 can	 physically	 interact	 with	 the	 uniquely	 conserved	 glycosylation	pattern	 of	 the	 envelope	 gp120	 protein	 of	 HIV-1	 virus	 thereby	 trapping	 the	 virus	 and	preventing	infection	of	the	virus.			 Wu	 et	 al.	 (2003)	 demonstrated	 that	 salivary	 agglutinin,	 specifically	 inhibited	 the	infection	of	HIV-1	by	binding	 to	 the	viral	 envelope	protein	gp120.	This	 resulted	 in	no	infection	of	the	virus	to	the	host	target	cells.	Furthermore,	electron	studies	conducted	by	Malamud	et	al	(1993)	showed	that	whole	saliva	aggregated	the	HIV	virus	in	a	0.45micro	pore	 size	 nitrocellulose	 filter	 membrane	 and	 proposed	 this	 as	 the	 reason	 why	 oral	transmission	of	HIV	is	rare	(Malamud	1993).	Therefore,	it	has	been	postulated	that	the	role	of	salivary	glycans	in	the	inhibition	of	HIV	infection	lies	in	physically	aggregating	the	
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virus.	This	 interaction	 could	possibly	occur	between	 the	mucin	 glycans	 and	 the	 sugar	sequence	of	the	viral	capsid	proteins				 5.4 Rationale	and	Aim		 This	study	aims	to	investigate	the	role	of	salivary	glycans	in-order	to	gain	some	insights	into	the	mechanism	through	which	mucins	inhibits	HIV-1	in	vitro.	By	removing	the	sugar	glycans,	 we	 aim	 to	 see	 if	 having	 a	 certain	 number	 of	 sugar	 residues	 or	 a	 specific	arrangement	of	the	residues	is	necessary	to	have	an	effect	on	the	anti-HIV-1	activity.	
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			 5.5 MATERIALS	AND	METHODS		 5.5.1 Materials		 The	materials	used	for	this	section	are	described	in	chapter	2	with	a	few	additions.	The	enzymatic	de-glycosylation	kit	was	purchased	 from	Sigma-Aldrich	(St.	Louis,	Missouri,	USA).	This	enzymes	in	this	kit	contained	PNGase	F,	α(2	,6)Neuramidase,	O-Glycosidase,	
β(1,4)	 Galactosidase	 and	 β-N-Acetylglucosaminidase.	 TRITON	 X-100	 together	 with	sodium	phosphate	was	purchased	from	Kimix	Chemical	and	Laboratory	Suppliers	(Cape	Town,	 South	 Africa).	 Bovine	 fetuin	 was	 purchased	 from	 Sigma-Aldrich	 (St.	 Louis,	Missouri,	USA).		 5.5.	2	Sample	Collection		 The	 method	 for	 collecting	 saliva	 was	 carried	 out	 as	 described	 in	 Chapter	 3	 with	 no	modifications.		 5.5.3 Purification	of	Salivary	Mucins		 The	 purification	 of	 salivary	 mucins	 was	 conducted	 using	 the	 methods	 described	 in	chapter	3.		 5.5.4 Sample	Preparation.		
De-sialylation.	
	 The	protein	backbone	of	mucins	consists	of	carbohydrate	side	chains	which	are	O-linked	to	 serine	 or	 threonine	 residues.	 The	 terminal	 residues	 on	 these	 oligosaccharides	 are	generally	N-acetylneuraminic	acid	(sialic	acids).	During	this	process,	Proteomics	Grade	Neuraminidase,	 a	 highly	 purified	 enzyme	 from	Arthrobacter	 ureafaciens,	was	 used	 to	cleave	 sialic	 acid	 residues	 from	 the	mucin	 glycoproteins.	 It	 releases	 α(2→3),	 α(2→6),	α(2→8)	and	α(2→9)	linked	sialic	acids	(Sigma-Aldrich).	
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Briefly,	 1.7	mg	 of	 purified	 freeze-dried	mucins	were	 dissolved	 in	 1	ml	 of	 1x	Reaction	buffer	(50	mM	sodium	phosphate,	pH	6.0).	Thereafter	4	µl	of	the	neuraminidase	enzyme	was	added	to	the	purified	samples	and	incubated	at	37°C	for	3	hours.	The	reaction	was	stopped	 by	 heating	 at	 100°C	 for	 5	minutes.	 Thereafter,	 the	 samples	were	 centrifuged	briefly,	and	the	supernatant	was	collected	and	dialysed	against	three	changes	of	water	and	freeze	dried	in	preparation	for	de-glycosylation.			
De-glycosylation	and	harvesting	of	the	polypeptide.	
	
	 Mucins	are	major	structural	glycoproteins	which	are	characterized	by	their	high	density	and	 high	 carbohydrate	 content	 (Corfield	 et	 al.	 2001).	 To	 investigate	 the	 functional	significance	of	 the	 carbohydrate	portion	of	mucins,	we	used	an	enzymatic	protein	de-	glycosylation	kit	(EDEGLY)	purchased	from	Sigma	Aldrich	(UK)	to	remove	the	O-linked	glycoproteins.	 The	 EDEGLY	 kit	 contains	 enzymes	 such	 as	 PNGase	 F,	 𝛽 (1→4)	Galactosidase,	 O-Glycosidase,	 Neuraminidase	 solution	 and	 𝛽-N-	 Acetylglucosamines	whose	function	is	associated	with	the	cleavage	of	O-linked	core	glycans	on	glycoproteins.	De-glycosylation	procedure	was	conducted	under	native	and	denaturing	conditions	 to	access	 which	 conditions	 would	 be	 optimal	 for	 the	 removal	 of	 mucin	 glycans.	 During	denaturing	conditions,	100	µg	of	purified	mucin	glycoprotein	was	dissolved	in	30	µl	of	deionized	water	in	an	Eppendorf	tube.	This	was	followed	by	the	addition	of	10	µl	of	5x	reaction	buffer	(Triton	x100)	and	2.5	µl	of	denaturing	solution.	The	solution	was	mixed	and	 heated	 for	 5	minutes	 at	 100	 OC	 .	 Thereafter,	 2.5	 µl	 of	 Triton	 x100	was	 added	 to	increase	 the	 activity	 of	 the	 enzymes	 and	1	µl	 of	 PNGase	F,	O-Glycosidase,	𝛼(2,3,6,8,9)	Neuramidase	 solution,	 1	 µl	 each	 of	 𝛽 (1→4)	 Galactosidase	 and	 𝛽-N-	 Acetyl-	glycosaminidase.	The	tube	was	incubated	for	3	hours	at	37℃. Under	native	conditions	,	100µg	of	purified	freeze	dried	purified	mucin	were	dissolved	in	35µl	deionised	water	 in	a	Eppendorf	tube.	To	this	reaction,	10µg	of	5X	reaction	buffer	(Triton	 x100)	 was	 added.	 1µg	 of	 PNGase	 F,	 𝛽 (1→4)	 Galactosidase-Glycosidase,	Neuraminidase	 solution	 and	𝛽-N-	 Acetylglucosaminidase	 each	was	 then	 added	 to	 the	reaction	 tube.	 The	 tube	 was	 incubated	 for	 72	 hours	 at	 37	 ℃ to	 allow	 optimum	 de-	glycosylation	to	occur.	Thereafter,	recovery	of	the	polypeptide	from	the	reaction	products	
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was	done	using	the	size	exclusion	gel	filtration	method	(section	2.4.4).	This	was	followed	by	 dialysis	 against	 two	 changes	 of	 ammonium	 bicarbonate	 (NH4HCO3)	 buffer	 over	 a	period	of	16	hours.	The	recovered	polypeptide	was	freeze	dried	and	the	extent	at	which	glycosylation	had	occurred	was	accessed	by	mobility	shifts	on	an	SDS-PAGE	gel.	The	de-	glycosylated	peptide	sample	was	stored	at	-20℃ for	HIV	neutralisation	assays.		 5.5.5 Identification	of	 Mucins		
Western	Blotting	
	 The	presence	of	MUC5B	and	MUC7	was	determined	using	the	Western	blotting	method.	After	 SDS	 Page	 electrophoresis,	 proteins	 and	mucins	 were	 electroblotted	 onto	 a	 wet	nitrocellulose	membrane	that	had	been	soaked	in	for	an	hour	in	transfer	buffer	(25mM	Tris	Base,	150mM	Glycine,	10%	Methanol	 at	pH	8.3).	Thereafter,	 three	 layers	of	 filter	paper	were	soaked	in	the	transfer	solution	and	were	placed	underneath	the	nitrocellulose	membrane	followed	by	the	gradient	gel	and	another	three	filter	papers	on	top	of	the	gel.	Mucins	were	then	transferred	by	vacuum	blotting	for	1	hour	at	40V	as	described	by	Mall	et	al.	(2007).	Following	this,	the	nitrocellulose	membrane	was	washed	for	twenty	minutes	with	Tris	buffered	 saline	 (TBS)	 buffer.	 In-order	 to	 prevent	 any	 non-specific	 binding,	 the	membranes	were	blocked	with	5%	(w/v)	low	fat	milk	in	TBS	buffer	with	Tween	(TBST),	(20mM	Tris	chloride,	500mM	NaCl,	0.05%	(v/v)	 tween	20)	 for	1	hour.	Thereafter,	 the	membranes	were	washed	in	TBS	buffer	for	ten	minutes	and	followed	by	incubation	with	the	appropriate	primary	antibody(Table	4)	which	was	diluted	in	in	5%	(w/v)	low	fat	milk	in	TBST.	The	membranes	were	then	washed	twice	in	TBST	buffer	followed	by	incubation	with	 alkaline	 phosphatase	 conjugated	 secondary	 antibody	which	 diluted	 in	 5%	 (w/v)	low-fat	milk	powder	in	1×	TBST	for	thirty	minutes	at	room	temperature.	An	anti-rabbit	IgG	alkaline	specific	antibody	secondary	antibody	was	used	for	both	MUC5B	and	MUC7	with	 a	 dilution	 factor	 of	 (1:50	 000)	 (Table	 4).	 After	 incubation,	 the	membranes	were	washed	 three	 times	 with	 TBST	 for	 ten	 minutes.	 The	 color	 was	 then	 developed	 by	incubating	 the	 membranes	 with	 half	 tablet	 of	 NBT/BCIP	 was	 dissolved	 in	 5	 ml	 of	phosphate-buffered	saline	(PBS)	to	give	a	final	concentration	of	0.175mg/ml.	
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Table	8	The	primary	and	secondary	antibodies	used	during	western	blotting	
	
	
Primary	Antibody	 Manufacturer	 Type	
Antibody	
of	 Dilution	
Factor	MUC5B	 Dallas	Swallow	 Rabbit	Monoclonal	 1:2000	MUC7	 Santa	Cruz	Biotechnology	 Rabbit	Polyclonal	 1:400	
Secondary	Antibody	 Manufacturer	 Type	
Antibody	
of	 Dilution	
Factor	Anti-rabbit	alkaline	antibody	
IgG	specific	 Sigma-Aldrich	 Goat	polyclonal	 1:50000	
	
	 5.5.6 Confirmation	of	mucin	size	and	purity		 The	confirmation	of	mucin	size	and	purity	was	done	as	described	in	Chapter	3	using	SDS	PAGE	analysis	followed	by	PAS	staining.			 5.5.7 HIV	Neutralization	assays	The	anti-HIV	activity	of	deglycosylated	MUC5B	and	MUC7	was	tested	against	the	DU422	and	 the	 YU2	 pseudo	 virus	 using	 the	 neutralization	 assay	 described	 in	 chapter	 3	(Montefiori	2009;	Sarzotti-Kelsoe	et	al.	2014).			 5.5.8.	Cell	viability	assay		 The	effect	of	deglycosylated	MUC7	and	MUC5B	on	 the	viability	of	TZM-bl/JC	cells	was	tested	 using	 the	 MTT	 assay	 as	 described	 in	 chapter	 3.	 The	 only	 modification	 to	 this	method	was	the	use	of	acidified	isopropanol	instead	of	10%	SDS	with	0.01M	HCl	as	the	solubilizing	agent	for	the	formazan	crystals.	
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		 5.5.9	Data	Analysis	We	used	the	methods	described	in	chapter	3	for	the	processing	of	the	data.	
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5.6 RESULTS		 5.6.1 Confirmation	of	Mucin	Purification	and	Identity.		 The	purification	of	salivary	mucins	was	in	line	with	the	representative	results	t	shown	in	Chapter	4.	These	samples	demonstrated	similar	protein	and	glycoprotein	profiles	after	CsCl	density	gradient	ultracentrifugation	and	Sepharose	CL-4B	gel	filtration.	Thereafter,	the	identity	of	the	V0	and	Vi	fractions	were	investigated	by	probing	the	samples	against	MUC5B	and	MUC7	antibodies	respectively.	 The	Vo	stained	positive	for	MUC5B	(Figure	23)	 while	 the	 Vi	 stained	 positive	 for	 MUC7	 (Figure	 24).	 Strong	 staining	 signal	 was	observed	 for	 both	 MUC5B	 and	 MUC7.	 However,	 MUC5B	 showed	 low	 electrophoretic	mobility	on	the	western	blot	a	characteristic	of	the	highly	glycosylated	mucin	(Wu	et	al.	1994).	MUC7	band	was	present	at	approximately	180	kDa	and	showed	more	mobility	compared	to	MUC5B	(	Figure	24).	Furthermore,	we	tested	our	samples	for	co-purification	a	problem	demonstrated	by	Thornton	et	al.	(2001)	using	slot	blot	analysis.	Our	results	showed	 no	 immunoreactivity	 when	 MUC5B	 samples	 were	 probed	 with	 anti-MUC7	primary	 antibody	 and	 when	 MUC7	 samples	 were	 probed	 with	 anti-MUC5B	 primary	antibody	(data	not	shown).	As	in	Chapter	4,	MUC5B	samples	showed	a	darker	PAS	staining	and	it	retained	at	the	top	of	the	running	gel	during	SDS	page	analysis	(Figure	25a).	MUC7	appeared	as	a	smear	on	the	10%	gradient	gel	demonstrating	heterogeneity	of	mucin	populations	(Figure	25b).	The	retention	of	MUC5B	at	the	top	of	the	running	gel	made	it	difficult	to	determine	its	exact	molecular	weight.	MUC7	showed	a	band	just	above	180kDa	and	the	PAS	staining	was	less	intense	as	compared	to	MUC5B	(Figure	25b)	
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				 Lane	 1	 2	 3	 4	 5		
	
Figure	23	Investigating	the	identity	of	four	freeze	dried	Vo	fractions	after	CsCl	density	gradient	ultracentrifugation	spin	
and	Sepharose	CL-4B	gel	filtration.	The	fractions	were	first	subjected	to	4-20%	SDS-PAGE	analysis	and	stained	with	PAS	
staining.	Thereafter,	a	Western	blot	analysis	was	performed	for	MUC5B.	Lane	1	is	the	molecular	while	lane	2-5	are	the	V0	
fractions.	The	arrow	indicates	the	area	of	interest.	
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180kDa	
	
	
	 Lane	 1	 2	 3	 4	 5	 6						
														 Figure	24	Investigating	the	identity	of	four	freeze	dried	Vi	fractions	after	CsCl	density	gradient	ultracentrifugation	spin	and	Sepharose	CL-4B	gel	filtration.	The	fractions	were	first	subjected	to	4-20%	SDS-PAGE	analysis	and	stained	with	PAS	staining.	Thereafter,	a	Western	blot	analysis	was	performed	for	MUC7.	Lane	1	is	the	molecular	while	lane	2-6	are	the	Vi	fractions.	The	arrow	indicates	the	area	of	interest.	
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		 a)		Lane		1				2						3						4				5			 6					7	 b)	 Lane	1	2	3	4	5		
	 		 Figure	25	Estimation	of	mucin	size	and	purity	of	a)	Vo	fractions	and	b)	Vi	fractions	on	a	4-10	%	gradient	gel	SDS-PAGE	followed	by	PAS	staining	of	mucin	glycoprotein.	Briefly,	1mg	of	purified	lyophilized	aliquots	were	dissolved	in	100μl	of	2%	SDS,	1%	glycerol	and	0.01%	bromophenol	blue	for	SDS-PAGE	gel	 investigation.	Lane	7	 for	a)	and	Lane	1	 for	b)	represents	10μl	of	Thermo	Scientific	Page	Ruler	Pre-stained	Protein	Ladder	while	a)	Lane	1-6	shows	10	μl	of	V0	b)	Lane	2-5	shows	10	μl	of	Vi	fraction.	The	arrow	represents	the	area	of	interest.	
250kD	 180kDa	
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		 5.6.2 Confirmation	of	Mucin	De-glycosylation			 Purified	samples	of	MUC5B	and	MUC7	samples	were	deglycosylated	under	denaturing	and	 native	conditions	to	assess	which	conditions	gave	optimal	removal	of	glycans.	Under	denaturing	 conditions,	mucins	 underwent	 enzymatic	 de-glycosylation	 for	 three	 hours	while	under	native	conditions	the	process	took	72	hours	(3	days).	Using	the	denaturing	method,	MUC5B	and	MUC7	(Figure	26	&	27)	appeared	as	smears	after	three	hours	demonstrating	the	heterogeneity	of	mucin	populations	(Harding	1984).	PAS	staining	of	both	samples	after	three	hours	showed	an	intense	band.	However,	both	mucin	samples	showed	low	mobility	in	the	gradient	gel	after	three	hours	perhaps	due	to	the	extensive	carbohydrates	side	chains	that	were	still	attached	to	the	mucins	(Figure	26	&	27).	This	correlated	with	the	intense	PAS	staining	observed.	In	addition,	the	removal	of	mucin	 glycans	 after	 72	 hours	 using	 the	 native	 method	 showed	 an	 increase	 in	electrophoretic	 mobility	 for	 both	 samples	 suggesting	 the	 removal	 of	 some	 glycans.	Deglycosylated	 MUC5B	 samples	 under	 native	 conditions	 showed	 less	 PAS	 staining	intensity	compared	to	MUC7.	Since	the	removal	of	sugar	glycans	is	a	complex	process,	the	 possibility	 that	 all	 the	 sugars	 were	 removed	 is	 impossible	 hence	 the	 above	observation	that	MUC5B	showed	low	staining	intensity	could	have	been	caused	by	the	naked	carbohydrate	regions	were	not	exposed	(Figure	26)	(Wu	et	al.	1994).	
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																															Lane									1							2								3								4									5							6																								
		 Figure	26	Investigating	the	enzymatic	removal	of	MUC5B	glycans	after	3	and	72	hours.	Briefly,	approximately	100µg	of	purified	freeze-dried	purified	mucin	were	dissolved	in	35µg	deionised	water	in	a	Eppendorf	tube.	To	this	reaction,	10µg	of	5X	reaction	buffer	(Triton	x100)	was	added.	1µg	of	PNGase	F,	𝛽 (1→4)	Galactosidase-Glycosidase,	Neuraminidase	solution	 and	 𝛽-N-	 Acetylglucosaminidase	 each	 was	 then	 added	 to	 the	 reaction	 tube.	 Thereafter,	 1mg	 of	 purified	lyophilized	aliquots	were	dissolved	in	100μl	of	2%	SDS,	1%	glycerol	and	0.01%	bromophenol	blue	for	SDS-PAGE	gel	investigation	 followed	 by	 a	 PAS	 staining.	 Lane	 1	 molecular	 weight	 maker,	 Lane	 2,	 4,	 6	 shows	 MUC5B	 that	 was	deglycosylated	 for	 3	 hours	 under	 the	 denaturing	 conditions	 while	 Lane	 3,	 5,	 7	 shows	 MUC5B	 sample	 that	 was	deglycosylated	for	72	hours.																					
130kda	
250kda	
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		 								Figure	27	Investigating	the	enzymatic	removal	of	MUC7	glycans	after	3	and	72	hours.	Briefly,	approximately	100µg	of	purified	freeze	dried	purified	mucin	were	dissolved	in	35µg	deionised	water	in	a	Eppendorf	tube.	To	this	reaction,	10µg	of	5X	reaction	buffer	(Triton	x100)	was	added.	1µg	of	PNGase	F,	𝛽 (1→4)	Galactosidase-Glycosidase,	Neuraminidase	solution	 and	 𝛽-N-	 Acetylglucosaminidase	 each	 was	 then	 added	 to	 the	 reaction	 tube.	 Thereafter,	 1mg	 of	 purified	lyophilized	aliquots	were	dissolved	in	100μl	of	2%	SDS,	1%	glycerol	and	0.01%	bromophenol	blue	for	SDS-PAGE	gel	investigation	followed	by	a	PAS	staining.	Lane	1	molecular	weight	maker,	Lane	2,	4,	6,8	and	10	shows	MUC7	that	was	deglycosylated	 for	3	hours	under	the	denaturing	conditions	while	Lane	3,	5,	7	and	9	shows	MUC7	sample	that	was	deglycosylated	for	72	hours.	
95kDA	
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5.6.3 HIV-1	Neutralization	Assay.		
De-glycosylated	MUC5B	and	MUC7	
	 All	samples	were	tested	for	their	ability	to	inhibit	the	infection	of	TZM-bl/JC	cells	by	the	YU2	and	Du422.1	pseudo	virus	using	the	HIV	neutralization	assay.	Samples	that	displayed	no	 inhibition	 or	 that	 showed	 no	 increase	 in	 inhibition	 with	 an	 increase	 in	 mucin	concentration	 were	 assigned	 an	 arbitrary	 value	 of	 2000	 μg/ml	 (triple	 the	 highest	concentration	 used	 during	 these	 experiments)	 which	 was	 log	 transformed	 as	 it	 was	impossible	to	extrapolate	an	IC50.	This	value	did	not	interfere	with	our	statistical	analysis	as	the	data	was	non-parametric.	The	 IC50	 of	 deglycosylated	 salivary	 mucin	 samples	 showed	 high	 variability	 between	samples	that	were	deglycosylated	for	three	hours	vs	samples	that	were	deglycosylated	for	3	days.	The	IC50	 for	samples	that	were	deglycosylated	for	3	hours	ranged	between	770ug/ml	to	1322ug/ml.	Most	of	the	samples	that	were	deglycosylated	for	72	hours	had	IC50	that	were	in	the	range	of	1222ug/ml	to1653ug/ml.	Only	one	sample	had	an	IC50	that	was	less	than	1000ug/ml	(Table	11).	There	was	a	significant	difference	in	the	inhibition	of	the	de-glycosylated	mucin	samples	against	the	DU422	virus	(Kruskal-Wallis,	p=0.0137)(Figure	28).	De-glycosylated	MUC5B	samples	 had	 the	 highest	 inhibitory	 activity	 against	 DU422	 virus	 compared	 to	 de-	glycosylated	MUC7	samples	(Kruskal-Wallis,	p=0.0312).	Pairwise	analysis	of	MUC5B	and	MUC7	after	their	corresponding	incubation	time	of	3	and	72	hours	respectively	showed	no	 significant	 difference	 in	 their	 inhibitory	 potential	 against	 the	DU422	 virus	 (Mann-	Whitney	U,	p=0.1836)	for	MUC5B	and	(Mann-Whitney	U,	p=0.0753)	for	MUC7	samples.	Interestingly,	 when	 purified	 mucin	 samples	 were	 tested	 against	 the	 YU2	 virus,	 no	significant	difference	in	the	inhibitory	potential	of	these	samples	was	detected	(Kruskal-	Wallis,	 p=0.2258)(Figure	 29).	 Pairwise	 analysis	 showed	 that	 deglycosylated	 MUC5B	sample	had	a	greater	 inhibitory	potential	(Mann-Whitney	U,	p=0.016)	against	the	YU2	virus	as	compared	to	the	deglycosylated	MUC7	sample	at	both	3	and	72	hours	(Mann-	Whitney	U,	p=0.0816)	and	(Mann-Whitney	U,	p=0.0636	)	respectively.	
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		 Figure	28	Comparison	of	the	anti-HIV	activity	of	deglycosylated	MUC5B	and	MUC7	samples	at	different	time	intervals	against	 the	 DU422	 pseudo	 virus	 (Kruskal-Wallis,	 p=0.0137).	 De-glycosylated	 MUC5B	 samples	 had	 the	 highest	inhibitory	 activity	 against	 DU422	 virus	 compared	 to	 de-glycosylated	 MUC7	 samples	 (Mann-Whitney,	 p=0.0312).	Pairwise	 analysis	 of	 MUC5B	 and	 MUC7	 after	 their	 corresponding	 incubation	 time	 of	 3	 and	 72	 hours	 showed	 no	significant	difference	in	their	 inhibitory	potential	against	the	DU422	virus	(Mann-Whitney	U,	p=0.1836)	for	MUC5B	and	(Mann-Whitney	U,	p=0.0753)	for	MUC7	samples.	
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			 Figure	29	Comparison	of	the	anti-HIV	activity	of	deglycosylated	MUC5B	and	MUC7	samples	at	different	time	intervals	against	the	YU2	pseudo	virus	(Kruskal-Wallis,	p=0.2258).	Pairwise	analysis	showed	that	MUC5B	deglycosylated	sample	for	3	and	72	hours	had	a	greater	inhibitory	potential	(Mann-Whitney	U,	p=0.016)	as	compared	to	the	deglycosylated	MUC7	sample	after	the	same	time	intervals	(Mann-Whitney	U,	p=0.0816)	and	(Mann-Whitney	U,	p=0.0636	)	respectively.	
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5.6.4 MTT	Assay	for	Cell	Viability		 The	cytotoxicity	of	deglycosylated	MUC5B	and	MUC7	was	tested	using	 the	MTT	assay.	 As	previously	described	in	chapter	4,	if	the	cell	viability	remained	above	70%	and	there	was	no	increase	in	cell	death	with	increase	in	sample	concentration,	mucins	were	considered	non-toxic.	In	cases	where	the	above	condition	was	not	met,	the	LC50	(50%	Lethal	dose)	was	calculated	using	the	variable	slope	curve	fit	function	in	GraphPad	Prism	(La	Jolla,	CA,	USA)	which	calculates	 the	 log(inhibitor)	vs.	normalized	 response.	We	also	established	that	in	some	cases,	the	amount	of	virus	was	the	limiting	factor	for	luciferase	production.	No	 detectable	 cytotoxicity	 was	 detected	 in	 half	 of	 the	 deglycosylated	 samples.	 The	remaining	 deglycosylated	 samples	 had	 LC50	 that	 ranged	 between	 668µg/ml	 to	1738µg/ml.	(Table	3,	3.1,	4	&	4.1	in	appendix).	Some	samples	showed	an	increase	in	cell	death	 as	 the	 concentration	 of	 the	 mucin	 samples	 increased	 but	 no	 reduction	 in	 cell	viability	over	50%	was	observed.	
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Table	9	Cytotoxicity	(LC50)	and	HIV-1	neutralization	values	of	DU422	virus	(IC50)	by	de-	
glycosylated	MUC5B	for	3	hours	and	72	hours.	
	
	
	 Samples	
MUC5B	3	hours	 MUC5B	3	days	LC50	(µg/ml)	 IC50	(µg/ml)	 LC50	(µg/ml)	 IC50	(µg/ml)	1	 No	toxicity	 	 1099	 No	toxicity	 	 1221	2	 No	toxicity	 	 1321	 No	toxicity	 	 2000	3	 No	toxicity	 	 1121	 No	toxicity	 	 1653	4	 No	toxicity	 	 2000	 No	toxicity	 	 1085	5	 No	  1209	  
 toxicity	 1332	  2000	6	 No	  567	  
 toxicity	 1421	  1421	7	 No	toxicity	 	 1000	 No	toxicity	 	 1431	8	 758	  No	  
  1332	 toxicity	 1332	9	 No	toxicity	 	 1161	 No	toxicity	 	 1111	
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Table	10	Cytotoxicity	(LC50)	and	HIV-1	neutralization	values	of	DU422	virus	(IC50)	by	de-	
glycosylated	MUC7	for	3	hours	and	72	hours.	
	
	
	
	
	
	 Samples	
MUC7	3	hours	 MUC7	3	days	LC50	(µg/ml)	 IC50	(µg/ml)	 LC50	(µg/ml)	 IC50	(µg/ml)	1	 No	toxicity	 	 1576	 No	toxicity	 	 1821	2	 No	toxicity	 	 1486	 No	toxicity	 	 1358	3	 No	toxicity	 	 119	0	 No	toxicity	 	 1677	4	 No	toxicity	 	 1087	 No	toxicity	 	 1242	5	 No	  1209	  
 toxicity	 2000	  1696	6	 No	  567	  
 toxicity	 1467	  1256	7	 No	toxicity	 	 1306	 No	toxicity	 	 1476	8	 758	  No	  
  1003	 toxicity	 1753	9	 No	toxicity	 	 1699	 No	toxicity	 	 1334	
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Table	11	Cytotoxicity	(LC50)	and	HIV-1	neutralization	values	of	YU2	virus	(IC50)	by	de-	
glycosylated	MUC7	for	3	hours	and	72	hours.	
	
	
	
	 MUC5B	3	hours	 MUC5B		3	days	LC50	(µg/ml)	 IC50	(µg/ml)	 LC50	(µg/ml)	 IC50	(µg/ml)	No	toxicity	 	 1332	 No	toxicity	 	 1221	No	toxicity	 	 1421	 No	toxicity	 	 1312	No	toxicity	 	 900	 No	toxicity	 	 1653	No	toxicity	 	 1332	 No	toxicity	 	 1085	No	  1209	  toxicity	 917	  1566	No	  567	  toxicity	 770	  992	No	toxicity	 	 992	 No	toxicity	 	 1332	758	  No	  
 1099	 toxicity	 1421	No	toxicity	 	 1211	 No	toxicity	 	 1000	
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Table	12	Cytotoxicity	(LC50)	and	HIV-1	neutralization	values	of	YU2	virus	(IC50)	by	de-	
glycosylated	MUC7	for	3	hours	and	72	hours.	
	
	
	
	
	
	 Samples	
MUC7	3	hours	 MUC7	3	days	LC50	(µg/ml)	 IC50	(µg/ml)	 LC50	(µg/ml)	 IC50	(µg/ml)	1	 No	toxicity	 	 1021	 No	toxicity	 	 1576	2	 No	toxicity	 	 1161	 No	toxicity	 	 1486	3	 No	toxicity	 	 915	 No	toxicity	 	 1190	4	 No	toxicity	 	 992	 No	toxicity	 	 1087	5	 No	  1209	  
 toxicity	 1332	  1233	6	 No	  567	  
 toxicity	 1421	  1467	7	 No	toxicity	 	 1000	 No	toxicity	 	 1306	8	 758	  No	  
  1321	 toxicity	 1003	9	 No	toxicity	 	 1121	 No	toxicity	 	 1699	
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5.7 DISCUSSION		 Mucin	research	has	primarily	focused	on	investigating	the	anti-HIV-1	activity	of	different	mucins	and	demonstrating	if	this	inhibitory	activity	is	retained	in	crude	secretions	(Habte	et	 al.	 2006;	Habte,	 de	Beer,	 Lotz,	 Tyler,	Kahn,	 et	 al.	 2008;	Habte,	 de	Beer,	 Lotz,	 Tyler,	Schoeman,	et	al.	2008;	Peacocke	et	al.	2012;	Mthembu	et	al.	2014).	Alterations	in	mucin	glycosylation	has	been	linked	with	different	diseases	suggesting	a	possible	link	between	mucin	polymorphisms	and	susceptibility	to	infection	(Habte	et	al.	2010;	Peacocke	et	al.	2012;	Mthembu	et	al.	2014).	However,	the	role	of	mucin	glycans	in	the	inhibition	of	HIV-	1 has	 been	 overlooked	 by	 researchers	 because	 of	 their	 structural	 complexity	 and	heterogeneity	(lwase	et	al.	1993).			 This	study	aimed	to	investigate	the	role	of	salivary	glycans	in	the	inhibition	of	HIV-1.	The	results	of	this	study	suggest	that	mucin	glycans	play	an	important	role	in	inhibiting	the	transmission	of	HIV-1.	De-glycosylated	MUC5B	showed	higher	inhibition	against	both	the	YU2	 and	 the	 DU422	 pseudo-virus	 compared	 to	 deglycosylated	 MUC7(Kruskal-Wallis,	p=0.0312).	Contrary	to	purified	MUC7	which	showed	a	higher	inhibition	towards	the	YU2	virus	 in	 chapter	 4,	 deglycosylated	 MUC7	 displayed	 minimal	 inhibition	 towards	 both	viruses	compared	to	deglycosylated	MUC5B	(Mann-Whitney	U,	p=0.0816).			 The	methods	used	for	the	purification	of	salivary	mucins	was	successful.	Western	blot	analysis	identified	the	V0	and	the	Vi	fractions	as	MUC5B	and	MUC7	respectively	(Figure	23	 and	 24)	 Furthermore,	 these	mucins	 showed	 difference	 in	mobility.	While	 MUC5B	showed	 a	low	electrophoretic	mobility	on	the	western	blot,	MUC7	showed	more	mobility	(Figure	24).	These	results	are	in	agreement	with	previous	work	that	has	been	done	in	our	laboratory	which	noticed	a	variation	 in	 electrophoretic	mobility	of	MUC7	and	MUC5B	samples	that	were	isolated	from	saliva	(Habte	et	al.	2010).	SDS	Page	analysis	followed	by	PAS	staining	retained	MUC5B	samples	at	the	top	of	the	running	gel	(Figure	25a).	MUC7	appeared	 as	 a	 smear	 on	 the	 10%	 gradient	 gel	 demonstrating	 heterogeneity	 of	mucin	populations	(Figure	25b).	The	retention	of	MUC5B	at	the	top	of	the	running	gel	made	it	difficult	to	determine	its	exact	molecular	weight.	However,	this	finding	supports	the	fact	
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that	MUC5B	 is	 large	 in	 size	 ,highly	 glycosylated	 and	 has	 extensive	 carbohydrate	 side	chains	(Wu	et	al.	1994).			 The	specific	mechanism	through	which	mucin	glycosylation	inhibits	the	transmission	of	HIV-1	 is	 still	 superficial.	 It	 is	 not	 known	whether	 the	 specific	 arrangement	 of	 mucin	carbohydrate	residues	is	important	in	mucin	interactions	with	HIV-1,	or	if	the	negative	charge	afforded	by	sialic	acid	and	sulfated	sugars	allows	binding	to	viral	receptors.	 It	has	been	postulated	the	carbohydrate	moiety	plays	an	important	role	in	the	ability	of	mucins	to	bind	and	aggregate	HIV-1.	(Habte	et	al.	2006;	Habte,	de	Beer,	Lotz,	Tyler,	Kahn,	et	al.	2008;	Peacocke	et	al.	2012;	Mthembu	et	al.	2014).	We	investigated	the	role	of	salivary	glycans	 using	 enzymes	 to	 de-glycosylate	 the	 purified	 MUC5B	 and	 MUC7.	 Our	 results	(Figure	26	&	27)	showed	that	mucin	glycans	can	be	removed	using	enzymes	due	to	the	increase	in	mobility	of	mucin	samples	after	de-glycosylating	the	mucin	samples	for	72	hours	 (Figure	 26	 &	 27).	 Furthermore,	 our	 results	 showed	 that	 native	 conditions	 are	optimal	 glycan	 removal.	 However,	 a	 limitation	 with	 using	 this	 method	 for	 de-	glycosylation	 is	 that	 the	 exact	 oligosaccharides	 that	 are	 removed	 during	 the	 de-	glycosylation	process	 is	not	known.	Therefore,	 in-order	 to	gain	an	 insight	as	 to	which	mucin	 glycans	 were	 removed,	 a	 full	 sugar	 analysis	 using	 the	 liquid	 chromatography	electrospray	 ionisation	 mass	 spectrometry	 (LC	 ESI-MS)	 method	 as	 described	 by	Thornton	 et	 al.	 (2000)	 needs	 to	 be	 done	 The	 high	 costs	 involved	 in	 conducting	 such	experiments,	restricted	our	laboratory	in	investigating	the	structural	variants	that	were	removed.	However,	this	should	form	the	basis	of	future	studies.			 Deglycosylated	MUC5B	showed	a	higher	inhibitory	activity	towards	the	Du422	virus	and	the	 YU2	 virus	 Mann-Whitney	 U,	 p=0.031	 and	Mann-Whitney	 U,	 p=0.016	 respectively	(Figure	 28	 &	 29).	 Interestingly,	 contrary	 to	 purified	 MUC7	 which	 showed	 a	 higher	inhibition	 towards	 the	 YU2	 pseudo-virus	 in	 chapter	 4,	 de-glycosylated	MUC7	 showed	minimal	 inhibition	 towards	 both	 pseudo-viruses	 (Mann-Whitney	 U,	 p=0.0816).	 The	higher	 inhibition	 display	 by	 de-glycosylated	 MUC5B	 suggests	 the	 possibility	 that	 the	extensive	oligosaccharides	which	accounts	for	78%	of	the	molecular	weight	of	MUC5B	(Levine	et	al.	1987)	are	not	easily	removed.	Hence,	as	mentioned	in	Chapter	4	,	a	higher	
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glycosylation	may	lend	MUC5B	the	ability	to	be	more	effective	during	viral	aggregation.	However,	 the	minimal	 inhibition	 displayed	 by	 deglycosylated	mucins	 as	 compared	 to	purified	mucins,	 suggests	 that	 indeed	mucins	use	 glycans	 to	 inhibit	HIV	 transmission.	Furthermore,	the	extensive	glycosylation	of	MUC5B	prevents	the	underlying	protein	core	to	 interact	with	any	viral	protein	suggesting	the	possibility	that	mucin	glycans	are	the	sole	structures	that	interact	with	viral	particles	(Wu,	Csako,	and	Herp	1994).			 Salivary	 glycans	 are	 known	 to	 aggregate	 bacteria	 and	 viruses	 thereby	 inhibiting	 viral	infectivity	 into	host	 cells	 and	 changes	 in	 the	pattern	of	 glycosylation	 and	 structure	 of	glycans	may	affect	their	aggregatory	activity.	(Bosch	et	al.	2000;	Prakobphol	et	al.	1999).	Interestingly,	the	glycosylation	pattern	of	salivary	mucins	particularly	MUC5B	in	females	is	affected	by	the	menstrual	cycle	(Prakobphol	et	al.	1999).	It	was	demonstrated	that	the	expression	of	MUC5B	and	the	glycosylation	pattern	is	 lowest	during	menstruation	and	although	it	increases	during	the	cycle,	the	levels	drops	again	until	the	ovulation	period	ends.	 In	 pregnant	 and	 lactating	 woman,	 the	 turnover	 rate	 of	 MUC5B	 glycosylation	 is	demonstrated	to	be	at	its	peak.	Contrary	to	this,	the	glycosylation	pattern	of	MUC5B	is	constant	in	men	and	in	women	who	have	reached	menopause	(Prakobphol	et	al.	1999).	Therefore,	 since	 glycosylation	 of	 MUC5B	 changes	 throughout	 the	 menstrual	 cycle,	 it	might	be	of	 interest	 for	 future	studies	to	check	 if	 there	 is	any	correlation	between	the	inhibitory	activity	of	MUC5B	and	the	different	stages	of	the	menstrual	cycle.			 This	 present	 study	 shows	 that	 deglycosylated	MUC5B	 is	 significantly	more	 potent	 in	inhibiting	 the	 DU422	 and	 the	 YU2	 pseudo-virus	 compared	 to	 de-glycosylated	 MUC7.	Therefore,	this	suggests	that	MUC5B	can	be	harnessed	and	used	as	a	primary	constituent	of	a	microbicide	that	can	be	used	to	inhibit	the	transmission	of	HIV-1.	MUC5B	is	a	major	constituent	of	saliva	and	under	resting	conditions,	it	is	produced	in	higher	concentrations	as	compared	to	MUC7	(Rayment	et	al.	2000;	Nieuw	Amerongen,	Bolscher,	and	Veerman	2004)	making	it	an	easier	source	to	use.	
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CHAPTER	SIX:	CONCLUSION		 According	to	the	report	which	was	published	by	UNAIDS	in	2017,	36.7	million	people	in	the	world	were	infected	with	HIV	and	of	that	total,	1.8	million	people	were	new	infections	(UNAIDS,	 2017).	 Sub-Saharan	 Africa	 was	 recognised	 as	 the	 most	 afflicted	 region	worldwide	 accounting	 for	 26	 million	 people,	 approximately	 68%,	 living	 with	 HIV.	 In	South	Africa	alone,	7.1	million	people	were	living	with	HIV	in	2017	with	approximately	270	000	new	infections	(UNAIDS,	2017).	Kwazulu	Natal	(KZN),	Gauteng	and	Eastern	Cape	were	 reported	 as	 provinces	with	 the	 highest	 incident	 rates	 of	 HIV	 in	 2016	 (National	Department	 of	 Health	 2015).	 Furthermore,	 an	 increase	 in	 HIV	 prevalence	 usually	correlates	with	an	increase	in	opportunistic	infections	such	as	TB	increasing	the	burden	of	disease	(Lawn	and	Wood	2006,	Soeters	et	al	2005).	With	the	struggle	that	South	Africa	is	facing	in	trying	to	fight	this	epidemic,	effective	treatment	and	preventative	strategies	are	required.	This	 indicates	the	urgent	need	for	research	exploring	ways	in	which	HIV	transmission	can	be	curbed.	This	study	aimed	to	determine	the	minimum	peptide	chain	length	and	structure	of	a	gel	forming	 mucin	 that	 retains	 the	 anti-HIV-1	 activity.	 This	 is	 the	 first	 time	 that	 our	laboratory	tested	crude	saliva	and	purified	salivary	mucins	against	a	subtype	B	strain.	Furthermore,	this	study	aimed	to	investigate	the	role	of	mucin	sugar	side	chains	in	the	inhibition	of	HIV-1.	The	results	of	this	present	study	showed	that	crude	saliva,	MUC5B	and	MUC7	are	able	to	inhibit	the	transmission	of	HIV	DU422.1	and	YU2	pseudo-virus	strain	to	TZM-bl/JC	cells.	While	MUC5B	showed	a	higher	inhibitory	potential	against	the	DU422	virus,	MUC7	had	a	greater	 anti-HIV-1	 activity	 against	 the	 YU2	 pseudo-virus	 strain.	 Crude	 saliva	 showed	comparable	HIV-1	inhibition	against	both	the	DU422	virus	and	the	YU2	virus.	In	addition,	mucins	that	were	reduced	and	digested	by	trypsin	still	retained	the	anti-HIV-1	activity	suggesting	 that	 even	 when	 the	 structural	 conformation	 of	 gel	 forming	 mucins	 are	compromised,	 they	 still	 retain	 their	 function.	 Interestingly,	 the	 de-glycosylation	 of	MUC5B	and	MUC7	prior	to	neutralisation	assays	reduced	the	anti-HIV	activity	of	these	mucins	 against	 the	 YU2	 virus	 and	 the	DU422	 pseudo-virus.	 This	 indicates	 the	 role	 of	mucins	glycans	in	the	anti-HIV-1	activity	and	answers	to	a	certain	extent	the	mechanism	through	which	salivary	mucins	inhibits	HIV-1.	However,	deglycosylated	MUC5B	showed	
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a	better	 inhibitory	activity	against	 the	YU2	virus	and	the	DU422	virus	proving	that	 its	extensive	glycosylated	nature	is	crucial	for	inhibition.	The	rare	transmission	of	HIV	via	the	oral	cavity	which	is	attributed	to	the	innate	system,	has	 raised	 questions	 on	 whether	 salivary	 components	 can	 be	 used	 as	 prophylactics	agents,	in	particular	mucins.	The	limited	success	of	vaccines	which	involves	the	adaptive	immune	 response	 has	 caused	 a	 great	 increase	 in	 research	 looking	 at	ways	which	 the	innate	system	can	protect	against	HIV-1.	The	major	constituent	of	whole	human	saliva,	mucins,	have	been	shown	to	inhibit	HIV-1	
in	vitro	by	the	aggregation	of	viral	particles	(Bergey	et	al.	1994;	Wu	et	al.	2003).	While	the	anti-HIV-1	activity	by	mucin	 rich	 saliva	 is	 specific	 to	HIV-1	and	not	 to	other	envelope	viruses	such	as	SIV	(Nagashunmugam	et	al.	1997),	its	inhibition	by	purified	mucins	is	not	clade	or	 strain	 specific	 (Habte	 et	 al.	 2006;	Peacocke	2011;	Peacocke	 et	 al.	 2012).	Our	results	showed	that	both	purified	salivary	mucins	display	an	inhibitory	activity	against	the	 subtype	B	 (YU2)	 strain	 and	 the	 subtype	C	 (DU422)	 strain,	 further	 supporting	 the	above	finding.	Furthermore,	salivary	agglutinin	which	is	the	second	largest	glycoprotein	found	in	saliva	has	also	been	shown	to	inhibit	HIV-1	In	vitro	(Wu	et	al.	2003).	A	study	conducted	in	our	laboratory	investigating	the	anti-HIV	activity	of	SAG	and	the	salivary	mucins	(MUC5B	and	MUC7)	showed	that	MUC5B	had	the	highest	inhibitory	potential	as	compared	to	the	other	two	 glycoproteins	 against	 the	 DU422	 virus	 (unpublished).	 Interestingly,	 our	 results	showed	that	MUC7	had	a	great	 inhibitory	potential	against	 the	YU2	virus,	a	subtype	B	strain.	Therefore,	by	 fully	understanding	how	mucins	protects	 the	body	against	HIV-1	entry,	we	can	potentially	reduce	viral	transmission	and	by	doing	so,	enhance	the	body’s	natural	 innate	 immune	 defences.	 If	 able	 to	 distinguish	 the	 key	 structural	 variants	 of	mucins	 which	 play	 part	 in	 this	 defence	 mechanism,	 we	 could	 use	 this	 as	 the	 core	components	of	a	vaginal	or	rectal	microbicide.	Thus	,	MUC5B	together	with	MUC7	must	be	investigated	further	to	assess	if	they	can	be	used	as	core	components	for	a	candidate	microbicide.	Microbicides	provide	women	with	a	preventative	tool	that	they	can	initiate	and	control.	These	microbicides	are	applied	to	the	vagina	or	the	rectum	to	reduce	the	transmission	of	sexually	transmitted	diseases	such	as	HIV.	This	is	especially	important	in	the	Sub-saharan	
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region	where	heterosexual	transmission	is	still	the	major	root	cause	of	many	HIV	related	cases.	In	addition,	it	is	known	that	women	are	more		highly	susceptible	to	HIV	than	men.	This	 gender	 inequality	 patterns	 makes	 women	 more	 susceptible	 to	 HIV	 due	 to	 the	different	 physiological	 and	 biological	 factors	 between	 men	 and	 women.	 The	 vaginal	surface	area	is	a	site	where	many	HIV	target	cells	are	present,	and	a	place	where	viral	transmission	 occurs.	 In	 addition,	 the	 concentration	 of	 HIV	 in	 semen	 is	 higher	 as	compared	 to	 vaginal	 secretions	 (Ramjee	 and	Daniels	 2013).	 The	 unreasonably	 higher	risk	 of	 infection	 in	women	 between	 the	 ages	 of	 15-24	 is	 due	 to	 the	 underdeveloped	genital	tract.	This	delicate	tract	makes	them	vulnerable	to	infections	and	tissue	damage	(Ramjee	and	Daniels	2013).	Apart	from	biological	factors,	it	is	worth	mentioning	that	social	factors	also	play	a	role	in	the	 spread	 of	 HIV.	 Richardson	 et	 al.	 (2014)	 reported	 a	 positive	 correlation	 between	gender	inequality	and	heterosexual	HIV	related	cases	based	on	the	data	he	obtained	from	the	 2010	 UNAIDS	 Global	 Report	 and	 the	 2011	 United	 Nations	 Human	 Development	(UNDP).	Patriarchal	culture	is	still	dominant	in	most	African	countries	including	South	Africa	and	it	makes	it	very	hard	for	women	to	negotiate	condom	use	as	they	are	viewed	inferior	 in	 society	 (Ramjee	 and	Daniels	2013).	The	mindset	 of	masculinity	 and	 sexual	promiscuity	 has	 resulted	 in	 the	 notion	 of	 having	multiple	 partners,	 a	 theory	 that	 has	greatly	led	to	the	spread	of	HIV	in	many	African	households	(Ramjee	and	Daniels	2013).	With	this	in	mind,	microbicides	can	provide	women	with	an	HIV	preventative	tool	that	they	 can	 use	 without	 the	 consent	 of	 their	 partners	 or	 in	 cultural	 or	 religious	circumstances	where	condom	use	is	not	endorsed.	Several	microbicides	have	been	tested	but	very	few	have	made	it	to	be	sold	commercially	(Abdool	Karim	and	Baxter	2012).	Only	two	microbicides	namely	1%	tenofovir	gel	and	dapivirine	rings	have	been	shown	to	reduce	the	risk	of	HIV	acquisition.	The	tenofovir	gel	has	had	some	conflicting	results	from	individuals	using	it.	The	phase	two	clinical	results	showed	a	39%	efficacy	in	candidates	who	used	the	gel	before	and	after	sexual	intercourse	and	54%	reduction	in	individuals	who	confirmed	consistent	adherence	(	Abdool	Karim	et	al.	2010).	Interestingly,	the	Microbicide	Trial	Network’s	VOICE	study,	Vaginal	and	Oral	Interventions	to	Control	the	Epidemic	(VOICE)	conducted	a	phase	llb	clinical	study	from	2009	 till	 2011	 testing	 tenofovir	 and	 two	 oral	 antiretroviral	 drugs	 and	 showed	 no	protective	effect	against	HIV	(https://www.clinicaltrials.gov/ct2/show/NCT00705679).	
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A	phase	three	clinical	trial	showed	no	difference	in	HIV	acquisition	among	the	control	and	placebo	group	(Rees	et	al.	2015).	Trial	results	from	the	monthly	use	of	the	dapivirine	ring	showed	that	it	had	the	potential	to	reduce	HIV	infections	by	50%	(Baeten	et	al.	2016).	The	fact	that	 both	microbicides	are	made	from	core	components	of	antiretrovirals,	raises	the	possibility	of	drug	resistance	if	inconsistently	used	following	infection	and	treatment.	This	 could	 lead	 to	 the	 formation	 of	 drug	 resistant	 HIV	mutations	 (Abdool	 Karim	 and	Baxter	2012).	The	 absence	 of	 any	 antiretroviral	 drugs	 in	 MUC5B	 makes	 it	 unlikely	 to	 induce	 viral	resistance	 as	 a	 prophylactic	 drug.	 Furthermore,	 the	 gel	 forming	 properties	 of	MUC5B	together	with	its	rheological	properties	makes	it	a	good	candidate	for	a	microbicide.	In	addition,	the	large	size	and	the	extensive	glycosylation	pattern	of	MUC5B	allows	for	the	effective	 aggregation	 of	 HIV-1,	 giving	 it	 higher	 anti-HIV-1	 potency	 than	 MUC7.	 This	further	 solidifies	 its	 role	 as	 a	 core	 component	 of	 a	 vaginal	 or	 rectal	microbicide.	 The	presence	of	mucins	in	the	genital	tract,	makes	it	impossible	for	MUC5B	to	cause	any	side	effects.	As	demonstrated	by	our	results,	even	after	the	removal	of	mucin	glycans,	MUC5B	still	 has	 the	 highest	 anti-HIV	 activity	 suggesting	 that	 it	 is	 difficult	 to	 compromise	 the	structural	abilities	of	this	mucin.	The	ability	of	HIV-1	to	evade	the	immune	system	during	initial	infection,	together	with	the	 presence	 of	 viral	 strains	 that	 are	 resistant	 to	 antiretrovirals	 makes	 it	 difficult	 to	completely	 eradicate	 this	 virus.	While	ARVs	provide	 sufficient	protection	 to	boost	 the	immune	system,	they	require	strict	adherence	and	managing	the	side	effects	is	usually	difficult.	Therefore,	 the	best	way	of	 controlling	 the	HIV	epidemic	 is	by	preventing	 the	transmission	of	the	virus.	Currently,	the	consistent	and	correct	use	of	condoms	and	the	dapivirine	ring	offers	a	preventative	tool	that	women	can	use.	The	innate	factors	provided	by	saliva	may	be	beneficial	in	providing	a	broad	neutralization	activity	against	different	HIV-1	strains	and	in	eliminating	the	likelihood	of	having	viral	resistance.	The	results	of	this	study	suggest	that	MUC5B	can	be	harnessed	and	used	as	an	innate	inhibitory	factor	which	can	prevent	HIV	transmission.	The	presence	of	glycans	may	be	important	for	this	anti-HIV-1	inhibitory	activity.	
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			 Appendix	1:	Buffers,	Reagents	and	Solutions		
Guanidinium	hydrochloride	in	PBS,	pH	6.5,	with	protease	inhibitors	1. 10	mM	PBS	
o 0.568	g	Na2PO4	in	400	ml	dH20	
o 0.960	g	NaH2PO4	in	800	ml	dH20	
o Add	reagent	1	to	2	until	pH	6.5	and	store	at	4°C	2. 4M	GuHCl	in	PBS,	pH	6.5	
o 382	g	GuHCl	in	1	litre	of	10	mM	PBS,	pH	6.5	3. Protease	inhibitors		
o 1	mM	PMSF	(0.174	g	in	1	litre)		
o 5	mM	NEM	(0.626	g	in	1	litre)		
o 10	mM	EDTA	(3.722	g	in	1	litre)			
Periodic	acid	Schiff	(PAS)	assay	for	glycoproteins	
	
	
	 1. Schiff’s	reagent		
o 10	g	pararosanniline	chloride	dissolved	in	1	litre	boiling	dH2O,	with	constant	stirring	
o Cool	solution	to	50°C	on	bench	and	add	200	ml	1	M	HCl		
o Add	3	g	activated	charcoal,	mix	for	5	minute	and	filter	to	remove	charcoal		
o Add	3	g	activated	charcoal,	mix	for	5	minute	and	filter	again		
o Store	at	room	temperature	in	a	dark	bottle		 2. Periodic	acid	solution	
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o 10	ml	7%	acetic	acid		
o 20	μl	50%	periodic	acid		 3. Decolourised	Schiff’s	reagent		
o 100	mg	sodium	metabisulphite		
o 6	ml	Schiff’s	reagent		
o Incubate	at	37°C	until	colourless		
o Prepared	fresh	for	every	assay				
Bradford	Assay	
	
o Bradford	reagent	is	diluted	1:5	with	dH2O			
4-20%	Sodium	dodecyl	sulphate	polyacrylamide	gel	electrophoresis	(SDS-PAGE)	
	
	
	 1. Sample	application	buffer		
o 2%	sodium	dodecyl	sulphate	(SDS)		
o 10%	glycerol		
o 0.01%	bromophenol	blue			 The	reagents	were	dissolved	in	dH2O	and	stored	at	room	temperature.				 2. 30%	Bis/Acrylamide		
o 30	g	acrylamide	
136		
o 0.8	g	bis		 The	reagents	were	dissolved	in	100	ml	dH2O	and	stored	in	a	dark	bottle	at	4°C				 3. 1.5	M	Tris-buffer	with	0.1%	SDS,	pH	8.8		
o 1.5	M	Tris		
o 0.1%	SDS		 The	reagents	were	dissolved	in	dH2O,	adjusted	to	pH	8.8	and	stored	at	4°C				 4. Spacer	gel	buffer		
o 0.25	M	Tris		
o 0.2%	SDS		 The	reagents	were	dissolved	in	dH2O	and	adjusted	to	pH	8.8.	This	buffer	was	stored	at	4°C		 5. 10%	AMPS		
o 10%	AMPS	dissolved	in	dH2O	
Stored	at	4°C	
	 6. Tank	buffer		
o 0.025	M	Tris		
o 0.19	M	glycine	
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o 0.1%	SDS		 The	reagents	were	dissolved	in	5	litres	of	dH2O,	adjusted	to	pH	8.8	and	stored	at	room	temperature			
4-20%	SDS-PAGE	
	 1. 4%	light	solution		
o 0.8	ml	30%	Bis/Acrylamide		
o 1.5	ml	1.5	M	Tris-buffer	with	0.1%	SDS,	pH	8.8		
o 3.7	ml	dH2O		
o 30	μl	10%	AMPS		
o 5	μl	TEMED			 2. 20%	heavy	solution	
o 4	ml	30%	Bis/Acrylamide,		
o 1.5	ml	1.5	M	Tris-buffer	with	0.1%	SDS,	pH	8.8,		
o 0.5	ml	dH2O,		
o 30	μl	10%	AMPS		
o .	5	μl	TEMED			 Using	a	serological	pipette,	2.3	ml	of	the	4%	light	solution	is	pipetted	and	thereafter	2.3	ml	of	 the	20%	heavy	 solution	 is	pipetted	 into	 the	 same	pipette.	A	 single	air	bubble	 is	passed	through	the	solution	to	create	the	4-20%	gradient.	
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Periodic	acid	Schiff	(PAS)	gel	staining	
	 1. Schiff’s	reagent		
o 1	g	pararosanniline	hydrochloride	dissolved	in	200	ml	boiling	distilled	water,	with	constant	stirring		
o Cool	solution	to	50°C	on	bench	and	20	ml	1	M	HCl		
o 	Cool	to	25°C	and	add	1	g	sodium	metabisulphite	and	leave	in	the	dark	for	12-24	hours		
o Add	2	g	activated	charcoal,	mix	for	1	minute	and	filter		
o .	Store	at	4°C	in	the	dark		 2 50%	ethanol		
o 50	ml	ethanol		
o 50	ml	distilled	water		 3. 1%	periodic	acid	and	3%	acetic	acid		
o 50%	periodic	acid		
o 3%	acetic	acid			
Slot	blot	
	 1. 20×	SSC		
o 175.3	g	sodium	chloride		
o 88.2	g	tri-sodium	citrate		 The	reagents	are	added	to	1	litre	dH2O,	adjusted	to	pH	7	and	stored	at	4°C		 2. 4×	SSC	
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o 200	ml	20×	SSC,	pH	7		
o 800	ml	dH2O	This	buffer	was	stored	at	4°C		
Western	blotting	and	slot	blot	
	 3. 1×	TBST		
o 1.21	g	Tris-HCl		
o 8.76	g	sodium	chloride		
o 0.5	g	Tween	20		 The	reagents	are	added	to	1	litre	dH2O,	adjusted	pH	8	and	stored	at	4°C		
Salt	azide	buffer	(0.2	M	NaCl	and	0.02%	NaN3)	
	
o 11.69	g	NaCl		
o 0.2	g	NaN3		
5%	and	10%	DMEM	
	
	
	
o 5%	DMEM		
o 50	ml	FBS		
o l	NEAA		
o l	of	200x	PenStrep		
o 0.5ml	of	100x	L-glutamine		 The	reagents	are	made	up	to	50	ml	with	a	DMEM	and	L-glutamine	solution	
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10%	DMEM	
	
o 5.0	ml	FBS		
o 0.50	ml	NEAA		
o 0.25	ml	of	200x	PenStrep		
o 0.5ml	of	100x	L-glutamine		
o The	reagents	are	made	up	to	50	ml	with	a	DMEM	and	L-glutamine	solution	
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Appendix	2:	Consent	form,	information	sheet	and	ethics		
Study	Title;	The	effect	of	reduction,	trypsin	digestion	and	de-glycosylation	of	salivary	mucins	in	the	inhibition	of	the	human	immunodeficiency	virus	type	1	Patient	information	sheet	Dear	Patient	We	are	doing	a	study	on	the	role	of	mucins	(the	“sticky”	portion	of	mucus	in	your	saliva)	in	the	inhibition	of	HIV-1	virus	infection.	This	research	study	will	be	conducted	by	Miss	Tsetse	under	the	supervision	of	Professor	Anwar	S.	Mall	in	the	Department	of	Surgery,	Old	Main	Building,	Groote	Schuur	Hospital.	HIV	transmission	via	the	oral	route	remains	rare	despite	the	detection	of	the	AIDS	virus	in	 the	 oral	 cavity.	 One	 apparent	 reason	 for	 this	 rare	 transmission	 is	 the	 presence	 of	antiviral	 factors	 such	as	 the	 innate	 inhibitory	molecules,	mucins,	 and	 soluble	proteins	which	are	found	in	saliva.	It	has	been	reported	that	mucins	can	inhibit	the	activity	of	HI	virus.	We	 aim	 to	 determine	 the	 structural	 variants	 of	 mucins	 which	 are	 essential	 for	 the	inhibition	of	HIV-1	infection	and	the	effect	reduction	and	trypsin	digestion	of	this	“sticky”	mucus	has	in	inhibiting	the	HIV-1	virus.	We	require	40	mls	of	Saliva.	You	will	be	expected	to	spit	 into	an	Eppendorf	tube	after	chewing	a	piece	of	plastic	parafilm	(You	are	required	not	to	swallow	it).	This	is	a	once	off	thing.	 You	will	 be	 asked	 to	 rinse	 your	mouth	 prior	 to	 the	 procedure,	 to	 prevent	 food	contamination	of	the	saliva.	Prior	to	saliva	collection,	an	HIV	test	will	be	conducted.	We	are	 planning	 on	 recruiting	 50	HIV	 negative	 patients	who	 are	 attending	 the	maternity	wards	of	Groote	Schuur	Hospital,	Cape	Town,	South	Africa	as	part	of	HAART	service	that	is	normally	offered	to	pregnant	women	in	maternity	wards	across	the	country.	In	doing	so,	we	ensure	our	cohort	is	HIV	negative.	We	hope	that	the	findings	of	this	study	will	give	us	a	better	understanding	of	the	role	saliva	(in	particular	mucins)	plays	in	the	inhibition	of	HIV-1.	Please	note	the	following:	
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1. Informed	consent	will	be	taken	before	sample	collection	takes	place.		 2. We	will	need	to	take	your	folder	number	(not	your	name)	from	which	we	will	get	the	details	of	your	age,	gender	and	ethnicity.	We	require	participant’s	 folder	numbers	such	that	in	the	case	of	an	anomaly	in	our	results,	or	in	case	the	results	we	get	from	certain	participants	do	not	 fit	 the	trend	observed,	we	can	be	able	 to	 fully	 justify/attribute	the	differences	in	findings.	We	do	hope	having	access	to	the	participant’s	folder	will	give	us	an	understanding	if	there	is	a	link	between	any	medical	conditions	the	participants	might	have	prior	to	providing	their	samples	and	our	results.	3. All	 this	 information	will	 remain	 strictly	 confidential	 and	we	promise	 that	 your	saliva	samples	will	not	be	used	for	any	other	purpose,	except	for	the	purpose	of	this	study.	4. You	have	every	right	to	not	participate	in	this	study.	If	you	do	not	wish	to	take	part	in	this	study,	it	will	not	affect	the	treatment	you	receive.	5. If	you	agree	to	participate	in	this	study	and	change	your	mind	at	a	later	date,	it	will	be	 fine.	 You	 will	 be	 removed	 from	 this	 study	 and	 your	 decision	 will	 not	 affect	 the	treatment	and	care	you	receive.	6. It	is	possible	that	we	will	publish	the	findings	of	this	study.	In	this	case,	your	name	will	not	be	mentioned	and	will	still	remain	confidential.	7. We	must	emphasize	that	all	samples	collected	for	this	study	will	not	carry	your	name	for	reference.	8. The	samples	will	be	stored	in	the	laboratory	for	re-analysis.		 If	there	are	any	questions,	please	ask	your	doctor	or	call	the	number	below.	If	you	think	of	any	questions	at	a	later	date,	please	contact	us	on	the	number	below.	Professor	A.	Mall		 Tel;	021	406	6168/6227		 HREC	TEL;	021	406	6338Room;	E52.26,	Old	Main	Building,	GSH	
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Request	for	saliva	samples	for	biochemical	analysis	Research	laboratory	Division	of	General	Surgery	OMB	Groote	Schuur	Hospital	UCT,	Medical	School,	Observatory,	7925	Tel;	021	406	6168/6227Fax;	021	448	6461	Please	fill	in	all	the	information	requested	Folder	No;	   HIV	status;	   
 Weeks	at	testing;	   
 For	laboratory	use	only		 Date	received;	   
 Computer	Index	No;	   
 Please	note	that	your	HIV	status	is	recorded	on	this	form.		 1. I	give	permission	that	my	saliva	can	be	taken	for	research	purposes	in	the	investigation	of	HIV	AIDS.	2. I	give	permission	that	a	portion	of	saliva	can	be	stored	indefinitely	for:		 a) Possible	re-analysis		 b) Research	purposes	subject	to	the	approval	of	the	University	of	Cape	Town	Research	Ethics	Committee,	provided	that	any	information	from	such	research	will	remain	confidential.	3. I	authorize	/	do	not	authorize	my	doctor(s)	(delete	where	not	applicable)	to	provide	relevant	clinical	details	to	the	researchers.	
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4. All	of	the	above	information	has	been	fully	explained	to	me	in	a	language	I	understand,	and	all	my	questions	were	answered.				 Participant’s	signature;		 	 Date;	   
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